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Abstract 
 
Histones are basic nuclear proteins that bind to genomic DNA. There are five subclasses: 
core histones H2A, H2B, H3 and H4, and linker histone H1. Release of extracellular 
histones has been shown in a range of critical illness animal models and human patients 
including sepsis and acute pancreatitis. Extracellular histones act as damage-associated 
molecular pattern molecules (DAMPs) on parenchymal epithelial and endothelial cells, 
cardiomyocytes, immune cells (neutrophils, monocytes, macrophages, dendritic cells 
and lymphocytes) and platelets to activate Toll-like receptors (TLRs; TLR2 and TLR4) 
and/or NLR Family Pyrin Domain Containing 3 (NLPR3) inflammasome as well as 
induce calcium influx, proinflammatory cytokine production, thrombin generation and 
cell death. Anti-histone strategies such as anti-histone antibodies or pharmacological 
neutralisers alleviate histone-induced toxicity.  
 
To progress the translational relevance of histones in circulation, this thesis explores the 
development of xMAP technology based assay for measuring relevant toxic histones 
and also the significance of histone determination in animal models and patients with 
acute pancreatitis.  
 
Truncated histones were generated by recombinant DNA technology and the purity was 
75.6-95.1%, except for histone H2A C-terminal (35.5%). Anti-histone single chain 
variable fragment (ahscFv) was also generated (purity > 95%) and shown to bind to 
histone subclasses by Western blot and IAsys resonant biosensor. Fluorescein 
isothiocyanate (FITC)-full length and FITC-truncated histones (H1.1 C-, H2A N-, H3.1 
N-terminal) bound to the cell membrane and induced calcium influx in EA.hy926 cells, 
while other truncated histones did not. ahscFv significantly prevented histone-induced 
cell death. To measure all toxic histones in one assay, Luminex xMAP multiplex 
technology was developed. Standard curves of both singleplex and multiplex assays 
were developed and used to measure the levels of circulating histones in plasma of 
patients with severe trauma, sepsis and pancreatitis. However, the recovery ratio in 
spiked plasma was low and the assay failed to detect histones in patient plasma which 
were detectable by Western blot. 
 
Release of circulating histones were investigated in mice with acute pancreatitis induced 
by either 4 or 12 injection of caerulein (50 µg/kg/h; CER-AP) or by infusion of 
pancreatic duct with sodium taurocholate (3.5%, 1 ml/kg; NaTC-AP). Four and 12 
injections of caerulein resulted in oedematous and necrotising CER-AP, respectively, 
with marked systemic inflammation and multiple organ injury observed in the 
necrotising CER-AP. NaTC-AP caused more diffuse pancreatic necrosis, systemic 
inflammation and multiple organ injury. Circulating histones, as measured by Western 
blots, were elevated early with further increases in necrotising CER-AP (peak > 100 
µg/ml) and NaTC-AP (peak > 140 µg/ml) as disease progressed but not in oedematous 
CER-AP which were comparable to saline controls. The levels of circulating histones 
were significantly associated with pancreatic necrosis and multiple organ injury 
parameters.  
 
Circulating histones were then measured from healthy volunteers and a consecutive 
cohort of acute pancreatitis patients admitted to Royal Liverpool University Hospital 
(RLUH) within 48 h of disease onset. The predictive values of circulating histones for 
persistent organ failure (POF), major infection and mortality were compared with 
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biochemical markers and clinical scores. A total of 236 patients (mild 156, moderate 57, 
severe 23 as per Revised Atlanta Classification) and 47 heathy volunteers were included. 
The median histone level in severe acute pancreatitis was 18.8 µg/ml (interquartile 
range: 5.9-33.8), significantly higher than mild 1.1 µg/ml (0.6-2.1) or moderate 1.3 
µg/ml (0.5-2.8) category which was comparable with heathy volunteers 1.0 µg/ml (0.5-
1.6). The area under the receiver-operating characteristic (AUC) curve of histones for 
predicting POF and mortality was 0.92 (95% confidence interval [CI]: 0.85-0.99) and 
0.96 (0.92-1.00) respectively, which was as or more accurate than tested biomarkers or 
clinical scores. For infected pancreatic necrosis and/or sepsis, the AUC of histones was 
0.78 (0.62-0.94). Histones did not predict or correlate with local pancreatic 
complications and transient organ failure, but negatively correlated with leucocyte cell 
viability (r = -0.511, P < 0.01). 
 
A study of consecutive acute pancreatitis patients with primary admission to RLUH (n 
= 260, blood sampling < 24 h) or referred (n = 52) from other hospitals and healthy 
controls (n = 47) were recruited. Referred patients had POF > 48 h (blood sampling < 
24 h of admission to ICU of the RLUH then daily for one week) within 3 weeks of 
disease onset. Histones, cytokines and routine biochemical markers were measured. 
Multivariable analyses determined associations between circulating histone levels and 
variables. There were 235 patients in Group 1 (no POF), 25 in Group 2 (POF < 24 h) 
and 52 in Group 3 (POF > 48 h). Circulating histones were significantly correlated with 
tested proinflammatory cytokines, clinical severity scores and individual organ injury 
parameters. Circulating histones were significantly more elevated in Group 3 compared 
to Group 2 but both were higher than in Group 1 or healthy volunteers. Multivariable 
analyses revealed that it was POF, but not pancreatic necrosis or other variables that 
most significantly associated with elevated circulating histones (odds ratio: 98.1, 95% 
CI: 14.4-669.0, P < 0.001). 
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Abbreviations 
 
ACD accidental cell death 
ACS abdominal compartment syndrome 
ahscFv anti-histone single chain variable fragment 
ALT alanine transaminase 
ANOVA analysis of variance 
APACHE II Acute Physiology and Chronic Health Examination II 
APC activated protein C 
APFC acute peripancreatic fluid collection 
aPTT activated partial thromboplastin time 
ARDS acute respiratory distress syndrome 
AUC area under curve 
BISAP Bedside Index for Severity in Acute Pancreatitis 
BUN blood urea nitrogen 
C1INH C1 esterase inhibitor 
CDRs complementarity-determining regions 
CECT enhanced computerised tomography 
CER caerulein 
CER-AP caerulein-induced acute pancreatitis 
CGD chronic granulomatous disease 
CI confidence intervals 
CRP C-reactive protein 
cscFv control single chain variable fragment 
CT computerised tomographic 
DAMPs damage-associated molecular patterns 
DIC disseminated intravascular coagulation 
DMEM Dulbecco’s Modified Eagle’s Medium 
DPI diphenylene iodonium 
EDTA ethylenediaminetetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
ESPEN European Society for Clinical Nutrition and Metabolism 
FI fluorescence intensities 
FITC fluorescein isothiocyanate 
GCLP Good Clinical Laboratory Practice 
GCS Glasgow Coma Scale 
H&E hematoxylin and eosin 
HMGB1 high mobility group box protein 1 
IAP intra-abdominal pressure 
ICU Intensive Care Unit 
IL interleukin 
IL-1Ra IL-1 receptor antagonist 
IPTG isopropyl β-D-1-thiogalactopyranoside 
IQR interquartile range 
ISTH International Society on Thrombosis and Haemostasis 
JAAM Japanese Association for Acute Medicine 
JMHW Japanese Ministry of Health and Welfare 
LB Luria-Bertani 
MCP-1 monocyte chemoattractant protein-1 
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MCTSI worst modified CT severity index 
MFI mean FI 
MODS multiple organ dysfunction syndrome 
MPT-RN mitochondrial permeability transition-medicated regulated necrosis 
NADPH nicotinamide adenine dinucleotide phosphate 
NaTC sodium taurocholate  
NaTC-AP sodium taurocholate-induced acute pancreatitis 
NCCD Nomenclature Committee on Cell Death 
NETs neutrophil extracellular traps 
Ni-NTA Nikeli-Nitrilotriacetic acid 
NLPR3 NLR Family Pyrin Domain Containing 3 
NLR negative likelihood ratio 
NPV negative predictive value 
OR odds ratio 
PAMPs pathogen-associated molecular patterns 
PaO2/FiO2 partial pressure arterial oxygen and fraction of inspired oxygen 
PCD programmed cell death 
PCR polymerase chain reaction 
PE phycoerythrin 
PEEP positive end expiratory pressure 
PI propidium iodide 
PLR positive likelihood ratio 
PMA phorbol myristate acetate 
PMT photomultiplier tubes 
POF persistent organ failure 
PPACK d-phenylalanyl-l-prolyl-l-arginyl chloromethylketone 
PPV positive predictive value 
PRRs pathogen recognition receptors 
PT prothrombin time 
PVDF polyvinylidene difluoride 
RAC Revised Atlanta Classification 
RCD regulated cell death 
RLUH Royal Liverpool University Hospital 
ROC receiver operating characteristics 
ROS reactive oxygen species 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM standard errors of means 
SIRS systemic inflammatory response syndrome 
SOFA Sequential Organ Failure Assessment 
SOPs standard operating procedures 
TLRs Toll-like receptors 
TNF tumour necrosis factor 
VDAC voltage dependent anion-selective 
WBC white blood cells 
WSACS World Society of the Abdominal Compartment Syndrome 
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Chapter 1– General introduction 
1.1 General introduction of critical illness 
1.1.1 Burdens of critical illness 
Critical illness is a condition describing patients with acute organ failure (e.g. sepsis, 
septic shock, severe acute pancreatitis, drug-induced liver failure, etc.), undergoing 
major surgical procedures, severe traumatic injuries, and end-stage life support who 
need admission to Intensive Care Unit (ICU)1. Critical illness is the predominant factor 
of deaths in adults and affects > 20 million world population annually, causing dramatic 
economic and social burdens1. Moreover, patients who survived from critical illness 
usually have significantly impaired quality of life as compared with general population2, 
3, and post-hospitalisation complications further increase expenses. In the USA, the 
direct critical care costs are approximately $3500 per each day (up to $263 billion 
annually) which accounts for 13-39% of total hospital costs4, 5. This figure represents up 
to 11.2% of total USA healthcare expenditure5. In the UK, the NHS report reveals that 
a Level 2 High Dependency bed costs £857 and a Level 3 Intensive Care bed costs 
£1932 per day6, and the average ICU stay is 5.7 days with a mortality rate of 32.4%7.  
 
The management of critically ill patients usually include treatment for aetiology factors, 
fluid resuscitation8, 9, anaesthesia10, pain relief11, nutritional support12, antibiotics10, and 
appropriate organ support and monitoring1. Despite the improvement of organ support 
modalities, the overall mortality of critically ill patients remains about 25% due to 
multiple organ dysfunction syndrome (MODS)13 and the mortality rate reaches 40%-
100% when ≥ 3 affected organs fail14. Therefore, understanding the pathogenesis and 
effective targeting MODS/organ failure are fundamental for breakthroughs in critical 
illness.  
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1.1.2 Organ or system dysfunction/failure 
The most leading cause for critical illness and ICU admission is sepsis15, a condition 
defined as life-threatening organ dysfunction/failure caused by a dysregulated host 
response to infection16. However, there are substantial amounts of patients also admitted 
to ICU due to acute organ failure induced by sterile inflammation from diseases such as 
severe acute pancreatitis17-19 and drug-induced liver failure20, 21. Regardless of aetiology 
and risk factors, these initial sterile local inflammations can cause systemic 
inflammation and sequential failure of distant organs without pre-existing advanced 
comorbidities. The affected organs/systems include pulmonary, cardiovascular, renal, 
haematological, central nervous as well as liver and gut.    
1.1.2.1 Acute respiratory distress syndrome (ARDS) 
ARDS is one of the most common reasons for ICU admission22. In 1967, Ashbaugh et 
al.23 first introduced this syndrome manifesting as cyanosis refractory to oxygen 
therapy, reduced lung compliance, diffuse infiltration changes on the chest X-ray. Since 
then, over the last 50 years the definition alterations were suggested in 198824, 199425, 
200526 and 201227 (also reviewed in ref22). The newly proposed Berlin definition27 
categories ARDS into 3 classes according to partial pressure arterial oxygen and fraction 
of inspired oxygen (PaO2/FiO2, mmHg) on a basis of positive end expiratory pressure 
(PEEP, minimum 5 cmH2O): mild, PaO2/FiO2 200-300; moderate, PaO2/FiO2, 100-199; 
severe, PaO2/FiO2 < 100. In a study
28 of 127 ARDS secondary to acute pancreatitis, the 
mortality rates of mild, moderate and severe ARDS were 0%, 9.4% and 15.8%, 
respectively. The most recent multicentre study29 demonstrates that the period 
prevalence of ARDS is 10.4% (3022/29144) in the ICU, with mortality of mild, 
moderate and severe is 34.9%, 40.3% and 46.1%, respectively. Current treatment for 
ARDS includes ventilation (non-invasive30, 31 and mechanical22, 29), fluid balance 
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restoration, neuromuscular blockade, prone positioning and referral to extracorporeal 
membrane oxygenation centre depends on individual condition22.  
1.1.2.2 Circulatory shock 
Circulatory shock, or failure, is featured as systematic inadequate cellular oxygen supply 
caused by hypotension and hypoperfusion typically with hyperlactatemia, a sign of 
abnormal cellular oxygen metabolism32. It affects about 1/3 patients in the ICU33 and 
sepsis-induced acute circulatory failure remains more than half of the cases34; 
hypovolaemia and cardiogenic factors are also common and are not mutually 
exclusive32. 
 
Circulatory shock is clinically diagnosed either by lack of fluid response or acidaemia 
on the basis of hypotension (systolic blood pressure < 90 mmHg, mean blood pressure 
< 70 mmHg, or need for vasoactive agents)32. It is distinctly different from acute 
decompensated heart failure which normally has advanced pre-existing comorbidities 
such as atrial fibrillation, coronary artery diseases, myocardial infarction and chronic 
pulmonary diseases35. However, myocardial injury as evidenced by elevated cardiac 
troponin (both I and T isoforms) levels can occur in both circulatory injury36, 37 and heart 
failure35. The initial treatment of circulatory shock is fluid resuscitation32, 38-40. Recently, 
early goal-directed fluid resuscitation has not been shown to be superior to conventional 
protocol in 3 multicentre randomised, controlled trials in septic patients38-40. However, 
the role of early-goal directed fluid resuscitation remains controversial in severe acute 
pancreatitis, better designed trials are warranted to address the type of fluid, the rate of 
administration, and how fluid therapy should be guided41. When fluid resuscitation fails 
to restore hypoperfusion, vasoactive agents are needed32, 42-44.   
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1.1.2.3 Acute renal failure 
Acute renal failure and its less severe form, acute renal injury, are characterised by rapid 
loss of renal function, resulting in an impaired ability to excrete metabolic waste 
(increased nitrogen products and/or decreased urine output) and maintain fluid and 
electrodes balance45, 46. This accounts for substantial amount of ICU admissions as a 
primary reason47-49 or develops as one of the secondary complications. Pre-existing 
chronic kidney diseases are most dominate risk factors for developing of acute renal 
failure50. Acute renal failure is classified as prerenal (e.g. hypovolaemia or hypotension), 
intrinsic renal (typically acute tubular necrosis) and postrenal (obstructive) categories 
according to the causing factors51. It is diagnosed by a combination of disease history, 
clinical presentations, physical examinations, blood nitrogen/creatinine ratio, urinalysis 
(sediment, protein, sodium and osmolality)45, 46, 51. According to different aetiologies 
and risk factors, the treatment of acute renal failure is composed of non-dialysis (volume 
expansion, use of diuretics and dopamine, N-acetylcysteine and calcium-channel 
blockers), supportive (correction of hyperkalaemia, sodium retention, hyperglycaemia, 
acidosis, provision of nutritional support and control of infection) and renal replacement 
therapy51. A continuous strategy is not superior to intermittent haemodialysis52, 53 and 
neither early is better than the delayed approach54.  
1.1.2.4 Acute liver failure 
Acute liver failure is characterised by a sudden onset of altered mental status and 
development of coagulopathy due to severe injury of hepatocytes or extensive 
necrosis55, 56, typically without pre-existing end stage liver diseases57. It is an uncommon 
but not rare cause for ICU admission, resulting in high short-term morbidity and 
mortality58, 59.  
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In the developed countries, the most common aetiology for acute liver failure is drug-
induced, e.g. acetaminophen accounts for > 57% acute liver failure in the UK annually58; 
while in the developing countries virus-induced prevails58, 59. Depending on weeks from 
jaundice to encephalopathy, there are three most noticeable systems to classify acute 
liver failure. The O’Grady system classifies acute liver injury to hyperacute (0-1 week), 
acute (1-4 weeks) and subacute (4-12 weeks) and the survival rate without emergency 
liver transplantation is good, moderate and poor, respectively58. The Bernuau system 
divides acute liver failure into fulminant (0-2 weeks) and subfulminant (2-12 weeks) 
subtypes59. The Japanese system dissects the disease into fulminant (0-8 weeks) and 
late-onset (> 8 week) stages, and the fulminant stage is further separated into acute (0-
10 days) and subacute (10 days-8 weeks) subclasses. The management of acute liver 
failure is challenging which requires multidisciplinary approach to deal with MODS and 
arrange liver transplantations in selected cases59.  
1.1.2.5 Haemostatic dysfunction 
Coagulation abnormalities are frequently observed in critically ill patients60. It is caused 
by the loss of haemostasis between coagulation and the fibrinolytic system and 
manifests as thrombocytopenia (platelet count < 150 ×109/L), prolonged global clotting 
times [prothrombin time (PT), activated partial thromboplastin time (aPPT)], reduced 
levels of coagulation inhibitors (antithrombin III, protein C, and protein S), or increased 
levels of fibrin degradation products (D-dimer and soluble fibrin monomer)61. The most 
common aetiology factor of thrombocytopenia is sepsis which accounts for 52% of 
cases, followed by disseminated intravascular coagulation (DIC), drug-induced, trauma 
and others60. DIC represents the most severe form of coagulopathy and is characterised 
by the widespread activation of coagulation proteases which result in endothelial 
dysfunction, intravascular fibrin formation, thrombotic occlusion, and eventually organ 
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failure61-64. Deranged coagulation status has also been evidenced in acute pancreatitis 
and is related to its severity65-67. DIC secondary to acute pancreatitis is reported in case 
studies68-71 and is associated extremely high mortality.  
 
Apart from risk factors, clinical presentations, physical examinations, the diagnosis of 
DIC involves laboratory analysing a plethora of coagulative and anti-coagulative related 
parameters including the platelet count, PT, aPTT, antithrombin, protein C, D-dimer and 
increasing extracellular DNA and DNA-binding proteins such as histones64, 72. In 1983, 
the Japanese Ministry of Health and Welfare (JMHW) proposed a graded scoring 
criteria for diagnosis of DIC73. The JMHW DIC criteria include SIRS components, 
platelet counts, PT, aPTT, fibrinogen, fibrin/fibrinogen degradation products with five 
points or more for the establishment of DIC. In 2006, these criteria have been revised 
subsequently by the Japanese Association for Acute Medicine (JAAM) by removing 
fibrinogen components from the JMHW criteria after a multicentre study74. Basic on a 
similar concept, the International Society on Thrombosis and Haemostasis (ISTH) 
introduced a novel scoring criteria for DIC75. The ISTH criteria include points for each 
components including platelet counts, increased fibrin marker levels and fibrinogen 
level, a score of ≥ 5 indicates overt DIC while < 5 is suggestive non-overt DIC. 
Compared with the JAAM criteria, the ISTH criteria abandon the Systemic 
Inflammatory Response Syndrome (SIRS) score element which is considered to be non-
specific for DIC and therefore are more stringent to diagnose DIC64. Not surprisingly, 
the mortality rate of DIC is doubled using the ISTH criteria when compared to the 
JAAM criteria (46% versus 22%)76, 77. The ISTH recommends that current management 
of DIC should include removal of aetiological factors, using prothrombin complex 
concentrate and anticoagulants (unfractionated heparin or low-molecular-weight 
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heparin for thrombotic phenotype), and initiating antifibrinolytic treatment when 
appropriate64, 78, 79.    
1.1.2.6 Neurological dysfunction 
Mental disorders, displaying as coma or impaired consciousness, can be caused directly 
by trauma, vascular and infective lesion of the brain, or indirectly by metabolic 
catastrophes such as organ failure(s), hypoglycaemia, diabetic ketosis, and drug 
intoxication80. There was lack of methodology to standardise assessing coma and 
impaired consciousness in traumatic head injury historically until the introduction of 
Glasgow Coma Scale (GCS) by Teasdale and Jennett in 197481. The GCS includes 
detailed measurement of motor responses, verbal responses and eye opening. Since its 
first introduction, it has been widely applied in daily clinical practice and research in the 
neurological or ICU settings over more than last 40 years82. However, recent studies 
show that scoring agreement between observers is only 32%83 or the diagnostic error 
rate of GCS is around 10%84. Some researchers raised concerns that the GCS does not 
incorporate brain reflexes, clinical signs of bad prognosis, or to measure verbal 
component in incubated patients and therefore it needs critical reappraisal again85.   
1.1.2.7 Gut dysfunction and abdominal compartment syndrome (ACS) 
Due to lack of generalised biochemical markers, gut dysfunction has been overlooked 
in the settings of critical care. In critical illness, the most common type of gut 
dysfunction is acute intestinal failure. Over the last 25 years, the definitions of intestinal 
failure have been changing constantly. Recently, The European Society for Clinical 
Nutrition and Metabolism (ESPEN)86 has defined acute intestine failure as type II 
functional classification: “prolonged acute condition, often in metabolically unstable 
patients, requiring complex multidisciplinary care and intravenous supplementation 
over periods of weeks or months”. ACS is diagnosed as intra-abdominal pressure (IAP) 
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> 20 mmHg with or without an abdominal perfusion pressure < 60 mmHg that is 
associated with new organ dysfunction/failure by World Society of the Abdominal 
Compartment Syndrome (WSACS)87. Prevention of excessive fluid resuscitation, 
monitoring IAP, analgesia, correct body positioning, evacuation of intra-luminal 
contents by gastroprokinetics, coloprokinetics, and enemas are critical factors88. If all 
these fail, then surgical decompression will be the last resort to treat ACS88, 89.   
 
1.1.3 Organ failure scores 
MODS, or organ failure(s), was systematically described and the severity of each organ 
failure was graded in 1990s. In 1995, Marshall et al.90 first reported a MODS score that 
is composed by 6 items including: respiratory (PaO2/FiO2 ratio), cardiovascular (heart 
rate and the ratio of central venous pressure to mean arterial pressure), renal (serum 
creatinine level), hepatic (serum bilirubin level), haematological (platelet count) and 
central nervous (GCS). Each system scores 0-4 depends on the respectively cut-off 
values. The same group then used hypotension and acidaemia to replace the original 
definition of cardiovascular dysfunction in the new scoring system (Brussels score). 
Based on similar idea, in 1996, Le Gall et al.91 proposed and validated a Logistic Organ 
Dysfunction System score to assess organ dysfunction status on the day of ICU 
admission. In the same year, Vincent et al.92 proposed a Sepsis-related Organ Failure 
Assessment (SOFA) score aiming to dynamically minor organ failure severity in the 
ICU settings. This score is fundamentally similar to the Marshall and Brussels scores, 
but several changes have been made: hypotension and acidaemia are replaced by use of 
inotropes to define cardiovascular dysfunction; respiratory support is also added to 
indicate respiratory dysfunction; oliguria is further supplemented to determine renal 
dysfunction. As the SOFA score is not specific to only sepsis but can represent whole 
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range of critical illnesses with organ failure, it is thereafter also called Sequential Organ 
Failure Assessment (SOFA) score (Table 1.1). In 1998, the SOFA score was validated 
in a multicentre study, showing that SOFA score was significantly higher in more severe 
organ failure and was strongly associated with mortality93. Since then, the SOFA score 
has been extensively employed by the ICU settings for daily evaluating severity and 
estimating prognosis94-96. 
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Table 1.1 The Sequential Organ Failure Assessment (SOFA) score 
 SOFA score 
Varibles 0 1 2 3 4 
Respiratory (PaO2/FiO2 mmHg) > 400 ≤ 400 ≤ 300 ≤ 200* ≤ 100* 
Cardiovascular (hypotension) No hypotension MAP < 70 mmHg Dop ≤ 5 or dob 
(any dose)†  
Dop > 5, epi ≤ 
0.1, or nore ≤ 0.1† 
Dop > 15, epi > 
0.1, or nore > 0.1† 
Renal (creatine, mmol/l; urine, ml/d) 110 110-170 171-299 300-440 or < 500 > 440 or < 200 
Liver (bilirubin, µmol/l) 20 20-32 33-101 102-204 > 204 
Coagulation (platelets, × 109/l) > 150 ≤ 150 ≤ 100 ≤ 50 ≤ 20 
Central nervous system (GCS) 15 13-14 10-12 6-9 < 6 
PaO2/FiO2, partial pressure arterial oxygen and fraction of inspired oxygen; MAP, mean arterial blood pressure; Dop, dopamine; Dob, dobutamine; 
Epi, epinephrine; Nore, norepinephrine; GCS, Glasgow Coma Scale.  
*Values are with respiratory support. 
†Adrenergic agents administered for at least 1 hour (doses given are in µg/kg per minute).
20 
 
1.2 Pathophysiology of organ failure 
1.2.1 Inflammatory cells and mediators 
1.2.1.1 Macrophages, dendritic cells and neutrophils 
Tissue resident macrophage and dendritic cells can phagocytose the cell debris and 
simultaneously secret pro-inflammatory cytokines to recruit circulating neutrophils and 
monocytes/macrophages. Meanwhile, chemicals released by these tissue resident cells 
can increase the vasodilatation and epithelium permeability resulting in phagocytes 
migration, blood proteins leakage to tissue and circulation. The conventional role of 
neutrophils in the pathogenesis of organ failure has been well recognised and 
characterised in diseases such as sepsis97, severe acute pancreatitis98, acute liver failure99 
and acute glomerulonephritis100. The role of neutrophils at least include degranulation 
and phagocytosis101-103. Although neutrophils defend host prominently, it is one of the 
major culprits in causing collateral cell damage by passively releasing damage-
associated molecular patterns (DAMPs) including reactive oxygen species, sodium 
hypochlorite, neutrophil elastase, high mobility group box protein 1 (HMGB1), 
histones, etc. and forming neutrophil extracellular traps (NETs)104, 105.  
1.2.1.2 NETs 
In 2004, a novel mechanism of neutrophils has been discovered by Brinkmann and 
colleagues106. They described a phenomena that includes vacuolisation, relaxation of 
chromatin, rupture of nuclear membrane, mixing up of chromatic and granular 
components and release of the chromatic-granular components to form the nets-like 
extracellular structure, which is called NETs106. As it is distinctly different from those 
of neutrophil apoptosis and necroptosis, a term of NETosis is coined to describe this 
phenomena by Steinberg and Grinstein in 2007107. NETs formation is released by the 
activated neutrophils triggered by the pathogens like bacteria and fungi108, or DAMPs104, 
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109, the cellular breakdown products including components from nucleus, mitochondria, 
cytosol and cell membrane that are immunogenic110. DNA consists the backbone of 
NETs, which is decorated by chromatic and granular proteins and peptides. As histones 
are abundant in the NETs components, the backbone DNA is mostly from nuclei instead 
of mitochondria which contain histone-like proteins rather than histones.  
 
It is believed that the main role of NETosis is to trap, kill and lyse the pathogens in a 
higher concentration of granular antimicrobial components, resulting in the enforcement 
of their microbicidal effects. The conduct of undergo phagocytosis or NETosis might 
depends on the size of pathogens. During counteracting larger size of bacteria or fungi, 
activated neutrophils cannot engulf the pathogens by phagocytosis. Instead, they process 
NETosis, then the lysed pathogens and debris of NETs can be cleared by macrophages. 
However, NETosis also can be triggered in inflammation and worsen the diseases. 
 
Reactive oxygen species (ROS) generation and autophagy are essential for undergo 
NETosis104. NETosis can be triggered by live bacteria, phorbol myristate acetate (PMA) 
or IL-8, but NETs formation is absent in stimulated neutrophils from patients with 
chronic granulomatous disease (CGD)104. CGD patients have the mutations in the 
phagocyte NADPH (nicotinamide adenine dinucleotide phosphate) oxidase, resulting in 
lack of ROS generation which is essential in the antimicrobials111. This scenario highly 
indicated that ROS generation is required for the NETosis. Fuchs and co-workers used 
diphenylene iodonium (an inhibitor of NADPH oxidase) to block NETosis which 
further confirmed the essential role of ROS generation in NETosis112. However, ROS 
alone is not sufficient to induce NETosis. Remijsen and colleagues used PMA to 
stimulate neutrophils which were pre-treated with wortmanin which inhibits autophagy 
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via inhibition of PI3K113. These pre-treated neutrophils did not show massive 
vacuolisation but remained the superoxide production, implying although ROS oxidase 
remains active when autophagy is pharmacologically inhibited, PMA is unable to induce 
NETosis. Instead, block either ROS oxidase or autophagy can led to activation of 
caspases and apoptosis. Therefore, NETosis requires both ROS generation and 
autophagy and apoptosis might function as a backup program when NETosis is 
inhibited.  
 
Beside the function of microbicide, NETs and its components can initiate inflammatory 
response102, 114, 115, cytokine release102, 114, 115, thrombin generation116-119, platelet 
aggregation119, 120, etc. Except infectious disease, excessive NETs formation has been 
found in patients with non-infectious diseases such as systemic lupus erythematous121, 
122, cystic fibrosis123, 124, depth vein thrombosis119, pancreatitis125-127, etc and impairs 
wound healing in diabetics128. In contrary, aggregated NETs have been shown to limit 
inflammation by degrading cytokines and chemokines in gout129. These paradox 
findings indicate that NETosis is a double-edged sword in immunity. Therefore, it is 
essential to understand the mechanisms of inducing and regulating NETosis, which 
might provide a potential therapeutic target. 
1.2.1.3 Cytokines and chemokines 
Cytokines are the small proteins secreted by cells with the functions of regulation of 
transcription, translation, healing, inflammation, etc130. The term ‘cytokine storm’ 
vividly described the image of an immune system gone awry and the systemic 
inflammatory response flaring out of control and cytokines including tumour necrosis 
factor (TNF) superfamilies131, 132,133, 134, interleukin (IL)-1 families135, IL-6 families136-
138,  and chemokine families139 are well studied. In systemic inflammation such as 
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observed in sepsis140, 141 or severe acute pancreatitis, the cytokine storm is driven by 
TNF, IL-1, IL-2, IL-6, reactive oxygen species and arachidonic metabolites which are 
counteracted by anti-inflammatory mediators IL-10, IL-4 and IL-1 receptor antagonist 
(IL-1Ra)142. Chemokines such as IL-8 and monocyte chemoattractant protein-1 (MCP-
1) are also released to enhance the recruitment of inflammatory cells to the primary 
injury site140-142.  
 
IL-1 family contains 11 members including IL-1α, IL-β, IL-18, IL-33 and IL-1Ra135, 143. 
Both IL-1α and IL-1β are pro-inflammatory cytokines which have functions of 
increasing acute-phase signalling, trafficking immune cells to the local infection site, 
activing epithelial cells and inducing more cytokine release. Caspase-1 inflammasome 
regulates the maturation and secretion of IL-1β, IL-18 and IL-33 in inflammatory 
responses. However, in sterile inflammation IL-1β and IL-18 is processed by neutrophil 
proteinase-3 and neutrophils are a major source of these pro-inflammatory cytokines.  
 
Elevated IL-1β has been reported lethal as blockage of IL-1R decreased mortality in 
experimental models144. IL-1 possess the capability of secondary production of IL-1 and 
TNF-α, but this inflammatory cascade can be regulated by IL-1Ra and IL-6. IL-1Ra is 
upregulated and competitively bind to IL-1R1 to the blockage of transduction of IL-1 
signalling145. Simultaneously, IL-6 secreted majorly from mononuclear phagocytic cells 
can inhibit IL-1 and TNF synthesis and stimulate synthesis of IL-1Ra, resulting in anti-
inflammatory response138. The other role of IL-6 is pro-inflammatory mediator by effect 
on B cell maturation and secretion of immunoglobulins, activation of T cells and 
induction of hepatocyte of acute phase proteins137, 138.  
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Chemokines are another group of cytokines that have a hallmark feature of recruiting 
immune cells into the injured site by induction of chemotaxis139, 146-149. IL-8 (also termed 
CXCL8) is secreted from variable cells triggered by stimulates especially IL-1 and 
TNF150, 151. The essential role of IL-8 is the traits of chemoattractant and degranulation 
of neutrophils148. MCP-1 (also known as CCL2) majorly regulates the migration and 
infiltration of monocytes, as well as T lymphocyte and natural killer cells152, 153. The 
recruited monocyte convert to macrophage to be involved in the battle with infection 
and inflammation154. 
 
Collectively, cytokines and chemokines released by the primary injured parenchymal 
cells and residential immune cells trigger a chain of responses to recruit migration of 
immune cells (neutrophils101, 103, 155, 156, dendritic cells157, 158, 
monocytes/macrophages159-162, mast cells163, 164 and other granulocytes) involved in 
innate immunity to the injured site165. The principle function of innate immune 
responses is to 1) bring phagocytes to the injured area to isolate, destroy and inactivate 
the invaders and/or remove the debris of cell death; 2) prepare subsequent healing. 
 
1.2.2 Cell death, DAMPs and DAMP receptors 
Scientists have been trying to define the classifications of different types of cell death 
since 19th century. The definitions are variable from morphology to immunological 
characteristics. Since 2005, Nomenclature Committee on Cell Death (NCCD)166 has 
been working on unifying criteria for the definition of cell death. Recently, NCCD in 
2015167 classified cell death into two broad categories: accidental cell death and 
regulated cell death (RCD), which contains programmed cell death. In contrary to 
ACD, RCD can be initiated by a genetically encoded molecular machinery, and the 
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course of RCD can be altered by application of specific pharmacologic and/or genetic 
modulations at least to some extent. The types of cell death including apoptosis168-172, 
autophagic cell death173-177, autosis178, necroptosis179-185, mitochondrial permeability 
transition-medicated regulated necrosis186-189, pyroptosis190, parthanatos191 and 
ferroptosis192-194 have been summarised in excellent reviews. 
 
A concept of Danger Model was proposed by Polly Matzinger in 1994195, which 
described that the immune system together with an extended network of other host tissue 
cells is capable of discriminate dangerous signals rather than only distinguishing self 
and non-self.  The dangerous signals can be elicited by pathogens, injured, infected and 
necrotic tissues, or cells under non-physiological death which release dangerous 
molecules with the capability to stimulate pro-inflammation. The Danger Model is the 
fundamental theory of DAMPs and in 2004 the concept of DAMPs was formally 
composed by Seong and Matzinger110. During tissue injury, the intracellular molecules 
or their derivatives are positively (secretion) or negatively released into the extracellular 
space or exposure on the outer leaflet of plasma membrane. The extracellular matrix is 
the source of DAMPs as well. Similar to pathogen-associated molecular patterns 
(PAMPs), DAMPs can elicit and modulate the immune system by effecting on the 
function of antigen-presenting cells (like macrophages and dendritic cells) and other cell 
types (like mast cells and neutrophils).  
 
Up to date, few membrane-bound or cytoplasmic pathogen recognition receptors (PRRs; 
also referred as pattern recognition receptors) have been provide to recognise DAMPs, 
including Toll-like receptors (TLRs), NLR Family Pyrin Domain Containing 3 
(NLPR3), RIG-I-like receptors, receptor for advanced glycation end products and 
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purinergic receptors, which shows that PAMPs and DAMPs share some receptors and 
indicate infection (pathogen-induced) and sterile inflammation have some similarities. 
Sepsis is initiated by the recognition of classical PAMPs via the PRRs196 which may 
induce uncontrolled inflammatory response, immunosuppression and thus successive 
organ failure(s)197. In non-infectious conditions such as during early phase of acute 
pancreatitis, acetaminophen-induced liver injury, myocardial infarction, ischaemia-
reperfusion-induced brain injury and blunt trauma, extensive cell death may occur which 
leads to profound cytokine/chemokines139, 198 and cellular contents release199-201. The 
source of DAMPs is principally from primary and secondary necrotic cell death202, 203, 
a process occurs in apoptotic cells that are not removed by phagocytic cells timely and 
sufficiently. DAMPs can also be recognised by the PRRs and non-PRR receptors 
expressed by the residential immune cells (e.g. macrophages and dendritic cells) to 
initiate pro-inflammatory responses (Figure 1.1 and 1.2)203. Based on the location of 
DAMPs derived from, DAMPs are mainly classified into three groups: extracellular 
matrix, cytosol and organelle, the latter includes mitochondrion, endoplasmic reticulum, 
granule and nucleus. The classification of DAMPs has been summarised in Table 1.2.  
 
1.2.3 Others 
Besides aforementioned themes, coagulation204, microcirculatory205, gut (bacterial 
translation206 or gut-lymph theory207, 208) and two-hit phenomenon209 have been 
proposed to play a role in the pathogenesis of organ failure. In summary, regardless of 
the aetiology, the initial injury has been converted to systemic inflammation, if persists, 
resulting in multiple organ failure. Systemic inflammation and organ failure then further 
promote local injury and immune cells to trigger synchronised RCD, a vicious cycle 
begins (Figure 1.3).    
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Figure 1.1 DAMPs from primary and secondary necrosis that trigger pro-
inflammatory response. Intracellular molecules that are normally hidden in the interior 
of the cells. In stressed conditions, if apoptotic cells are engulfed by phagocytic cells 
timely and efficiently, there will be no discernible immune response from the host; while 
primary necrotic or secondary necrotic cells (uncleared apoptotic cells) release their 
cellular contents which are recognised by DAMP receptors, initiating the pro-
inflammatory response (from Kono et al.203).  
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Figure 1.2 Mechanisms for sterile inflammation triggered by necrotic cells. Primary or secondary necrotic cell death lead to release of cellular 
contents such as DAMPs and intracellular cytokines interleukin (IL)-α and IL-33. DAMPs activate Toll-like receptors (TLRs) and receptor for 
advanced glycation end products (RAGE) to promote inflammation; activation of TLR also primers the generation of IL-1β via NLRP3 (NOD-, LRR- 
and pyrin domain-containing 3); IL-1β, IL-α and IL-33 activate IL-1 receptor (IL-R) to further promote inflammation (from Chen et al.165). 
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Table 1.2 Classification of DAMPs 
DAMPs Cell death modality receptors 
Extracellular matrix 
Fibrinogen - TLR4 
Heparan sulphate 
fragments 
- TLR4 
Hyaluronan - TLR2 and TLR4 
Cytosol 
S100 proteins Necrosis RAGE, TLR4 
Heat shock proteins Apoptosis/secondary 
necrosis and necrosis 
TLR2, TLR4 
IL-1α Necrosis IL-1R 
Galectins Secondary necrosis and 
necrosis 
CD7, CD43, and CD45 
Organelles 
Mitochondrion 
Mitochondrial DNA Necrosis TLR9 
ATP Apoptosis/secondary 
necrosis and necrosis 
P2X7, P2Y2 
N-formyl peptides Necrosis FPR-1 
Cytochrome c Secondary necrosis and 
necrosis 
LPG? 
Cardiolipin Apoptosis ? 
Carbamoyl phosphate 
synthase-1 
? ? 
Endoplasmic reticulum 
Calreticulin Immunogenic apoptotic cell 
death 
CD91 
Granule 
Cathelicidines Necrosis and NETosis TLR7, TLR9 and RAGE 
Myeloperoxidase Necrosis and NETosis ? 
Neutrophil elastase Necrosis and NETosis TLR4? 
Defensins ? TLR4, CCR6 
Nucleus 
High-mobility group box 1 Secondary necrosis and 
necrosis 
RAGE, TLR2, TLR4 and 
TLR9 
DNA Necrosis and NETosis TLR3 
Histone Necrosis and NETosis TLR2, TLR4 and TLR9? 
TLR, Toll-like receptor; RAGE, receptor for advanced glycation endproducts; FPR-1: 
Formyl Peptide receptor 1; LPG: leucine-rich alpha-2-glycoprotein-1; CCR, CC 
chemokine receptors.  
 
 
 
30 
 
 
Figure 1.3 Regulated cell death-induced auto-amplification inflammation loop. 
After the stimulation from primary insults, cells are undergoing accidental (ACD) and 
regulated cell death (RCD). While ACD is currently unmanageable, the initial RCD can 
be blocked or alleviated by specific inhibitor depends on the principle RCD pathway, 
e.g. sanglifehrin A (SfA) and cyclosporin (CsA) are used for targeting mitochondrial 
permeability transition-mediated RCD (MPT-RN); necrostatin-1 (Nec-1), Nec-1s and 
Nec-33 are used for RIPK1-mediated cell death. ACD and uncontrolled RCD results in 
local inflammation, systemic inflammation and multiple organ failure (i.e. shock). 
Systemic inflammation and organ failure in turn acerbate local injury, leading to 
synchronised RCD and subsequent release of more DAMPs (from ref210).  
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1.3 The emerging role of extracellular histones in critical illness  
1.3.1 Extracellular histones are key inflammatory mediators  
Elevated levels of circulating nucleosomes have been observed in acute conditions such 
as organ failure induced by trauma, stroke and sepsis211, and are correlated with disease 
severity212. In 2009, a landmark study by Xu et al.213 identified extracellular histones as 
key inflammatory mediators which caused organ failure and death in animal models of 
sepsis. Thereafter, the mechanisms of how extracellular histones cause tissue injury and 
organ failure begun to be understood.  
 
1.3.2 Histone binding molecules 
In 2010, an elegant study by Pemberton et al. 2010214 has shown that histones 
precipitated a range of proteins include lipoproteins, proteinase inhibitors, competent 
proteins, coagulation factors, immunoglobulins and others in human plasma 
(Supplementary Table 1). Intravenous injection of radiolabelled calf thymus histones 
has been shown to be bound to heparin sulphate in the capillary glycocalyx of the lung 
of rabbit215. Also, absorption of histones have been found on natural polysaccharides, 
especially alginic acid and pectin216. Recently, novel molecules that bind to histones 
have been identified (Supplementary Table 2), these include TLRs (TLR2 and TLR4; 
TLR9 involvement is controversial), C-reactive protein (CRP), recombinant 
thrombomodulin, Mer receptor, αvβ5 integrin, neutralised serum albumin, N-acetyl-
heparin, antithrombin activity depleted heparin, inter-α inhibitor protein, high-
molecular-weight hyaluronan, MBP-p33, pentraxin 3 and C1 esterase inhibitor 
(C1INH). All these data greatly contribute to our understandings of histone 
biodistribution, mechanisms of cytotoxicity and potentially therapeutic targets.  
32 
 
1.3.3 Effects of extracellular histones on different cell types 
The effects of extracellular histones in vitro and ex vivo are summarised in 
Supplementary Table 3. The cytotoxicity extracellular histones have been clearly 
shown in parenchymal, immune and red blood cells. Data collectively suggest that 
extracellular histones (normally ≥ 20 µg/ml) were toxic to these cells via TLR2/4 and 
NLRP3 mediated signalling pathway. At higher concentrations, histones directly 
caused “pore” on cell membrane thus induce calcium influx and subsequent rapid cell 
death. Anti-histone treatment generally significantly reduced histone-induced toxicity. 
 
1.3.4 Release of extracellular histones in animal models of critical illness and 
treatment strategies 
The release of extracellular histones in sepsis (Supplementary Table 4), acute lung injury 
(Supplementary Table 5), acute liver injury (and ischaemia-reperfusion injury including 
stoke, myocardial infraction and renal injury; Supplementary Table 6), acute pancreatitis 
(and peritonitis and glomerulonephritis; Supplementary Table 7) are systematically 
summarised. The local and systemic release of circulating histones and NETs have been 
generally observed. Exogenous administration of non-pathological doses of calf thymus 
histones converted acerbate local injuries in acute lung injury, liver injury and 
pancreatitis models. Moreover, the extent of extracellular histone release correlate with 
proinflammatory cytokines/chemokines, systemic inflammation, organ injury and 
mortality in critical illness murine models. In vivo infusion of fluorescein isothiocyanate 
(FITC)-labeled calf thymus histones (45 mg/kg) revealed that the lung had the highest 
accumulation of FITC intensity, followed by spleen, kidney, plasma, liver, heart and 
brain217. The histone-induced haemostatic dysfunction is summarised in Supplementary 
Table 8. Exogenous administration of pathological doses of calf thymus histones 
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induced thrombocytopenia with elevation of cytokines/chemokines, systemic 
inflammation, multiple organ injury and mortality.  
 
In all these critical illness models, direct anti-histone treatments, such as anti-histone 
antibodies, activated protein C (APC), heparin and heparin derivatives, CRP, albumin, 
etc. reduced local and systemic extracellular histones, alleviated severity and mortality. 
Targeting histone receptors (TLR2, TLR4, NLRP3 and NLRP3 components) or binding 
molecules also hold promises for reducing disease severity.  
 
Now we clearly understand histone-induced cytotoxicity at least in large rely on the 
positively charged amino acids, thus neutralising histones would be an excellent 
strategy. However, to develop novel anti-histone strategies there are much cautions to 
be taken. The most studied anti-histone strategy is anti-histone antibody, but using of 
antibody may lead to autoimmune problems. Heparin may be effective in patients at 
high doses but may put patients at risk of bleeding due to the small therapeutic window. 
CRP, an acute phase protein, reduces histone-induced organ injury, but acute phase 
proteins (i.e. CRP and serum amyloid P) have been shown to delay the clearance of 
nucleosomes218 and core histones219. Polycations also neutralise histones, but 
accumulated polycations lead to lung injury. APC fails to show efficacy in critical illness 
patients. Natural herbal medicine may be a good resource for drug discovery in this 
regard. The natural polysaccharides alginic acid and pectin absorb histones but do not 
bind to other plasma proteins216, minimising the chance of affecting anticoagulation 
proteins.  
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1.3.5 Measurement of circulating histones 
As the toxicities of circulating histones described above, it is clear that determination 
and monitoring of the levels of circulating histones in patients or experimental animals 
can guide clinical therapy and help researches. The current available commercial assay 
for circulating histones is based on enzyme-linked immunosorbent assay (ELISA) 
which only measures histone-DNA complexes. Western blot remains to be the only 
method for the measurement of all circulating histones currently. Western blot is a very 
common and wildly used method which detects the target protein in a reduced and 
denatured condition. Proteins are separated by molecular weight using sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis procedure, followed by transferred to a 
membrane, typically nitrocellulose or polyvinylidene difluoride (PVDF), where they are 
stained with the specific antibody to the target protein. Running with a linear range of 
recombinant target protein (called as standards), we can quantify sample concentration 
using the equation formed by standard concentration and density.  
 
It has been reported that the toxicity of each monomer is different. Histone H4 is the 
most toxic one followed by histone H3. If measured by Western blot, it is impossible to 
determine the exact populations of circulating histones unless doing 5 monomers 
individually, which requesting much more samples and working time. Therefore, a more 
comprehensive, robust and convenient method is required.     
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1.4 Hypotheses of the proposed work 
Nowadays, there is an increasing interest to use circulating nucleosomes in diagnosis 
and prognosis in conditions such as sepsis, stroke and autoimmune diseases as well as 
in the diagnosis, staging, prognosis, and monitoring of therapy in cancer211. In acute 
inflammation condition (i.e. acute pancreatitis), extensive cell death may occur and 
lead to release of chromatin components into the extracellular environment. The 
circulating nucleosomes have marked differences to their breakdown products, 
circulating histones and cell-free DNA220. Circulating histones may present as histone-
DNA complexes, free monomers, or degraded forms. The former has been shown to 
be much less immunogenic than the free histone monomers220. However, the issue of 
whether the degraded histone forms have cytotoxicity have not been systematically 
addressed, nor there are available assay to quantify their circulating levels. Recently, 
release of extracellular histones221 and formation of NETs125 have been observed in 
experimental acute pancreatitis125 and anti-histone antibody rescued mice from death222. 
Furthermore, elevated plasma nucleosomes (histone-DNA complexes) have been 
demonstrated in acute pancreatitis patients, and their levels correlated with disease 
severity125, 223.  
We hypothesised that circulating histones would also elevate in experimental acute 
pancreatitis and correlate with severity parameters. In parallel, we also hypothesised 
that on admission circulating histone levels can predict persistent organ failure and 
may further increase with disease progressing. 
 
We also interested to test whether degraded histone forms still carry cytotoxicity effect 
and we endeavoured to develop an assay to measure all types of circulating histones 
with xMAP technology.  
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Chapter 2 – Toxicity of circulating histones 
 
2.1 Introduction 
 
Histones are a family of alkaline proteins which package and order DNA into structural 
units called nucleosomes (Figure 2.1)224. With the feature of positive charge, core 
histones (histone H2A, H2B, H3 and H4) form an octamer which is wrapped by 147 
base pairs negatively charged DNA225. The histones H3 and H4 form a stable H3-H4 
tetramer, whereas H2A and H2B form two H2A-H2B dimers which are less stable226. 
Histone H1/H5, the linker histone, binds the nucleosome at the entry and exit site of 
DNA, which is essential for regulating DNA de-condensation during transcription and 
post-transcriptional modifications227-231.  
 
In the chapter 1, the extracellular histone-induced cell toxicity and its mechanisms have 
been introduced in details. Circulating nucleosomes released from nuclear chromatin 
during extensive tissue injury and cell death are degraded into individual histones in the 
liver232 where these histones are also rapidly cleared218. These findings demonstrate that 
the monomer histones can be further cleaved or degraded into N or C terminal histones 
after release into circulation. It is also well known that enzymes like activated protein C 
can cleave histones into their truncated forms. Therefore, histones entry into circulation 
as different complexes including degraded circulating histones. However, whether these 
circulating histones possess cytotoxicity remains unknown.  
 
In this chapter, we sought to investigate the cytotoxicity of both monomer and truncated 
histones and further to examine whether anti-histone strategy confers protective effects.   
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Figure 2.1 Structure of core histones and nucleosome. Two pairs of histones H3 and 
H4 form a tetramer which is incorporated by 2 dimers composed by histones H2A and 
H2B to form an octamer. This histone octamer is wrapped up by ~147 bp of DNA to 
form nucleosome. (From reference Chen et al. Cell Death and Diseases 2014199)   
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2.2. Martials and Methods 
2.2.1 Generation of N and C terminal recombinant histones 
2.2.1.1 Sequence design 
Histones H1.1 and H1.4 possess most of the identical amino acids sequence in the 11 
identified H1 isoforms233, 234. H2A and H2B are the most frequent isoforms of their 
respectively categories234. H3.1 is the most ubiquitously expressed among 3 H3 
isoforms (H3.1, H3.2 and H3.3)234. There is only one H4 isoform, the canonical H4234. 
DNA sequences of H1.1, H2A, H2B, H3.1 and H4 were employed as templates. H1.1 
DNA sequence was synthesised by Eurofins MWG Operon and the rest of histone 
plasmids (pHCE-histone) were a gift from Dr Hitoshi Kurumizaka (RIKEN Genomic 
Sciences Centre, Yokohama, Japan). All the sequence design related information for 
truncated histones are summarised (Table 2.1). 
2.2.1.2 Generation of pET-16b-N or C terminal histone plasmid 
Key steps for generating pET-16b-N or C terminal histone plasmid (Figure 2.2):  
A. Amplification of pHCE-histone plasmid: pHCE-H2A, pHCE-H2B, pHCE-H3.1 and 
pHCE-H4 plasmids were amplified by using the Subcloning EfficiencyTM DH5αTM 
Chemically Competent Cells Escherichia coli (Invitrogen, USA). The DH5α 100 µL 
was thaw on ice and 1 µL of each plasmid was immediately added after thawing, 
followed by 20 min incubation on ice. Then a heat shock at 42oC for exactly 45 s was 
applied in water bath and the eppendorf was immediately placed back on ice. The 
eppendorf was supplemented with 250 µL Luria-Bertani (LB) medium and stood for 
20 min to allow the bacteria to recover. Bacteria were incubated at 37oC for 45 min with 
shaking at 200 rpm, and pelleted by spinning at 12,000 × g for 30 s. After removing 150 
µL redundant supernatant, the bacteria were resuspended in the remaining medium and 
spread homogenously on the LB agar plate containing 100 µg/mL ampicillin (pHCE 
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vector is ampicillin resistant). An overnight incubation at 37oC was followed. On the 
second day, a single colony from the agar plate was picked up and cultured in 5 mL 
LB/ampicillin medium in a 15 mL Falcon tube at 37oC and 200 rpm for overnight. On 
the third day, bacteria were harvested by spinning at 3,000 × g for 30 min and plasmids 
were extracted using QIAprep Spin Miniprep Kit (Qiagen, Netherlands) following the 
manufacturer’s protocol and kept in -20oC. 
B. Digestion and purification of histone DNA: the purified pHCE-histone plasmids and 
histone H1.1 synthesised DNA were digested by restriction endonucleases Ndel and 
BamHI (both from New England Biolabs, USA). The each digested mixtures was loaded 
into 1% agarose gel to isolate histone DNA from the vector. The lower bands, histones, 
were cut and extracted using QIAquick Gel Extraction Kit (Qiagen, Netherlands) 
following the manufacturer’s protocol. Histone DNA was eluted in 20 µL H2O and kept 
at -20oC. 
C. Generation of N or C terminal histone DNA: the purified histone DNA and designed 
primers N or C terminal of each histones were used to do polymerase chain reaction 
(PCR) following the manufacturer’s protocol (GoTaq® PCR Core Systems, Promega, 
UK). All of the N or C terminal histone DNA were extracted (1.2% DNA agarose gel 
was used), digested (Ndel and BamHI), purified and stored as before. 
D. Ligation and amplification of pET-16b-N or C terminal histone plasmid: both Ndel 
and BamHI digested pET-16b vector and N or C terminal histone DNA were mixed 
(molar ratio: 1:10) for ligation using the Quick LigationTM Kit (New England Biolabs, 
USA). Then pET-16b-N or C terminal histone plasmid was transformed to the DH5α 
bacteria for the amplification.  
E. DNA sequencing: the purified plasmids were sequenced by Beckman Coulter 
Genomics (Takeley, UK) and all the DNA sequences were 100% marched. 
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Table 2.1 Sequence design information for truncated histones 
Name Gene Bank No. Residues 5’-primer 3’-primer 
H1.1 N ter NM_005325 1-110 CTAGTTATACATATGTCTGAAACAGTGCCTCCCGC TTCTAGGATCCCTAGTTGAGCTTGAAGGAACCCGA 
H1.1 C ter NM_005325 111-214 CTAGTTATACATATGAAGAAGGCGTCCTCCGTGGAA TTCTAGGATCCTACTTTTTCTTGGGTGCCGCTTTC 
H2A N ter NM_003513.2 1-62 CTAGTTATACATATGTCTGGTCGCGGCAAAC CTAGGATCCCTACTCGGCGGTCAGGTACTCAAGC 
H2A C ter NM_003513.2 63-130 CTAGTTATACATATGATCCTGGAGCTGGCGGGCAATG CTAGGATCCCTACTTTCCCTTGG 
H2B N ter NM_021058 1-63 CTAGTTATACATATGCCAGAGCCAGCGAAG CTAGGATCCCTAATTCATGATGCCCATG 
H2B C ter NM_021058 84-126 CTAGTTATACATATGGACATTTTCGAGCGCATC 
 
CTAGGATCCTACTTAGCGCTGGTGTACTT 
 
H3.1 N ter NM_003537.3 1-74 CTAGTTATACATATGGCTCGTACTAAACAG CTAGGATCCTATTCTCGCACCAGGCGCTGGAAC 
H3.1 C ter NM_003537.3 75-136 CTAGTTATACATATGATCGCCCAAGACTTCAAGACC CTAGGATCCTACGCTCTTTCTCC 
H4 N ter NM_003545.3* 1-41 CTAGTTATACATATGGAAACCCGTGGCGTGCTGAA 
 
CTAGGATCCTCATTAACCGCCAAAACCATACAGGGT 
 
H4 C ter NM_003545.3* 51-103 CTAGTTATACATATGATTTATGAAGAAACCCGTG CTCTAGGATCCTCATTAACCGCCAAAACC 
*Mutated from NM_003545.3 (See reference Tanaka et al. Methods 2004235) 
41 
 
 
Figure 2.2 Generation of N or C terminal histone plasmid using recombinant DNA 
technology. The experiment steps involved amplification of pHCE-histone plasmid, 
digestion and purification of histone DNA, generation of N or C terminal histone DNA, 
and ligation and amplification of pET-16b-N or C terminal histone plasmid.  
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2.2.1.3 Expression, extraction and purification of N or C terminal histone proteins 
Purified pET-16b-N or C terminal histone plasmid, extracted from DH5α, was 
transformed into the C41 (DE3) Escherichia coli and cultured on agar plate containing 
100 µg/mL ampicillin (pET-16b vector is ampicillin resistant). Six single colonies were 
respectively cultured in 3 mL LB/ampicillin medium in the 15 mL Falcon tubes at 37oC 
and 200 rpm until the optical density was 0.5 at absorbance of 600 nm. Isopropyl β-D-
1-thiogalactopyranoside (IPTG; Melford, UK) of 1 mM was added into 4 tubes while 
the other 2 tubes without IPTG were used as negative controls. Tubes were incubated 
for another 4 h. The bacteria of 20 µL in each tube were taken to run a sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel to check the expression of 
N or C terminal histone. After confirmation of histone protein expression, 1 L bacteria 
were cultured until the optical density reached 0.5 before adding 1 mM IPTG. After > 4 
h incubation with IPTG, bacteria were harvested by centrifugation at 5,000 × g for 10 
min at room temperature. Bacteria pellets were resuspended in 20 mL Resuspension 
Buffer and kept at -80oC overnight. On the next day, bacteria mixture was disrupted by 
sonication on ice 3 min × 3 at an interval of 3 min. Pellet and supernatant were collected 
by centrifugation at 15,000 × g for 30 min at 4oC. Pellet was resuspended in 20 mL 
Binding Buffer followed by sonication and centrifugation as above again. As the pET-
16b vector contains the Histidine-tag coding sequences, the expressed N or C terminal 
histone was purified by the Histidine-tag/Nikeli-Nitrilotriacetic acid (Ni-NTA) system 
(Qiagen, USA) and assessed by 15% SDS-PAGE gel. First, 1.5 mL Ni-NAT Agarose 
resin (Qiagen, USA) was poured into a 10 mL purification column. Allow the resin to 
settle completely by gravity, followed by a wash step with 50 mL H2O. Equipment Ni-
NAT Agarose with 100 mL Resuspension Buffer, then resin was settled by gravity at 
room temperature. The second supernatant was added into column and passed through 
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by gravity. Then column was washed with 200 mL Wash Buffer. The wash through was 
collected for later check. Expressed protein was eluted in 20 mL Elution Buffer. All the 
steps were performed at 4oC by gravity. Elute was transferred into the dialysis bag with 
a cut-off 3.5 kD (Spectrum Labs, USA) and dialysed against urea in 2 L Dialysis Buffer 
for overnight at 4oC (change buffer twice). The pass through, wash through and elution 
dialysis (10 µL per each collection) was removed for 15% SDS-PAGE gel and 
Coomassie Brilliant Blue staining. The buffer recipes during this process are 
summarised in Table 2.2.   
Table 2.2 Buffer recipes for expression, extraction and purification of histone proteins 
Buffer Chemicals  
Resuspension Buffer 150 mM Tris-HCl (pH 7.4) + 50 mM NaCl, 1 mM PMSF 
(add freshly) 
Binding Buffer Resuspension Buffer + 6 M Urea 
Wash Buffer 20 mM Tris-HCl (pH 7.4)  + 200 mM NaCl + 50 mM 
imidazole + 3 M urea 
Elution Buffer 20 mM Tris-HCl (pH 7.4) + 200 mM NaCl + 250 mM 
imidazole + 3 M urea 
Dialysis Buffer 20 mM Tris-HCl (pH 7.4) + 200 mM NaCl + 5% 
glycerol  
Tris-HCl, Tris(hydroxymethyl)aminomethane hydrochloride; PMSF, phenylmethane 
sulfonyl fluoride. 
 
2.2.2 Generation of pan anti-histone ahscFv and cscFv  
The anti-histone single chain variable fragment (ahscFv) and its control single chain 
variable fragment (cscFv) were generated by using the recombinant DNA technology. 
Their primers were listed (Table 2.3). The details of pan anti-histone ahscFv and cscFv 
establishment was described in Dr Dunhao Su’s PhD thesis entitled “Production, 
Characterisation and Application of Humanised Anti-Histone Antibodies in Critical 
Illness” which is available at University of Liverpool library. In brief, ahscFv was 
designed on the basis of complementarity-determining regions (CDRs) of anti-histone 
antibodies from human with autoimmune disorders. For the development of cscFv, the 
CDRs were changed but the rest of sequence of ahscFv was kept. Gene sequences 
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pCR2.1-ahscFv and pCR2.1-cscFv were synthesised and verified by Eurofins MWG 
Operon. The function and affinity of ahscFv and cscFv were determined by Western 
blot and biosensor, respectively.  
Table 2.3 The primers for ahscFv and cscFv  
Name 5’-primer 3’-primer 
ahscFv ATGGATTCACCATATGGAA
ATTCAGCT 
TGGCAAGCGGATCCCTAAT
TATT 
cscFv ATGGATTCACATATGGAAA
AC 
TGGCAAGCGGATCCTTACT
GGCA 
 
2.2.3. Cytotoxicity of histones towards endothelium cells 
2.2.3.1 Membrane binding  
Human endothelial cell line EA.hy926 were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 20% Fetal Calf Serum (FCS). Both human 
recombinant histone subclasses (New England Biolabs, USA) and house generated 
truncated histones were conjugated with fluorescein isothiocyanate (FITC, Invitrogen, 
USA) following the manufacturer’s protocol. Cells of 5 × 105 were incubated with 10 
µg/mL FITC-histone for 10 min followed by membrane binding observation using 
confocal microscope (Zeiss LSM510 system, Carl Zeiss Jena GmbH, Germany).  
2.2.3.2 Calcium influx 
Each histone and trauncated histone-induced calcium influx was reflected as the 
increase of intracellular calcium concentration ([Ca2+]i). Cells were loaded with 3 μM 
Fura-2AM for 20 min and washed with Calcium Assay Buffer (pH 7.4) containing 20 
mM Hepes, 120 mM NaCl, 4.7 mM KH2PO4, 1.2 mM MgCl, 1.25 mM CaCl2, and 10 
mM glucose. The Fura-2AM was monitored continuously by a F-7000 fluorescence 
spectrometer (Hitachi, Japan) at excitation 340 nm and 380 nm and emission at 510 nm 
as previous decribled236. The [Ca2+]i was calculated using the software provided.  
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2.2.3.3 Cell viability 
Full length, truncated and calf thymus histones as well as serum from acute critical 
illenss patients (ethical approval obtained) were used.  EA.hy926 cells of 1 × 106 were 
seeded and treated with different types of histone (each 20 µg/mL) or serum. After fixed 
in 70% ethanol for 30 min at -20oC, the cell viablity was determined by flow cytometry 
(BD Biosciences, USA) using 10 µg/mL propidium iodide (PI) staining. Viable cells 
have intacted nuclei with a distinct diploid DNA peak (2N), while damaged nuclei cells 
have a broad peak of hypodiploid particles (< 2N).  
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2.3 Results 
2.3.1 Generation of truncated histones 
Eight out of 10 truncated histones were successfully generated by using the recombinant 
DNA technology (Table 2.4), while histone H2B C ter and H4 N ter were synthesised 
peptides (Figure 2.3). The purity of all truncated histones were 75.6-95.1% measured 
by the histogram density, except histone H2A C (35.5%). 
Table 2.4 Expression and purity of truncated histones 
Name Predicted WM (Da) Actual WM (Da) Purity (%) Storage Buffer 
His10-H1.1 N ter 10893 13072 90.6 Tris-HCl 
H1.1 C ter- His10 10835 14551 80.1 Tris-HCl 
His10-H2A N ter 6512 8436 95.1 Tris-HCl 
H2A C ter- His10 7509 8489 35.5 Tris-HCl 
His10-H2B N ter 6958 9004 92.7 Tris-HCl 
H2B C ter peptide 4617 6710 83 H2O:ACN = 5:1 
His10-H3.1 N ter 8266 9733 90.8 Tris-HCl 
H3.1 C ter- His10 7024 7912 75.6 Tris-HCl 
H4 N ter peptide 4264 7155 94.4 H2O 
H4 C ter- His10 6065 7284 79 Tris-HCl 
His6, Hexahistidine; Tris-HCl, Tris(hydroxymethyl)aminomethane hydrochloride; 
ACN, acetonitrile.     
                                                                              
 
Figure 2.3 Expression and purity of truncated histones. Except histone H2B C and 
H4 N, all truncated histones were expressed by E. Coli using the recombinant DNA 
technology. Histone H2B C and H4 N were synthesised peptides. Each histone protein 
(5 µg) was loaded in 18% SDS-PAGE gel and stained by Coomassie Brilliant Blue. N, 
N-terminal; C, C-terminal. 
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2.3.2 Generation of ahscFv and cscFv 
The molecular weight of expressed ahscFv and cscFv were 27 and 29 kDa respectively, 
measured by Coomassie Brilliant Blue and their purity were > 95% (Figure 2.4A). Both 
of them were stored in PBS (+ 5% glycerol). The western blot revealed ahscFv bound 
to histone H1 and H3 while cscFv did not (Figure 2.4B and C). The ahscFv successfully 
recognised all the human recombinant histone subclasses and calf thymus histones, as 
demonstrated by western blot (Figure 2.5A) and biosensor analyses (Figure 2.5B). The 
western blot demonstrated that ahscFv had higher band density with H1, H2B and H4, 
followed by H3 and H2A. The biosensor assay showed similar results, albeit a strongest 
binding of ahscFv to H3 was observed.   
 
Figure 2.4 ahscFv and cscFv expression and their histone binding capacity. ahscFv 
and cscFv (each 5 µg) were loaded in 15% SDS-PAGE gel. (A) Stained by Coomassie 
Brilliant Blue; Probed by (B) Biotin-histone H1, or (C) H3, and streptavidin-HRP after 
membrane transfer shows that only ahscFv bound but cscFv did not. HRP, horseradish 
peroxidase. 
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           A 
             
             B 
           
Figure 2.5 ahscFv recognises all the monomer histones. (A) The binding between 
ahscFv and histones was confirmed by western blot: recombinant histones (5 µg of each) 
and calf thymus histones (ctHistones, 25 µg) were loaded and transferred to PVDF 
membrane, then probed by HRP conjugated ahscFv; (B) The binding of recombinant 
human histone subclasses (each 1 μM concentration) to ahscFv was determined by 
IAsys resonant biosensor, in which the ahscFv was immobilised on aminosilane surfaces 
using BS3.  
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2.3.3 Histones bind to cell membrane and induce calcium influx 
The detailed membrane binding by full length and truncated histones in EA.hy926 cells 
are shown in Table 2.5 and an example is shown in Figure 2.6. All the FITC-full length 
histones and 3 FITC-truncated histones (H1.1 C, H2A N, H3.1 N) bound to the cell 
membrane. All the remaining tested FITC-truncated histones were not shown to bind 
cell membrane. 
Table 2.5 Histone membrane binding in EA.hy926 cells 
 H1 H2A H2B H3.1 H4 
Histone F N C F N C F N C F N C F N C 
Binding + - + + + - + - - + + - + - - 
F, full length; N, N-terminal; C, C-terminal.  
 
  
Figure 2.6. Membrane binding of histone in endothelial cells. (A) Confocal images 
of EA.hy926 cells 10 minutes after incubation with FITC–labelled histones (10 µg/ml) 
alone (arrows indicate FITC-labeled histones). (B) FITC-labelled histones preincubated 
with ahscFv (100 µg/ml). Scale bar: 20 mm. FITC, fluorescein isothiocyanate. 
 
 
 
50 
 
The calcium influx induction by full length and truncated histones in EA.hy926 cells are 
shown in Figure 2.7. The full length and truncated histones which bound to cell 
membrane also dramatically induced calcium influx as determined by increased [Ca2+]i. 
The histone H4 induced highest [Ca2+]i (H4 > H2A N > H3.1 > H2A > H2B > H1.1 C 
> H1 > H3.1 N).  
 
Figure 2.7 Histones induce calcium influx. FITC-labelled histones (each 20 µg/ml) 
were used to determine histone membrane binding in EA.hy926 cells; Intracellular 
calcium concentration ([Ca2+]i) was measured by confocal microscopy using fluorescent 
dye Fluo-2AM. *P < 0.01 when compared to the untreated (UT) group, Student’s t test. 
Black, full length histone; Blue, histone N terminal; Red, histone C terminal. 
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2.3.4 Histones induce cytotoxicity  
The histone-induced cell viability changes in EA.hy926 cells are demonstrated in Figure 
2.8. In line with the findings with cell membrane binding and calcium influx profile, all 
full length and 3 truncated histones (H1.1 C, H2A N, H3.1 N) also significantly induced 
cell death (reflected by PI uptake) when each of them (20 µg/mL) were incubated with 
cells for 1 h. The other truncated histones did not have discernible effects on cell 
viability.  
 
Figure 2.8 Histones induce cytotoxicity. Histone-induced cytotoxicity in EA.hy926 
cells were measured by cell uptake of propidium iodide. Each full length and truncated 
histones (20 µg/mL) was incubated with the cells for 1 h before testing cell viability *P 
< 0.05 when compared to the untreated (UT) group, Student’s t test. Black, full length 
histone; Blue, histone N terminal; Red, histone C terminal. 
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2.3.5 ahscFv prevents against histone-induced cytotoxicity  
The cell viability of EA.hy926 cells treated by calf thymus histones or sera from acute 
critical illness and the effects of ahscFv are shown in Figure 2.9. The cell viability was 
nearly halved after incubated with histones (20 µg/mL) for 1 h. The histone-induced 
reduction of cell viability was significantly improved by co-administration of ahscFv 
(200 µg/mL). Sera from acute critical illness (all had histone levels > 50 µg/mL) also 
caused markedly decrease of cell viability which was elevated by adding ahscFv.    
 
 
Figure 2.9 ahscFv prevents against histone-induced cytotoxicity. Histone-induced 
cytotoxicity and the effects of ahscFv and cscFv (each 200 µg/mL) in EA.hy926 cells 
were measured by cell uptake of propidium iodide. *P < 0.05 when compared to the 
untreated group or cscFv group; †P < 0.05 when compared to the respective serum 
treated group or serum + cscFv treated group per each disease category, Student’s t test. 
ctHistones, calf thymus histones.  
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2.4 Discussion  
In order to elaborate with current research frontiers about the toxticity of circulating 
nucelosomes211 and histones199, in this chapter, we endeavoured to generate truncated 
histones that mimicking circulating degradated histones and further systematically 
assessed  the effects of full length and truncated hisotones on cell membrane binding, 
calcium influx and thus the cytoxticity. To our knowledage, this is the first time to 
generate 8 truncated histones (H1.1 N, H1.1 C, H2A N, H2A C, H2B N, H3.1 N, H3.1 
C, H4 C) using recombinant DNA technology. However, we did not succeed in 
generatering H2B C and H4 N, thus the syntheic peptides of them were used for 
subsequent experiments. All 10 tuncated histones were confirmed by the protein dye 
Coomassie Brilliant Blue which showed the respective molecular weight of individual 
histone on the SDS-PAGE gel.  
 
Consistent with existing literature, we found that all the full length histones bound to 
cell membrane, induced calcium influx and reduced cell viability. Histone H4 induced 
highest [Ca2+]i, which was followed by H3, other core histones and the linker histone. 
These data provide quantitative evidence that at least partially explained why H4 and 
H3 are the most toxic monomer histones. This phenomena actually fits into the sequence 
of how individual histones are released during cell injury: H1 releases first, then H2A 
and H2B, followed by H3 and finally H4. The latter two histones form the most stable 
nuceolsome core237. Whether the histone releasing sequence correlates with the toxticity 
of individual histones warrants further investigation. Adding to the above findings, we 
also unravelled that 3 truncated histones (H1.1 C, H2A N, H3.1 N) possessing 
membrane binding capacity and thus was able to induce calcium influx. In line with this, 
the cell viability was greatly reduced by these truncated histones compared to the 
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untreated group or treated by other truncated histones (H1.1 N, H2A C, H2B N, H2B C, 
H3.1 C, H4 N, H4 C). The lesser cell toticity of the other truncated histones may be 
explained by that none of these histone bound to cell membrane nor induced calcium 
influx. These novel findings highlight the importance of circulating histones as 
inflammatory mediators as they are still toxic even when degraded. The translational 
value of these findings are also paramount: (1) developing an assay to determine the 
ciruclating histone levels has great clincial prospective; (2) degradation of circulating 
histones may not completely remove the toxticity (e.g. by activated protein C). This 
translational aspect will be further discussed in the chapter 7, the overview chapter.    
 
In parallel, we also generated pan ahscFv for antagonising the toxticity of cirulating 
histones. The ahscFv and its control were confirmed by protein dye of their respective 
molecular weight. The binding capacity of ahscFv was ascertained by the probed biotin-
histones, while the cscFv did not bind to any histones. Furthermore, the pan ahscFv 
identified calf thymus histones and all the 5 monomer histones with a highest binding 
afinity to H3, followed by H1, H4, H2B and H2A. The ahscFv nearly restored histone-
induced decrease of cell viability by either calf thymus histones or circulating histones 
containing serum from critical illness patients. Further humanisation of ahscFv may 
have clinical applicability for diseases in which circulating histones play an important 
role.    
 
Other attempts of neutralising histone action should be centred around the molecular 
mechanisms of histone toxicity. It is known that polycations are able to form pores in 
lipids238, yet according to other reports polycations may use specific transmembrane 
channels239 or rely on intracellular signalling molecules239, 240. In several cell types the 
55 
 
cytotoxicity of histones was sensitive to lanthanoids, okadaic acid and genistein241, 
which points to certain specificity in the mechanism of membrane permeabilisation. If 
indeed histones open some endogenous large-pore channels, leading to loss of cytosolic 
constituents, then the candidate list of such channels is about 8-9 member long242 and 
includes P2X7R, transient Receptor Potential channels (TRPA1 and TRPV1), maxi 
anion, plasma voltage dependent anion-selective (VDAC), connexin hemichannel, 
pannexin hemichannel and maitotoxin-induced pore. Some of these channels (like Pnx1 
and P2X7 or maitotoxin- and P2X7, etc.) can work in synergy. P2X7 opening is often a 
part of anti-microbial response, so that some antimicrobial peptides (such as cathelicidin 
LL37243, 244 and human neutrophil peptide-1245) can activate this receptor (although it 
seems that LL37 and defensins may also form pores themselves242). LL37 is a positively 
charged peptide (charge +6, 30 amino acids), and human neutrophil peptide-1 (known 
also as alpha-defensin) is slightly charged (+3, 30 amino acids). Histone H4 is also a 
major anti-microbial agent246, and fetuin-A (structurally related to cathelicidin LL37) is 
known to complex with H2A247. Histone H2A has strong antimicrobial properties 
itself248. P2X7 opening can be amplified by positively charged antibiotic polymixin B
249. 
It was suggested that P2X7 pore may be the same as maitotoxin-activated cationic 
channel250-252. Paradoxically, histones H3 and H2B, inhibit perforin- or toxin-mediated 
cell lysis253, 254. As for pannexins, both histone-induced membrane permeabilisation and 
pannexin1 conductance are inhibited by La3+/Gd3+, while connexins are well known 
to be sensitive to okadaic acid, just like histone-induced cell death241.   
 
Thus, testing whether any “professional” large-conductance channels play a role in 
histone-induced toxicity warrants further investigation.  As many of these channels have 
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specific inhibitors, it may be justified to use such inhibitors in conditions of elevated 
plasma histones alone or in combination with anti-histone strategies.  
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Chapter 3 – Develop a rapid, robust and comprehensive assay to monitor the 
toxic histones in circulation 
 
 
3.1 Introduction 
3.1.1 Toxicity of circulating histones 
Extensive cell death occurs in the acute phase of many human diseases and is a common 
feature observed in many critically ill patients210, 255, 256. However, the contribution of 
this process to the overall progression of the disease has been overlooked until recently. 
During the cell death, nuclear breakdown products, particularly histones which is one 
of the damage-associated molecular pattern molecules (DAMPs)199, are released into 
the circulation and are rarely detectable unless there is extensive cell death, due to rapid 
hepatic clearance218. Recently, extracellular histones have been shown to induce 
endothelial damage, cytokine elevation, platelet aggregation and coagulation activation 
in vitro and mortality in mouse models199. The toxicity of circulating histones is 
described in the chapter 1. In chapter 2, we systematically investigated the toxicity of 
circulating histones in details with a focus on truncated histones (mimicking degraded 
circulating histones). Despite realising the importance of measuring circulating histones, 
there is no rapid, robust and comprehensive assay to detect the levels of toxic histones. 
 
3.1.2 History and principle of xMAP technology 
3.1.2.1 History  
xMAP technology is a microsphere-based immunofluorescence assay. This assay 
composed of flow cytometer and fluorescence. In 1977, Horan and colleagues257 
reported the first use of flow cytometry for analysis of microsphere-based 
immunoassays. Because of the ability to distinguish different particles by size and 
colour, flow cytometer possesses the ability of multiplexed analysis with different 
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microsphere populations. In the last decade, Luminex Corporation developed a more 
comprehensive platform by merging flow cytometer with fluorescence, namely 
FlowMetrixTM which performs multiplexed measurement of up to 64 analytes 
simultaneously258. Later, xMAP technology, with measurement of up to 500 analytes, 
has been updated (xMAP® Technology Technical Note 2010).  
3.1.2.2 The workflow of xMAP technology 
xMAP technology contains of sets of carboxylated microspheres which stained with two 
dyes, red (> 650 nm) and orange (585 nm). The polystyrene microsphere has a diameter 
of 5.6 µm and bears carboxylate functional group on the surface. Therefore, any amine-
containing molecules including antibodies can virtually bind to the microspheres 
respectively via a two-step carbodiimide reaction. Each microsphere has a sufficient 
surface for coupling 1-2 × 106 molecules. Luminex Corp provides 500 distinct sets of 
microspheres which can be classified by the unique orange/red emission profile of each 
set excited by laser. The size of different set of microspheres is uniformed and can be 
identified by the 90-degree light scatter, also called side-scatter gate, to make sure only 
the uniform single particles are classified.  Microsphere aggregations and other particles 
within the samples are eliminated. For identification of different bead sets, the feature 
of the varying amounts of proprietary two dyes emitting fluorochromes allows the 
classification of the individual sets of microspheres. Using the size and orange/red 
colour, the xMAP can count the amount of microspheres in different bead sets. Except 
the orange/red colours, green colour is applied for counting the events captured by the 
molecules bound to the microspheres. A green colour dye conjugated antibodies, 
normally Streptavidin-Phycoerythrin (PE), are used. The emission wavelength from 
microspheres and streptavidin-PE are received and converted into electrical signals by 
photomultiplier tubes (PMT), then are digitalised, converted and displayed as 
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fluorescence intensities (FI). The xMAP quantitates the green, orange and red 
fluorescence of each microsphere using the FL1, FL2 and FL3 detectors, respectively. 
All the data are collected by the software and analysed based on the internal standards. 
The workflow is shown in the Figure 3.1. 
3.1.2.3 The advantages of xMAP technology 
xMAP technology is considered as an alternative to enzyme-linked immunosorbent 
assay (ELISA). The comparison between them in different analytes, samples time and 
costing are summarised in Table 3.1258-260. The principal advantage of xMAP 
technology is the multiplexing capability. ELISA immobilises the capture antibody in 
the surface of microplate well consequently only one analyte can be detected in one kit. 
Conversely, xMAP technology immobilises antibody on the surface of microsphere, 
allowing researchers to pool different sets of microspheres into a well for multiplexing 
analytes testing. Furthermore, a virtue of the suspended microspheres provides a smaller 
surface area compared to a microplate well, which requiring small sample volume and 
reducing non-specific binding. Different from ELISA replying on enzyme-mediated 
amplification of signal, xMAP technology utilises the fluorescence which is more direct, 
stable and sensitive. Therefore, less volume of sample is required. This character of 
xMAP assay is essential when working with limited samples (like paediatric samples, 
cerebrospinal fluid, synovial fluid, mouse serum, etc.). As all the interested analytes are 
measured in one go, xMAP assay avoids sample frozen-thaw cycles as well. 
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Figure 3.1 The workflow of xMAP technology. (The xMAP workflow is summerised based on references Fulton et al. Clinical Chemistry 1997258 
and Vignali Journal of Immunological Methods 2000259) 
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Table 3.1 Advantages of xMAP technology compared to ELISA 
 xMAP Technology ELISA 
Number of analytes 10 10 
Number of 96-well plates 1 10 
Total sample volume 12.5-25 µL > 250 µL 
Total time required  3 hours > 30 hours 
Assay range 5 to 6 logs dynamic range 3 to 4 logs dynamic range 
Cost < £2,000 > £3,000 
 
 
3.1.2.4 Why choose this method 
After cell death, histones are released into the circulation, decondensed and degraded 
into dimers (H3/H4 and H2A/H2B), monomer (H1, H2A, H2B, H3 and H4) and 
truncated histones (N and C terminal of each histone)232. In the previous chapters and 
our previous studies, the toxicity of extracellular histones has been proved both in vitro 
and in vivo. Therefore, a multiplexing assay is required to monitor the levels of histones 
and provide the guidance to clinicians.  
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3.2 Martials and Methods 
3.2.1 Separation and storage of samples 
Peripheral blood was collected into S-Monovette sodium citrate 10 mL tube (Sarstedt, 
Germany) from patients and healthy donors after consenting and with the ethical 
approval (Liverpool Ethics Committee). Blood was separated by spinning at 2,600 × g 
for 20 mins at 4oC for 20 min with break off. Plasma was removed without disturbing 
the white layer and kept at -80oC till using.  
 
3.2.2 Multiplexing assay 
3.2.2.1 Carbodiimide coupling 
To determine the affinity of anti-histone single chain variable fragments (ahscFv), 
detection antibody and the specificities of the capture antibodies, the immobilised 
individual histones were utilised. Also, the capture antibodies were coupled to the 
microspheres to make the “capture sandwich” assay. The coupling protocol is below. 
 
Five regions (33, 34, 35, 36 and 37) of Luminex MagPlex microspheres were brought 
from Luminex Corporation (USA). Each microsphere of 200 µL were added into 1.5 
mL reaction tube (Protein Lobind, Eppendorf, Germany). Microspheres were fixed by 
placed in the magnetic separator for 30 s and liquid was removed carefully. 
Microspheres were washed twice with 200 µL of Activation Buffer (100 mM Na2HPO4, 
Ph 6.2) and incubated in 80 µL Activation Buffer plus 10 µL Sulfo-NHS (50 mg/mL; 
Pierce, USA) and 10 µL EDC (50 mg/mL; Pierce, USA) for 20 min, 650 rpm, at room 
temperature on a roll mixer in the dark. Then activated microspheres were washed three 
times with 500 µL Coupling Buffer (50 mM MES hydrate, Ph 5.0; Pierce, USA). Buffer 
was removed from last wash. Histone antibodies (each 5 µg) or designed concentrations 
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of histones in 250 µL Coupling Buffer was mixed with microspheres.  The mixture was 
incubated 2 h, 650 rpm at room temperature on a roll mixer in dark. Microspheres were 
washed three times with 500 µL Wash Buffer and resuspended in 100 µL Block Store 
Buffer, then stored at 4oC protecting from the light. Buffer recipes are summarised in 
Table 3.2. Anti-histone antibodies are summarised in Table 3.3. 
 
Table 3.2 Buffer recipes of carbodiimide coupling 
Buffer Chemicals  Company 
Activation Buffer 100 mM Na2HPO4, pH 6.2 Sigma, UK 
Coupling Buffer 50 mM MES hydrate, pH 5.0 Pierce, USA 
Wash Buffer PBS + 0.05% Tween20 Sigma, UK 
Block Store Buffer  PBS + 1% BSA Sigma, UK 
PBS, phosphate buffered saline; BSA, bovine serum albumin. 
 
 
Table 3.3 Anti-histone capture antibody list 
Antibody Antigen Catalogue  Company 
Anti-histone H1.0 Human histone H1.0 N ter SAB401366 Sigma, UK 
Anti-histone H2A Human histone H2A C ter L88A6 Cell Signalling, UK 
Anti-histone H2B Human histone H2B C ter Ab1790 Abcam, UK 
Anti-histone H3.1 Human histone H3.1 N ter H9289 Sigma, UK 
Anti-histone H4 Human histone H4 N ter Ab70701 Abcam, UK 
 
3.2.2.2 Microspheres recovery counting 
After coupling procedure, the microspheres recovery counting is necessary. The stock 
microsphere was vortexed thoroughly for 20 s. Took 2 µL from the stock and mixed 
with 998 µL Wash Buffer in a 1.5 mL Eppendorf tube. The tube was vortexed for 1 min. 
Microspheres solution of 100 µL per well was transferred into a 96-well filter plate 
(Millipore, UK). Plate was placed on a shaker for 10 min, 900 rpm at room temperature 
before applying to the Bio-Rad Mutilplex plate reader (USA). Bio-Rad 200 was used to 
count microspheres. Parameters were set as Sample Size: 50 µL, Time Out: 80 s, Total 
Beads: 10,000. The number of microspheres in the bead stock was calculated as: Beads 
per µL stock = counted beads × dilution factor / 30. 
64 
 
3.2.2.3 Biotinylation of antibodies 
The ratio of biotin and detection antibody in molar is essential. Ideally, 20 or 50-fold of 
biotin are used in the biotinylation procedure in many literatures. A 20-fold of biotin 
was used in this protocol and the mass of biotin was calculated based on the molecular 
weight of itself and the antibody, M (Sulfo-NHS-LC-LC-Biotin, Pierce):  670 Da (670 
g/mol), M (anti-histone antibodies): 150 kDa (150,000 g/mol), M (ahscFv): 27 kDa 
(27,000 g/mol). Sulfo-NHS-LC-LC-Biotin was dissolved in PBS and calculated volume 
was incubated with detection antibody in PBS for 2 h on ice. The excessed biotin was 
removed by the desalt column (Pierce, USA). The concentration of biotinylated 
antibody was adjusted to 250 µg/mL by addition of glycerol and stored at -20oC.  
3.2.2.4 ahscFv dose optimisation   
The 5 different sets of histone coupled microspheres were pooled (20,000 beads per 
region). 96-well filter plate was blocked with 100 µL Blocking Store Buffer per well for 
10 min at room temperature. Buffer was removed by vacuum filtration (Bio-Rad, USA). 
Pooled microspheres of 25 µL was added in each well. Microspheres solution was 
removed as before. Biotinylated detection antibody (30 µL) was added as: 0, 0.1, 0.5, 
2.5, 12.5, 25 µg/mL. Plate was incubated for 1 h, 650 rpm at room temperature and 
washed three times with 100 µL Wash Buffer. Streptavidin-PE (2 µg/mL in Block Store 
Buffer; BioLegend, UK) of 30 µL was added per well and incubated for 30 min in the 
same condition. Microspheres were washed as before and resuspended in 100 µL Assay 
Buffer. Before reading, shake plate for 1 min at 900 rpm. Set parameters as before and 
gate between 7,500 – 15,000.  
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3.2.2.5 Check the specificity of capture antibodies 
Five regions of histone coupled microspheres and biotinylated anti-histone antibody (0, 
5, 15, 20 and 25 µg/mL) were used to check the specificity. Please see the protocol in 
3.2.2.4 section.  
3.2.2.6 Create single-plex of each histone and multiplex in pure system 
Five specific antibodies were confirmed in the 3.3.2.5 section and coupled to 5 different 
regions of microspheres respectively. All the regions were counted and the desired 
mount of each region was diluted to 400 beads/µL. ahscFv was biotinylated 
(concentration of stock: 125 µg/mL). After blocking the 96-well filter plate, for the 
singleplex, 25 µL of beads (1000 beads per well) and 25 µL of recombinant individual 
histone (three-fold serial dilution: 30 µg/mL to 0.12 µg/mL in Block Store Buffer and 
blank) were added. Plate was incubated for 2 h, 650 rpm and at room temperature and 
washed with Wash Buffer 100 µL × 3. Then incubated with 30 µL of ahscFv-biotin (25 
µg/mL) for 1 h, 650 rpm and at room temperature. Plate was washed as before and 
incubated with 30 µL of streptavidin-PE (2 µg/mL) for 30 min, 650 rpm at room 
temperature. Plate was washed as before and beads were resuspended in 100 µL of 
Block Store Buffer (plus 0.05% Tween20). Plate was shaken for 1 min at 900 rpm before 
reading. For the multiplex, 5 regions of beads were pooled, 1000 beads per region per 
well. Five recombinant histones were mixed and diluted serially. Concentration 
calculated per histone was as the same as the singleplex. The rest steps were as the same 
as the singleplex. 
3.2.2.7 Standard curve recovery and sample dilution ratio 
The effect of different matrix is essential in immunoassay: the standard curve is 
normally shifted in serum or plasma compared to the buffer pure system. Therefore, we 
used normal human plasma as a matrix to optimise the standard curve. The ratio between 
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plasma and buffer is 1:5. We spiked the plasma/buffer with a serial concentration of 
histones. Because of the proteases in plasma, the cocktail protease inhibitors (Roche, 
Germany), d-phenylalanyl-l-prolyl-l-arginyl chloromethylketone (PPACK; Merck, 
Germany) and ethylenediaminetetraacetic acid (EDTA) were added to protect the 
clotting and protein degradation. The ratio of sample dilution was detected. 
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3.3 Results 
3.3.1 The optimum dose of ahscFv to individual histones 
The ahscFv at all different concentration can bind to the individual histones but it 
appeared that the binding to histone H4 and H3 were higher than H1, H2A and H2B as 
reflected by mean FI (MFI) values. The binding of biotinylated ahscFv to detect the 
immobilised histones was concentration dependent with a dose of 25 µg/mL nearly 
reach plateau for all the histones (Figure 3.2).  
 
 
 
 
Figure 3.2 The optimum dose of ahscFv to individual histones. Different 
concentrations of biotinylated ahscFv were used to detect the immobilised histones. 
ahscFv can bind to all the individual histones but it has higher affinity to histone H4 
and H3, while lower affinity to H1, H2A and H2B. The optimal concentration of 
ahscFv was 25 µg/mL. 
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3.3.2 All the capture antibodies are specific to the target histones 
The specificities of all the capture antibodies were determined by the immobilised 
histones. Individual histones were coupled to different region of microspheres and the 
capture antibodies were conjugated with biotin (biotinylated). Each capture antibody 
was incubated with mixed histone coupled microspheres. Each capture antibody showed 
dose-dependent binding signal to the target histone, while had minimum cross reaction 
with other histones (Figure 3.3). 
 
3.3.3 Measuring individual histones in Singleplex and Multiplex  
Each capture antibody was coupled to different region of microsphere and the beads 
counting are shown in Table 3.4. Each histone was detected both in Singleplex and 
Multiplex (Figure 3.4). The MFI values in both Singleplex and Multiplex of histones 
H2A, H2B and H3 were constant, implying these 3 antibodies did not have cross-
reaction or interference in Multiplex compared to Singleplex. However, MFI values in 
Multiplex of histones H1 and H4 were higher than that in Singleplex. 
Table 3.4 Beads counting of couple histone antibodies  
Antibody Region Beads count_1 Beads count_2 Average Beads/µl 
H1 33 898 719 808.5 6738 
H2A 34 749 712 730.5 6088 
H2B 35 791 770 780.5 6504 
H3 36 768 743 755.5 6296 
H4 37 1044 1059 1051.5 8763 
Beads per µL stock = Average × 500/ 30. Dilution factor was 1:500.  
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Figure 3.3 Effects of detection antibodies to target histones. Each histone (5 µg) was 
immobilised to different region of beads. To determine the specificity of each capture 
antibody, different concentrations of biotinylated antibody (0, 0.1, 0.5 and 2.5 µg/mL) 
were incubated with the mixture of immobilised histones. Graphs A-E indicate the 
specificities of the 5 detection antibodies. 
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Figure 3.4 Individual histones were measured in Singleplex and Multiplex assays. 
Graphs A-E depict measured individual histone concentration.  Except histones H1 and 
H4, the MFI values in Singleplex and Multiplex assays were similar in histones H2A, 
H2B and H3, indicating the specificity of these three capture antibodies. The MFI values 
of Multiplex were higher than those of Singleplex both in H1 and H4, indicating these 
two capture antibodies might have cross reaction between histones.  
 
71 
 
3.3.4 Histone detection is dramatically masked by normal human plasma 
Generally, it is better to dilute patient plasma at least 1:5 to avoid the plasma interference 
to the antibody and the sample clotting. As a result, we tried to optimise the matrix 
effects by using addition of normal human plasma in PBS (+ 1% BSA) Buffer (1:5 v/v) 
after creating the standard curves in the Buffer. The MFI values for all histones 
decreased in the spiked plasma when compared to those in the Buffer (Figure 3.5). 
 
3.3.5 Optimisation of matrix effects according to standard curves 
As the depression of plasma to histone detection, we tried to optimise the measurement 
by adjusting detergent volume, salt concentration, pH value, temperature, incubation 
time, denature reagents and acid precipitation. 
3.3.5.1 Addition of Tween20 maximally increases the detection signal  
There are abundant of proteins in normal plasma214, 261-263, which are prone to hamper 
the binding between capture antibody and histone. Therefore, different concentrations 
of Tween20 were added to dissociate the interference between histones and plasma 
proteins. The addition of Tween20 resulted in increasing histone signals and the 
background comparing to those without Tween20 in plasma/PBS matrix. However, the 
concentration of Tween20 was inversely proportional to background within the 
Tween20 addition groups. Considered the detection signal and background, we decided 
to use 0.2% Tween20 as the optimal concentration (Figure 3.6).  
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Figure 3.5 Normal human plasma depresses the histone detection in Multiplex 
assay. Green line is the MFI value detected in PBS (+ 1% BSA) Buffer and the red line 
is the MFI value of histone spiked normal human plasma/PBS (+ 1% BSA) Buffer (1:5). 
For all histones (A-E), the MFI values significantly decreased in spiked plasma than 
those in the Buffer. 
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Figure 3.6 Addition of Tween20 maximally increases the detection signal in 
Multiplex. Graph A-E describe the effects of different concentrations of Tween20 (0, 
0.05%, 0.1%, 0.2%, 0.5% and 1%) to dissociate histone-plasma protein interaction. The 
addition of Tween20 increased the detection signals while the increased background 
was observed in all the histones detection. However, the higher concentration of 
Tween20, the lower background of histones. Compare the background and detection 
signals, 0.2% Tween20 is the optimal concentration. 
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3.3.5.2 Addition of NaCl increases histone H3 signal 
Addition of Tween20 increased the histone detection signals by dissociating histone-
plasma protein interaction, but the effect did not make 100% recovery. Salt conditions 
can also effect the protein-protein interactions. Therefore, different concentrations of 
NaCl were added in the presence of Tween20. Adding 150 mM of NaCl showed a higher 
signal with the lowest background in the presence of 0.2% Tween20 (Figure 3.7). 
 
Figure 3.7 Salt condition increases histone H3 detection signal. Different 
concentrations of NaCl were added to dissociate histone-plasma proteins interaction in 
the presence of different concentrations of Tween20. 
3.3.5.3 Circulating histones in positive patient plasma can’t be detected  
The positive patient plasma samples with high levels of histones determined by Western 
blot were measured along with the standards in pure buffer and normal human plasma. 
In the condition of 0.2% Tween20 and 150 mM NaCl, the 6 patients’ plasma samples 
were undetectable even compared to the spiked normal plasma (Figure 3.8). 
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Figure 3.8 Histones in patient plasma are undetectable by the Multiplex assay. (A) 
Six patients’ plasma histone levels were determined using Western blot by measuring 
histone H3. Presence of different concentrations of circulating histones in human 
patients. Patient 1 and 2 have the highest level of histone H3 (> 15 µg/mL) while patient 
4 and 6 have the lowest levels (< 5 µg/mL). (B) Even with the salt and detergent 
condition (PBS + 150 mM NaCl + 0.2% Tween20), the Multiplex measurement of 
patient 1 to 5 were less than 10 µg/mL and patient 6 was more than 10 µg/mL. The 
results from Western blot and Multiplex assay were not constant, indicating that 
multiplex assay can’t detect positive patient plasma. 
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3.3.5.4 Tween20 and salt condition can’t improve the detection in patient plasma  
As the signals in spiked normal plasma have been increased in the Tween20 and salt 
condition, we tried to optimise the measurement of patient plasma. Three positive 
patients’ plasma were incubated in 150 mM NaCl/PBS buffer with different 
concentrations of Tween20 (0.02%, 0.05%, 0.1%, 0.2% and 0.5%) to dissociate histone-
plasma proteins interference. The signals did not increase in patients’ samples (Figure 
3.9).  
 
 
 
Figure 3.9 Tween20 and salt conditions can’t optimise the detection of circulating 
histones in patient plasma. Different concentrations of Tween20 were added to 
dissociate histone-plasma proteins interaction in the presence of 150 mM NaCl. There 
was no significant difference among these 5 groups. Despite Tween20 and salt condition 
increased signals in spiked normal plasma, no improvement seem in patient plasma. 
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To confirm this result, we measured 20 more patients and 5 normal healthy donors’ 
plasma in the condition of 0.2% Tween20 and 150 mM NaCl. We found that signals of 
histones measured by Multiplex assay were not constant with those determined by 
Western blot. Signals in normal healthy plasma were even higher than some positive 
patient plasma. Moreover, signals in spiked normal plasma decreased gradually 
paralleled to histone concentrations until 1.11 or 0.37 µg/mL then increased again in the 
following lower concentrations. Based on these results, we conclude that circulating 
histones are strongly bond to plasma proteins and the capture antibodies can bind to 
some plasma proteins as well. 
3.3.5.5 Pre-incubation with acid, urea or Triton-X100 can’t increase the signals 
As the bind of histone-plasma protein is very difficult to break resulted in masking the 
epitope of histones, we tried to pre incubate sample with acid, urea and Triton-X100 for 
20 min at room temperature respectively. However, signals in patient plasma can’t 
increase either (Figure 3.10). 
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Figure 3.10 (continued) 
          
Figure 3.10 Pre-incubation with acid, TritionX100 and urea can’t improve the 
detection of circulating histones in positive patient sample. Individual histone spiked 
normal plasma (each 10 µg/mL) and one positive patient plasma was pre-incubated with 
urea (9 and 6 M), HCl (pH 2.5, 1.5 and 0.7), or TritonX100 (4% and 2%) at room 
temperature for 20 mins before incubation of capture antibodies (A-E). Under the 
condition of pH 2.5 and 4% TritonX100 pre-incubation, all spiked histones had higher 
detection signals without significantly increased background. In pH 1.5 histone H3 and 
in pH 0.7 the rest of histones showed dramatically increased background even higher 
than the spiked signals without improving the detection of the positive patient plasma.  
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3.4 Discussion 
Histones are released into the circulation after massive cells damage during the critical 
illness like trauma, sepsis, severe acute pancreatitis, etc199. The toxicity of circulating 
histones has been proved both in vitro and in vivo. In the Chapter 2, we have shown that 
not only monomer circulating histones but also truncated histones are toxic to 
endothelial cells. As monitoring others DAMPs such as circulating nucleosomes211 have 
an increasing value in acute critical illness, to determine levels of circulating histones 
especially at early stage may have great translational value.  
 
The existing method for testing the levels of circulating histones is Western blot, which 
has the limitation of time consuming (2 days procedure) and only 6 samples can be 
tested in one membrane. To build up a more robust and comprehensive assay, we 
adopted a bead based immunofluorescence technology: Luminex xMAP technology. 
We have created the standard curves for all the five monomers in the pure buffer system. 
However, all the standard curves were dramatically depressed by the addition of human 
plasma, which indicates plasma proteins have the capability to interact with circulating 
histones resulted in the epitope blockage or the cleavage. Then we tried to dissociate 
histone-plasma protein interaction. 
 
High salt condition can dissociate protein-protein interaction in part. In low pH 
condition (less than 2.7), histones are still soluble while many of the other plasma 
proteins might dissociated and precipitated264. Detergent, like Tween20, contributes the 
dissociation somehow. We found that addition of 0.2% Tween20 or 150 mM NaCl 
increased the signals in spiked standard curves. However, neither detergent nor high salt 
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condition could increase the signals in patient plasma. The low pH pre incubation did 
not work either.  
 
More than 30 components in normal plasma have been identified to bind histones by 
mass spectrometry14. Our study also showed C-reactive protein (CRP) elevated after 
presence of circulating histones in trauma patients and can form CRP-histone complex 
to reduce the toxicity of histone265. Moreover, we found complement C4 was pulled 
down by immobilised histones in plasma during the acute inflammation phase265. All of 
these results illuminate plasma has the capability to neutralise circulating histones 
released after cell death, which might be the host protective response. However, when 
massive cells death occurred, the amount of circulating histones exceed the maximal 
buffering capability of plasma, resulted in the aggravation of disease.  
 
The key for this assay is to dissociate histones from plasma proteins or generate a more 
specific antibody.      
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Chapter 4 – Circulating histone levels reflect disease severity in animal models of 
acute pancreatitis 
 
4.1 Introduction 
Acute pancreatitis is an inflammatory disorder of the pancreas which ranges from mild, 
self-limiting form to local complication as well as systemic inflammation and multiple 
dysfunction syndrome (MODS)266. Although the understanding and surgical 
management of acute pancreatitis has improved significantly in the last two decades, 
there is no licensed specific medicine for this disease. To bridge this gap, better 
understanding the pathogenesis of acute pancreatitis and its associated local 
complications and MODS is paramount important267. Due to difficulties of accessing 
human pancreas samples and uncertainty of the admission time of acute pancreatitis 
patients, research on early cellular events are rarely carried out in human pancreatic 
acinar cells, not alone currently there is no acceptable methodology to culture primary 
pancreatic acinar cells.  
 
As a result, animal models of different species have been employed to investigate acute 
pancreatitis, but in recent years there has been a prevailing trend towards using murine 
models, especially mice. These mouse models not only provide an opportunity to 
characterise the role of a specific gene or protein’s in the pathogenesis of acute 
pancreatitis but also enable development of novel therapeutic strategies that target these 
signalling pathways. Experimental acute pancreatitis models can be generally divided 
into non-invasive and invasive models. The non-invasive animal models can be induced 
by simple protocols such as special secretagogue hyperstimulation, diet feeding, amino 
acid injection, or infection with specific viruses. Invasive models of acute pancreatitis 
require surgical intervention that is technically demanding and requires more expertise 
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along with specialised resources. The latter are useful for replicating the obstructive 
aetiologies of pancreatitis, particularly for investigating gallstone-, vascular- or trauma-
induced acute pancreatitis268.  
 
An ideal animal model should include relevant aetiology, pathobiology, clinical course, 
histology and outcome, mirroring acute pancreatitis in humans. The current 
experimental acute pancreatitis models in use have their respective advantages and 
limitations. The most representative and widely used model are induced by repeated 
intraperitoneal injections of caerulein and intra-pancreatic ductal infusion of bile acid, 
respectively. The caerulein-induced acute pancreatitis (CER-AP) model is easy to 
conduct, highly reproducible, parallels a vast number of in vitro studies, making it the 
most favourable model for acute pancreatitis. It is also compatible with other models, 
sharing histopathological changes consistent with early phase of human acute 
pancreatitis269. Sodium taurocholate (NaTC) is the most frequently used bile acid to 
induce biliary acute pancreatitis. The distant organ injury and mortality are in 
accordance with concentrations of bile acid infused, making it very popular to study 
biliary acute pancreatitis270. Recently, a novel NaTC-induced acute pancreatitis (NaTC-
AP) in mice has been developed by Laukkarinen and her colleagues, further facilitates 
its prevalence.  
 
Similar to that in other critical illnesses, such as severe sepsis34 and trauma271, in which 
cellular breakdown products such as high mobility box 1 (HMGB1)272, mitochondrial 
DNA273 and extracellular histones213, collectively called damage-associated molecular 
patterns (DAMPs) may play a significant role in acute pancreatitis274. Histones are well-
conserved proteins that are essential for DNA packaging and gene regulation225. During 
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tissue damage and cell death, nuclear chromatin is cleaved into nucleosomes, which are 
released extracellularly232 and further degraded into individual histones. Recent studies 
demonstrate their direct toxicity to endothelial cells as well as causing activation of 
platelets275 and leukocytes to promote thrombosis276, disturb the microvascular 
circulation and stimulate cytokine release271. In animal models, elevation of circulating 
histones is observed in inflammatory diseases such as sepsis213, acute kidney injury277, 
liver injury278 and peritonitis279. Histone infusion causes animal death through MODS, 
which can be rescued by anti-histone antibodies271. The major mechanism for toxicity 
is due to histones binding phospholipids on cell membranes resulting in calcium influx 
and cellular injury271. In clinical practice, high circulating histone levels have been found 
in patients with severe blunt trauma and sepsis271. These levels are significantly 
associated with injury severity scores and sequential organ failure assessment (SOFA) 
scores as well as the incidence of respiratory and circulatory failure271. It is known that 
extensive cell death occurs in severe, particularly necrotising pancreatitis. However, 
there has been no direct evidence of linking circulating histones with the severity of 
acute pancreatitis.  
 
In this chapter, we set out for the first time to sequentially measure circulating histone 
levels in mouse acute pancreatitis models at various time points to explore whether the 
release of circulating histones correlates with disease severity.  
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4.2 Materials and methods 
4.2.1 Animals and reagents 
C57BL/6 male mice of average weight (~22 g) from the SLAC Experimental Animal 
Centre (Shanghai, China) were housed at 23  2°C under a 12 h light/dark cycle with ad 
libitum access to standard laboratory chow and water at the Research Centre of Gene 
Modified Mice, State Education Ministry Laboratory of Developmental Genes & 
Human Diseases (Southeast University, China). All procedures were performed 
according to state laws and monitored by local inspectors in compliance with 
Institutional ethical review processes of Southeast University.  
 
The selection of acute pancreatitis models and the time points of blood collection and 
euthanization were based on our previous experience and preliminary experiments. All 
the reagents were at the highest grade from Sigma (Gillingham, UK) unless stated 
otherwise.  
 
4.2.2 CER-AP 
Supraphysiological concentration of caerulein, a cholecystokinin analogue, was 
dissolved in normal saline at a concentration of 10 μg/mL. Mice received either 4 or 12 
repeated intraperitoneal injections of caerulein (50 µg/kg) at 1 h apart to induce 
oedematous pancreatitis280 and necrotising pancreatitis281, respectively. Control mice 
received same volume of normal saline injections. Blood was taken from tail veins 
before and various time points after first injection. Mice receiving 4 caerulein injections 
were sacrificed at 22 h (n = 10). Mice receiving 12 caerulein injections were sacrificed 
at 22 and 36 h after first injection (n = 10 for each time point). Control mice (n = 10) 
were sacrificed at 22 h.  
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4.2.3 NaTC-AP 
NaTC-AP was performed by infusion of NaTC into the biliopancreatic duct with a slight 
modification of previous protocol282. Mice were anaesthetized by intraperitoneal 
injection of 10% chloral hydrate (5 mL/kg) before operation. A midline laparotomy was 
performed and the first loop of the duodenum together with a portion of pancreas was 
externalised. After successful cannulation of the biliopancreatic duct, 50 mg/kg NaTC 
(3.5%, w/v; 1 ml/kg bw) were infused.  The success of this infusion is indicated by 
visualising methylene blue (0.2% w/v mixed with taurocholate) in the head of pancreas 
under a dissecting microscope. For control, 10 mice were subjected to the same surgical 
procedure without intraductal perfusion of Na-TC (sham group). Blood was taken 
before and at various time points after disease induction. Mice in Na-TC infusion group 
were euthanized at 22 and 36 h (n = 10 for each time point) and mice in the sham group 
were sacrificed at 22 h (n = 10). 
 
4.2.4 Samples collections  
Blood was collected and immediately centrifuged to separate plasma. Plasma was stored 
at -80oC before use. Pancreas and lungs were extracted and fixed with 4% (w/v) 
paraformaldehyde for 24 h followed by 70% ethanol until embedded in paraffin.  
 
4.2.5 Detection of circulating histones 
The levels of circulating histones were detected using Western blot, as described 
previously271. In brief, plasma was subjected to a sodium dodecyl sulphate 
polyacrylamide (SDS-PAGE) using recombinant histone H3 protein as standard and 
detected by Western blot using anti-histone H3 antibody (Abcam, UK). Total histones 
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were calculated based on the molecular ratios of individual histones within the nucleus, 
as described previously265, 271.  
 
4.2.6 Blood biochemistry 
Amylase, CK-MB, alanine transaminase (ALT) and creatinine were detected using 
AU5800 Clinical Chemistry System (Beckman coulter). 
 
 
4.2.7 Histopathology examination and scoring 
Organs were embedded and sections stained with hematoxylin and eosin (H&E). After 
H&E staining, each slide was graded by two independent observers who were blinded 
to experimental groups, according to a previously established protocol283 but with the 
vacuolisation score was omitted. The severity and extent of pancreatic oedema, 
inflammatory cell infiltration and necrosis were each given a score of 0-4 and the 
overall histopathology score was calculated as the sum of the individual scores. For 
each parameter (e.g. oedema), 10 random fields were chosen and scored and the 
average score used for data analysis.  
 
4.2.8 Statistical analysis 
Results were presented as means  standard errors of means (SEM) obtained from 
three or more independent experiments. Analysis of variance (ANOVA) was used to 
assess differences in parametric primary and secondary outcomes. For non-normally 
distributed, continuous variables the non-parametric Kruskal-Wallis H test was. The 
association of pathological scores with the levels of circulating histones was analysed 
using simple linear regression. P values of < 0.05 were considered to indicate 
significant differences. 
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4.3 Results 
4.3.1 Modelling acute pancreatitis 
In this study, 5 groups of mice were used, caerulein ×4, caerulein ×12 with 12 
injections of saline (saline ×12) as control; NaTC intraductal infusion with a sham 
group as control in which same surgical procedures were performed but without 
intraductal infusion. Amylase was analysed in the blood taken at 22 h. All 3 
pancreatitis groups showed dramatic increases in amylase (Figure 4.1A), which were 
significantly higher than that in the saline ×12 and sham groups (P < 0.01), indicating 
that acute pancreatitis was induced. Within the 3 pancreatitis groups, amylase levels 
were lowest in caerulein ×4 group and highest in NaTC group.  Amylase in the sham 
group was not significantly higher than that in the saline group, which indicates that 
the surgical procedure alone did not cause pancreatitis.  
 
Injury to heart, kidneys and liver were assessed by measuring CK-MB (Figure 4.1B), 
creatinine (Figure 4.1C) and ALT (Figure 4.1D), respectively. The mock surgical 
procedure (sham group) did increase CK-MB and ALT, which was likely due to stress 
responses. Caerulein ×12 caused significant increases in ALT. NaTC increased all the 
3 markers but not when the same dose was administered intravenously (data not 
shown). These changes are therefore mainly due to pancreatitis. 
 
Pathological examination showed that the caerulein × 4 induced obvious pancreatitis 
but hardly any necrotic areas were found in sections of the pancreas from all mice in 
the group. Instead, oedema, neutrophil infiltration and duct enlargement were the 
dominant pathological changes (Figure 4.1Ea), which are consistent with previous 
reports284. In contrast, caerulein ×12 caused obvious acinar cell death, as reported 
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previously285 and substantial areas of necrosis were observed in the pancreas (Figure 
4.1Eb). NaTC generated more severe pancreatitis with large areas of necrosis as well 
as haemorrhage in the pancreas (Figure 4.1Ec) than caerulein ×12. More obvious 
oedema and neutrophil infiltration were also observed in the caerulein ×12 and NaTC 
groups than in the caerulein ×4 group. Pathological changes in the lungs consisted 
mainly of increased thickening of alveolar walls, which were much more obvious in 
the NaTC group (Figure 4.1Ed-f) to indicate acute lung injury occurring in severe 
pancreatitis. No obvious pathological changes in liver, heart and kidneys were 
observed under optical microscopy (data not shown).  
 
4.3.2 Twelve but not four injections of caerulein caused significant increase in 
circulating histones 
Using Western blot, circulating histones were barely detectable in the saline group. 
Caerulein ×4 only caused slight increases in circulating histones at each time point tested 
(Figure 4.2A,B). Levels of circulating histones only reached statistical significance at 
15 h after the first caerulein injection when compared with that before injection (2.5 ± 
1.7 vs. 0.7 ± 0.3 µg/mL, P < 0.05). In contrast, caerulein ×12 induced dramatic elevation 
of both full length histone H3 and degraded H3 at 12, 24 and 36 h, as evidenced by 
strong bands on Western blots (Figure 4.2A,C). Levels of circulating histones reached 
a peak at 24 h and returned to near normal around 48 h after injection (data not shown). 
Peak levels of circulating histones were significantly higher than that in the caerulein ×4 
group and these concentrations have been reported to be toxic in other experimental 
models213.  
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Figure 4.1 Generation of mouse models for oedematous and necrotising 
pancreatitis. (A-D): Blood amylase for pancreas (A), CK-MB for heart (B), creatinine 
for kidneys (C) and ALT for liver (D) were measured from 5 groups of mice: control 
group (UT) with saline i.p. × 12, mock surgical procedures without duct perfusion 
(Sham), caerulein i.p. × 4 (CER×4) and ×12 (CER×12) and duct perfusion of 
taurocholate  (NaTC). Means ± SEM are presented. *ANOVA test P < 0.05 when 
compared to saline group. (E): Pathological examination of pancreas (upper panels) and 
lungs (lower panels) of the 3 mouse acute pancreatitis models. Typical images are 
presented. Black arrows in panels (b) and (c) indicate necrosis of acinar cells. Arrows 
in (f) indicate increased alveolar wall thickening. Bar = 100 µm. 
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Figure 4.2 Circulating histones in acute pancreatitis models induced by i.p. 
injection of caerulein. (A) Circulating histone H3 from Caerulein ×4 (CER×4) and ×12 
(CER×12) mouse models were detected using Western blot with recombinant H3 
protein as standard. (B) Means ± SEM of total histones in CER×4 and (C) CER×12 
models. *ANOVA test showed significant increase compared to pre-injection (P < 
0.05). 
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4.3.3 Pancreatic duct infusion of NaTC caused the most significant elevation of 
circulating histones 
In the NaTC-AP, circulating histones levels increased significantly from 4 h after NaTC 
infusion (23.2 ± 9.2 μg/mL; Figure 4.3A, B). There were steady elevations of circulating 
histone levels that reached a peak around 14 h (149.6 ± 40.6 μg/mL) (Figure 4.3B). 
There were no significant increases of circulating histones in mice in either the sham 
surgery group or the group receiving intravenous injections of NaTC at all matched time 
points (data not shown), indicating that the high circulating histone levels were not due 
to the surgical procedure or systemic toxicity of NaTC but due to NaTC-induced 
necrotising pancreatitis. Comparing the peak values in three acute pancreatitis models, 
we found that circulating histones were significantly higher in the NaTC group than in 
the caerulein ×12  group (149.6 ± 40.6 vs. 103.5 ± 17.3 μg/mL, P = 0.02) with both 
being much higher than the caerulein ×4  group (2.5 ± 1.7 μg/mL,  P <  0.05; Figure 
4.3C).  
 
4.3.4 Circulating histone levels correlated with disease severity 
Typical pancreatic histopathological changes are presented in Figure 4.1Ea-c and scores 
for all experimental groups are shown in Figure 4.4. Intraperitoneal saline injections and 
sham operation did not cause any discernible pancreatic histopathology changes. All 3 
acute pancreatitis models showed obvious pancreatic morphological changes which 
were semi-quantified by histopathological scores, including overall score and its 
breakdown components – oedema, inflammation and necrosis (Figure 4.4).  Caerulein 
×12 and NaTC models were significant higher than caerulein ×4 model in all scores. No 
significant differences in oedema and inflammation scores were seen between caerulein 
×12 and NaTC models but the necrosis scores were significantly higher in NaTC model 
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than in caerulein ×12 model (P = 0.02). By simple linear regression, peak values of 
circulating histones significantly correlated with necrosis scores (r = 0.63, P = 0.001) 
but not with inflammation (r = 0.27, P = 0.074) or oedema (r = 0.21, P = 0.132) scores 
(Table 4.1). These data suggest that damaged pancreatic acinar cells may be a major 
source of circulating histones.  
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Figure 4.3 Circulating histones in NaTC-AP. (A) A typical Western blot of histone 
H3 in blood taken from a NaTC-AP at different time points. Top band is full length H3 
and the lower band is degraded H3 (H3d). (B) Means ± SEM are presented to show the 
time course of the elevation in circulating histones.*ANOVA test P < 0.05 when 
compared with that before duct perfusion. (C) Comparison of the means ± SEM in peak 
values of total histones from 3 AP models and 2 control groups (Saline and Sham). *P 
< 0.05 vs. controls; #P = 0.01 vs. caerulein × 4 (CER×4); ǂP = 0.02 vs. caerulein × 12 
(CER×12).  
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Figure 4.4 Pathological scores of pancreas of mouse acute pancreatitis models. 
Sections of pancreas collected at 22 h after acute pancreatitis induction were scored as 
described in Methods. Means ± SEM of the scores for (A) oedema, (B) inflammation 
and (C) necrosis as well as (D) combined (total = oedema + inflammation + necrosis) 
are presented. ANOVA test, *P < 0.05 when compared to caerulein ×4 (CER×4).  #P < 
0.05 when duct perfusion (NaTC) was compared to caerulein ×12 (CER×12). 
 
 
Table 4.1 Correlation of circulating histones to pancreas pathological scores  
Pathological scores n r P 
Inflammation 30 0.27 0.074 
Oedema 30 0.21 0.132 
Necrosis 30 0.63 0.001 
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4.4 Discussion 
This study is the first to demonstrate that there is a significant increase in circulating 
histones in experimental acute pancreatitis. In our animal models, we show that the 
significant elevation of circulating histones correlate well with pancreatic necrosis and 
is accompanied by increased systemic injury such as to the lung, heart, kidneys and 
liver, which are the most frequently affected distant organs by acute pancreatitis286, 287.  
 
Many types of acute pancreatitis animal models have been reported and the commonly 
used models include caerulein-induced models and biliopancreatic duct infusion 
models288. These models are also routinely used in our laboratories. In this study, we 
have generated acute pancreatitis models with 3 distinguishable levels of severities, with 
which we have established the association of levels in circulating histones with severity 
scores, particularly of necrotic scores of pancreas in pathological examination. In human 
acute pancreatitis, nuclear breakdown products such as HMBG1289, 290 and DNA291, 292 
have already been shown to be released into the circulation and correlated with disease 
severity. Treatment with anti-H3 antibody suppresses serum HMGB1 levels and 
improves survival of L-arginine-induced acute pancreatitis in mice222. High levels of 
circulating histones in critical illnesses have been only reported recently and our study 
supports a similar principle that the levels of nuclear breakdown products in circulation 
reflect the severity of tissue damage and the extent of cell death. Histones as the most 
abundant proteins in nuclei may serve as a much better biomarker for stratification of 
disease severity.  
 
In general, severe damage of any organ will release large amounts of histones into the 
circulation. When this exceeds the clearance capacity of the body, histones become 
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detectable in the circulation. Many diseases, such as severe trauma, burns, organ 
infarctions and sepsis, will incur simultaneous damage of large number of cells and 
lead to high levels of circulating histones271. In the mouse model of necrotising 
pancreatitis, a large number of acinar cells may die in a short time period and release 
large amounts of histones into the circulation where they can be detected. The strong 
correlation between the levels of circulating histones with pancreatic necrosis scores 
in mouse models of acute pancreatitis supports the notion that necrosis of acinar cells 
is a major source of histones. On the other hand, during acute inflammatory responses 
from a variety of aetiologies, inflammatory cells and neutrophils especially will 
accumulate and release their nuclear contents that include histones and DNA in the 
form of extracellular traps or neutrophil extracellular traps (NETs)34. Histones in 
NETs have also been shown to be toxic to the host36, 37. Since NET formation and 
release has not yet been studied in acute pancreatitis, we cannot rule out a significant 
role of NETs in the severity of acute pancreatitis.  
 
The finding that concentrations of circulating nucleosomes and histones are strongly 
associated with the severity of trauma and other modes of cellular injury suggests 
possible usefulness as a new parameter for estimating tissue damage. Circulating 
histones are likely to be more directly linked to the underlying pathophysiological 
changes than other indices that are commonly used in clinical practice. In pancreatitis 
for example, levels of blood amylase are used as a diagnostic parameter although 
circulating histone levels might prove to be a better index of acinar cell death since 
amylase in patients with necrotising pancreatitis can be relatively low due to loss of 
acinar cells293. Increases in serum amylase mainly reflect leakage from acinar cells 
whilst significant increases in circulating histones indicate nuclear and cellular 
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breakdown. Since circulating histones appear to be directly linked to pathological 
damage in necrotizing pancreatitis, there is the potential for using circulating histones 
to stratify the severity of acute pancreatitis, particularly as there are no satisfactory 
clinical scoring systems, radiological modalities or biochemical makers to fulfill this 
purpose so far294, 295.   
 
The pathological roles of high circulating histone levels in severe pancreatitis are still 
not clear. Since the most lethal complication of severe pancreatitis is MODS, histones 
may contribute to acute lung injury, as discovered in animal experiments, and lead to 
respiratory failure which occurs in nearly 50% of patients with severe pancreatitis296. In 
line with previous findings of circulating histones being directly toxic to epithelial 
cells297, endothelial cells213, platelets275 with secondary tissue injury through 
microvascular thrombosis275, 298, these effects might lead to a secondary hit to the 
pancreas and other organs in increasing disease severity and worsening outcomes. Our 
findings suggest that release of histones from pancreatic damage may have devastating 
consequences and neutralising circulating histones may be of therapeutic value. The 
development of anti-histone therapies to suppress this second hit after the onset of acute 
pancreatitis might therefore be a rational therapeutic approach in the future.   
 
In conclusion, histones are released into the circulation following the death of 
pancreatic acinar cells. This promises to be of significant translational potential, both 
in terms of measuring circulating histones as a biomarker of the severity of pancreatitis 
and targeting the toxicity of circulating histones to improve the outcome of patients 
with necrotising pancreatitis. 
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Chapter 5 – Circulating histone levels predict persistent organ failure and 
mortality in patients with acute pancreatitis within 24 hours of admission 
 
5.1 Introduction 
 
Acute pancreatitis is one of the leading gastrointestinal disorders that require urgent 
clinical care with an increasing incidence299. The clinical course of acute pancreatitis is 
variable ranging from mild (80%, uneventful clinical course), through moderate (local 
complication or transient organ failure) to severe disease (persistent organ failure, 
POF)300-302. Infected pancreatic necrosis303, 304 and/or sepsis286 are another major 
complications contributing to mortality at any stage. However the principal early cause 
of early death is the presence of POF286, 305-307. Early recognition of patients at risk of 
POF is critical to guide fluid resuscitation and initiate high dependency or intensive care 
treatment, to reduce morbidity and mortality301, 308. Indeed, early stratification of disease 
severity improves clinical outcomes and significantly reduces length of hospital stay309. 
 
Improvements in imaging, such as computerised tomographic (CT) scans, have not 
proven superior to clinical scoring systems in early prediction of acute pancreatitis 
severity294, 295. A recent multicentre study has shown that existing clinical scores such 
as Systemic Inflammatory Response Syndrome (SIRS), Bedside Index for Severity in 
Acute Pancreatitis (BISAP), Acute physiology and Chronic Health Examination II 
(APACHE II), Sequential Organ Failure Assessment (SOFA) either alone or in 
combination, have reached their maximal efficacy for early prediction of POF in acute 
pancreatitis patients and are of limited clinical use295. This is supported by a latest meta-
analysis concluding that there is no adequate predictor for POF within 48 h of hospital 
admission310. A wide spectrum of clinical biomarkers for acute pancreatitis severity has 
been investigated over the last two decades. These include routine biomarkers295, 311-314, 
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pancreas-specific enzymes313-316, acute phase proteins such as C-reactive protein 
(CRP)313, 314, 317, cytokines313, 314, immunological components314,  transcriptomics318, 
proteomics319 and others314. Most of them are of low to moderate predictive value314 and 
there is a pressing need for the identification and development of more powerful 
predictive markers in for these at risk patients. 
 
Recently, damage associated molecular patterns (DAMPs), such as high-mobility group 
box 1 (HMGB1), cell-free DNA and nucleosomes, have been investigated in human 
acute pancreatitis and most studies showed their blood levels correlate with severity of 
the disease223, 274. Histones are well-conserved nuclear proteins that are essential for 
DNA packaging and gene regulation. During tissue damage and cell death, nuclear 
chromatin is cleaved and released extracellularly where it is degraded into individual 
histones232. Circulating histones, the most abundant nuclear proteins, are rapidly cleared 
by the liver218 and are barely detectable in the blood unless there is extensive cell 
death211, as in severe sepsis213, 320, 321 and trauma271. Recent studies demonstrate 
circulating histones act as DAMPs to induce sterile inflammation and contribute to SIRS 
and organ failure274. Extracellular histones are also toxic to endothelial cells213, 271, 
platelets275, 276 and leukocytes116. Furthermore, they have been reported to activate 
coagulation, disturb microvascular circulation and stimulate cytokine release271, 322, 323. 
In mouse models, histone infusion causes animal death through multiple organ failure, 
which can be rescued by anti-histone antibodies213, 271, 321. Clinically, high levels of 
circulating histones have been found in patients with severe blunt trauma271 and 
sepsis320, with associations to the development of respiratory failure271, new-onset 
cardiac complications320 and thrombocytopenia324. We have previously demonstrated 
that circulating histone levels rise very early in mouse acute pancreatitis models, and are 
101 
 
also strongly associated with disease severity and distant organ injury325. Therefore, we 
hypothesised that plasma levels may predict major clinical outcomes in patients early in 
acute pancreatitis.  
 
In this chapter, we investigated the ability of circulating histones to predict severe acute 
pancreatitis within 24 h after onset of abdominal pain in 236 consecutive patients. 
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5.2 Patients and methods 
5.2.1 Study population and ethics 
Consecutive acute pancreatitis patient admissions at The Royal Liverpool University 
Hospital (between June 2010 and March 2014) were enrolled once written informed 
consent was obtained. Inclusion criteria: (1) first episode of acute pancreatitis as 
defined by Revised Atlanta Classification (RAC)300; (2) blood samples obtained, 
processed and stored within 24 h of admission. Exclusion criteria: (1) age < 18 or > 
85 years; (2) advanced pulmonary, cardiac, renal diseases or malignancy; (3) 
pregnancy, chronic pancreatitis, pancreatic neoplasm or trauma as aetiologies; (4) time 
of abdominal pain onset to admission > 24 h.  
 
Peripheral blood samples from acute pancreatitis patients (n = 236) were collected 
within 24 h of admission (median of 24 h [range 5-48] after onset of abdominal pain) 
as well as from healthy volunteers (n = 47).  White blood cells (WBC) were isolated 
and viability assessed by 0.1% trypan blue (Life Technologies, Warrington, UK) using 
a CountessTM automated cell counter (Invitrogen, Glasgow, UK).  Serum and plasma 
were isolated and stored at -80°C in the National Institute for Health Research (NIHR) 
Liverpool Biomedical Research Unit Acute Pancreatitis Biobank, according to 
protocols approved by local research ethics committees (REC reference: 10/H1308/31 
on 11/02/2010).  
 
5.2.2 Study design 
Demographic, laboratory, radiographic, microbiological, surgical and clinical outcome 
data were prospectively recorded and maintained in an e-database following standard 
operating procedures (SOPs) according to Good Clinical Laboratory Practice (GCLP) 
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standards. SIRS, BISAP, APACHE II and SOFA scores were calculated within 24 h of 
admission295, according to published definitions. The first and the worst modified CT 
severity index (MCTSI) were enumerated using contrast-enhanced CT scans.  
 
POF was defined as a truncated SOFA score of ≥ 2 for ≥ 48 h that manifested in failure 
of at least one of the respiratory, cardiovascular or renal systems302. In patients with pre-
existing chronic kidney diseases (stage 1-3), a two-point worsening of kidney function, 
defined by estimated glomerular filtration rate326, was used to define renal failure 
regardless of circulating creatinine levels. Local complications were defined as the 
presence of acute peri-pancreatic fluid collections (or pseudocysts), pancreatic necrosis 
(acute necrotic collections or walled-off necrosis), splenic or portal vein thromboses, 
gastric outlet obstruction, or colonic necrosis as per RAC300. Major infection was 
defined as the appearance of either infected pancreatic necrosis, sepsis, or both, which 
developed at least 3 days after admission. 
 
5.2.3 Clinical biomarker analysis 
Plasma histone levels were determined by quantitative Western blot previously 
established protocols265, 271, 320, 321, 324. Interleukin (IL)-6 and IL-8 (R&D, Abingdon, 
UK) were measured in plasma by enzyme-linked immunosorbent assay (ELISA) as per 
manufacturers’ instructions. All measurements were performed in duplicates or 
triplicates by experienced laboratory staff, blinded to clinical data. Urea, creatinine, CRP 
and other routine clinical biomarkers were reported by the Department of Clinical 
Biochemistry, Royal Liverpool University Hospital, Liverpool, UK. 
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5.2.4 Statistical analysis 
Descriptive data were reported as median with interquartile range (IQR) and number 
(percentage) for continuous variables and categorical parameters, respectively. 
Continuous variables were compared by the Mann-Whitney U test (2 groups) and 
Kruskal-Wallis H test (3 groups). Categorical data were compared using Chi-square or 
Fisher’s exact tests. The correlation of circulating histones with MCTSI and WBC 
viability was assessed by Spearman rank correlation. Statistical significance was defined 
as P < 0.05. Receiver operating characteristics (ROC) curves were constructed for 
circulating histones and other markers in the prediction of POF, major infection and 
mortality. The area under curve (AUC) with 95% confidence intervals (CI) of 
circulating histones for each clinical outcome was compared with clinical scores and 
biomarkers. The optimum cut-offs for sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV), positive likelihood ratio (PLR) and negative 
likelihood ratio (NLR) of the assessed parameters were derived from the ROC curves.   
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5.3 Results 
5.3.1 Patient characteristics  
A total of 236 consecutive patients (mild: 156 (66.1%); moderate: 57 (24.2%); severe: 
23 (9.7%)) fulfilling the inclusion and exclusion criteria were observed in this study. 
The baseline characteristics and clinical outcomes for each patient group are outlined in 
Table 5.1. In this cohort 9.7% (23/236) patients developed POF, 25.4% (60/236) 
developed local complications; with the incidence of acute peri-pancreatic and acute 
necrotic collection 12.7% (30/236) for both. Major infection occurred in 3.8% (9/236) 
of the patients. The overall mortality was 3.8% (9/236) and all the patients that died 
were from the severe acute pancreatitis group. 
 
5.3.2 Circulating histones elevate on admission and indicate disease severity  
To assess whether circulating histones are associated with disease severity in acute 
pancreatitis patients we firstly measured levels among healthy volunteers, mild, 
moderate and severe acute pancreatitis patients. Figure 5.1 shows that circulating 
histones were barely detectable in healthy volunteers and comparable between both 
mild and moderate AP patients (median [quartiles] 1.1 [0.6, 2.1] vs. 1.3 [0.5, 2.8] 
µg/ml, P > 0.05).  Circulating histones were only significantly elevated in patients 
with severe disease (18.8 [5.9, 33.8] µg/ml, P < 0.001), indicating their association 
with disease severity. 
 
We then compared the relevance of measuring circulating histones to current clinical 
scores and biomarkers used to assess severity of acute pancreatitis patients (Table 5.2). 
Like circulating histones, SIRS, BISAP, APACHE II and SOFA scores all increased 
with disease severity within 24 h of hospital admission and were significantly elevated 
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in severe acute pancreatitis patients, compared to mild or moderate groups. General 
biomarkers including circulating urea, creatinine, hematocrit, IL-6 and IL-8 were also 
significantly higher in patients with severe disease. In contrast, CRP levels showed no 
significant association with disease severity within 24 h of admission, which only 
became significantly after 48 h. These data indicate that following acute pancreatitis 
onset, histones appear within the circulation more rapidly than CRP and 
synchronously with severe clinical manifestation, which may hold potential benefit 
for early prediction of disease severity within these patients.  
 
5.3.3 Circulating histones are the earliest indicator of disease severity 
POF during the first week of hospitalisation is a marker of fatal outcome in acute 
pancreatitis patients306. In this cohort, 9.7% (23/236) of patients developed POF and 
along with significantly more clinical complications within the first week of hospital 
admission (Table 5.1). This was also reflected by significant increased clinical scores 
on admission, which included; SIRS, BISAP, APACHE II and SOFA (Table 5.2). The 
AUCs for all the scores were moderate (range 0.68-0.81, Table 5.3) in predicting POF, 
and both the sensitivity (51-66%) and specificity (74-83%) were poor, most likely due 
to the transient nature of organ failure in acute pancreatitis patients. Circulating histone 
levels within 24 h of admission out performed current clinical scores (Table 5.3) and 
showed a far stronger predictive value (AUC: 0.92; 95%CI: 0.85-0.99) when 
compared to both CRP (AUC: 0.54; 95%CI: 0.37-0.71) (Figure 5.2A) and urea (AUC: 
0.75; 95%CI: 0.63-0.86) (Figure 5.2B). Furthermore, CPR (AUC: 0.89; 95%CI: 0.84-
0.94) (Figure 5.2A) and urea (AUC: 0.82; 95%CI: 0.71-0.94) (Figure 2B) only showed 
relatively strong predictive value of POF at 48 h following admission. Using the 
optimal circulating histones cut-off value (5.4 μg/ml) for the prediction of POF, they 
107 
 
comparatively surpassed all other parameters measured within this study, with a 
sensitivity, specificity, PPV, NPV, PLR and NLR were 82.6%, 94.4%, 61.3%, 98.1%, 
14.7 and 0.18, respectively (Table 5.4). Furthermore, when combining circulating 
histones levels with either of the above parameters, the predictive values were not 
further increased. These data suggest that measuring circulating histones within 24 h 
after hospital admission accurately and better predicted POF, compared to predictors 
currently used in routine clinical practice.  
 
5.3.4 Circulating histones have moderate predictive values for major infection  
We next assessed the value of measuring circulating histones in predicting major 
infection, compared to current clinical scores and biomarkers. Circulating histones had 
a moderate predictive value (AUC 0.78; 95%CI: 0.62-0.94) for major infection. CRP 
was less effective within 24 h (AUC: 0.72; 95%CI: 0.50-0.94) but became more so at 
48 h (AUC: 0.83; 95%CI: 0.75-0.92) (Figure 5.3A).  Measuring urea at either 24 (AUC: 
0.86; 95%CI: 0.74-0.97) or 48 h (AUC: 0.92; 95%CI: 0.86-0.97) more effectively 
predicted major infection than circulating histones within 24 h of admission (Figure 
5.3B). Similarly, we found that BISAP (AUC: 0.83; 95%CI: 0.72-0.94), APACHE II 
(AUC: 0.87; 95%CI: 0.75-1.00) and SOFA (AUC: 0.82; 95%CI: 0.64-0.99) scores had 
stronger predictive value for major infection than measuring circulating histones 
within 24 h, as did both creatinine (AUC: 0.83; 95%CI: 0.71-0.96) and IL-8 (AUC: 
0.80; 95%CI: 0.67-0.94). However, circulating histones exceeded other parameters 
tested in this study (Table 5.3, Figure 5.3C). At a cut-off of 5.4 μg/ml, the sensitivity, 
specificity, PPV, NPV, PLR and NLR of circulating histones for the prediction of 
major infection were 44.4%, 88.8%, 12.9%, 97.6%, 3.7 and 0.63, respectively (Table 
5.4). 
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5.3.5 Circulating histones have high values in predicting mortality 
Circulating histones had a higher predictive value for mortality (AUC: 0.96; 95%CI: 
0.92-1.00) than any other parameter within 24 hours (Table 5.3), including both CRP 
(Figure 5.4A) and urea (Figure 5.4B) and was comparable to urea (AUC: 0.97; 95%CI: 
0.95-0.99) at 48 h. At an optimal cut-off of 5.4 μg/ml, the sensitivity, specificity, PPV, 
NPV, PLR and NLR for circulating histones were 88.9%, 89.9%, 25.8%, 99.5%, 8.8 
and 0.12, respectively (Table 5.4 and Figure 5.4). Urea at a cut-off of 8 mmol/l had a 
sensitivity, specificity, PPV, NPV, PLR and NLR of 100%, 93.2%, 37.5%, 100%, 14.8 
and 0.00 respectively (Table 5.4 and Figure 5.4B) at 48 h. Both BISAP (≥ 2) within 
24 h and CRP (≥ 250 mg/l) at 48 h had reasonable predictive values, but with PLR 
values (4.6 and 4.4, respectively) much lower than those of both circulating histones 
within 24 h and urea at 48 h (Table 5.4 and Figure 5.4). Combining circulating histones 
(≥ 5.4 μg/ml) with either urea (≥ 8 mmol/l, at 48 h) or CRP (≥ 250 mg/l, at 48 h) did 
not increase specificity compared to the individual parameters alone.  
 
5.3.6 Circulating histones on admission correlate with leucocyte viability but not 
local complications 
We reported that circulating histones significantly correlated with pancreatic necrosis 
scores in animal models. However, the correlation between histone levels on 
admission and the first MCTSI (r = 0.17, n = 99, P = 0.094), or the worst MCTSI (r = 
0.195, n = 99, P = 0.054) were not significant. During disease progression, pancreatic 
necrosis normally occurs 24 h after onset so would therefore not directly affects the 
histone levels within the first 24 h, but may be contributory after this time. Another 
source could be the release histones from immune cells following cellular damage or 
death. We measured the percentage viable WBC in peripheral blood of 62 patients 
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within this cohort, and found a significant negative association between circulating 
histone levels and WBC viability within 24 h of admission (r = -0.515, P < 0.01; Figure 
5.5). These data indicate that inflammation-induced immune cell death may be a major 
source for early elevations in circulating histones. 
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Figure 5.1 Comparison of circulating histone levels in normal and patients with 
acute pancreatitis on admission. Plasma histones levels (g/ml) were quantified in 
health volunteers (normal; n = 47) and in mild (n = 156), moderate (n = 57) and severe 
(n = 23) acute pancreatitis patients within 24 h of admission. Median ± interquartiles 
with peak values are presented. *P < 0.05 when compared with other groups.  
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Table 5.1 Demographic and clinical outcomes of the study population 
 Total  
n = 236 
Mild  
n = 156 
Moderate  
n = 57 
Severe  
n = 23 
P value* 
Gender, female, n (%) 124 (52.5) 91 (58.3) 22 (38.6) 11 (47.8) 0.04† 
Age (year), median (IQR)  55.5 (42.3-69) 56 (42-68) 52 (40-67) 62 (52-76.5) 0.064 
Updated Charlson score, median (IQR) 0 (0-1) 0 (0-1) 0 (0-1) 0 (0-1) 0.158 
Aetiology      
    Biliary, n (%) 120 (50.8) 83 (53.2) 29 (50.9) 8 (34.8) 0.256 
    Alcohol, n (%) 48 (20.3) 30 (19.2) 13 (22.8) 5 (21.7) 0.835 
    Others, n (%) 68 (28.8) 43 (27.6) 15 (26.3) 10 (43.5) 0.259 
Time to admission (h), median (IQR) 8 (4-14) 8 (4-14) 6 (4-12) 11 (6-15) 0.111 
Time from admission to sampling (h), median (IQR)  15 (9-20) 14 (8.3-19.8) 17 (9.8-20) 16 (12-20) 0.588 
Worst modified CT severity index, median (IQR) 4 (2-7.5) 2 (0-2) 6 (4-8) 6 (6-8) <0.001† 
Acute peri-pancreatic fluid collection, n (%) 30 (12.7) 0 (0) 23 (40.4) 7 (30.4) <0.001† 
Pancreatic necrosis, n (%) 30 (12.7) 0 (0) 19 (33.3) 11 (47.8) <0.001† 
Infected pancreatic necrosis and/or sepsis, n (%) 9 (3.8) 0 (0) 1 (1.8) 8 (34.8) <0.001‡ 
Need for antibiotics, n (%) 34 (14.4) 9 (5.8) 9 (15.8) 16 (69.6) <0.001§ 
Nutritional support, n (%) 13 (5.5) 0 (0) 0 (0) 13 (56.5) <0.001‡ 
Necrosectomy and/or percutaneous drainage, n (%) 11 (4.7) 0 (0) 3 (5.2) 8 (34.8) <0.001§ 
Mortality, n (%) 9 (3.8) 0 (0) 0 (0) 9 (39.1) <0.001‡ 
Length of hospital stay (day), median (IQR) 7 (4-14) 5.5 (3-9) 14 (11-21) 29 (13.5-65.5) <0.001§ 
IQR, interquartile range; MCTSI, modified computerised tomography severity index; CT performed: mild (31/156), moderate (49/57), severe (20/23).  
*P value indicates comparison among three groups. †Mild vs. moderate or severe was significant. ‡Severe vs. mild or moderate was significant. §Any 
two groups comparison was significant. 
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Table 5.2 Comparison of clinical scores and biomarkers among different severity groups 
 Mild  
n = 156 
Moderate  
n = 57 
Severe  
n = 23 
 P value* 
 
Clinical scores within 24 h of admission     
    SIRS 1 (0-1) 1 (1-2) 2 (1-2) 0.002† 
    BISAP 1 (0-1) 1 (0-1) 2 (1-2) < 0.001‡ 
    APACHE II 5 (3-7) 7 (5-9) 10 (6-12.5) < 0.001† 
    SOFA 0 (0-1) 1 (0-2) 2 (1-4) < 0.001† 
Biomarkers within 24 h of admission      
    WBC (×109/l) 12.4 (9.9-15.3) 14.2 (11.5-17.4) 14.4 (11.2-19.3) 0.002‡ 
    Neutrophil/lymphocyte ratio 6.9 (4.1-14.8) 8 (4.3-14.7) 7.7 (5.3-23.6) 0.520 
    Haematocrit (%) 40.1 (38-42.9) 43.5 (39.3-45.6) 42.8 (37.6-45.4) 0.003‡ 
    Urea (mmol/l) 5 (3.7-6.1) 4.8 (3.7-6.3) 7.3 (5.2-8.9) 0.001§ 
    Creatinine (μmol/l) 71 (61-88) 83 (65-99) 104 (75-157.5) < 0.001† 
    CRP (mg/l)  7.5 (5-23.3) 10 (5-33.8) 10 (5-136.5) 0.288 
    IL-6 (pg/ml) 13.8 (7-57.8) 30.8 (8.6-96.2) 65.1 (21.7-143.4) 0.022// 
    IL-8 (pg/ml) 9.9 (0.4-19.1) 13.9 (5.4-28.9) 44.5 (18.8-64.2) < 0.001// 
    Circulating histones (μg/ml) 1.1 (0.6-2.1) 1.3 (0.5-2.8) 18.8 (5.9-33.8) < 0.001§ 
Biomarkers at 48 h admission     
    Urea (mmol/l) 3.5 (2.6-4.7) 3.5 (2.7-5.5) 8.7 (5.2-11.7) < 0.001§ 
    Creatinine (μmol/l) 66 (53.5-79) 65 (54.5-86) 71 (57-172) 0.08§ 
    CRP (mg/l) 38 (11-116) 234 (159-316.5) 327.5 (250-368.3) 0.001† 
SIRS, Systemic Inflammatory Response Syndrome; BISAP, Bedside Index for Severity in Acute Pancreatitis; APACHE II, Acute physiology and 
Chronic Health Examination II; SOFA, Sequential Organ Failure Assessment; WBC, white blood cell; CRP, C-reactive protein; IL, interleukin.  
*P value indicates comparison among three groups. †Any two groups comparison was significant. ‡Mild vs. moderate or severe was significant. 
§Severe vs. mild or moderate was significant. //Mild vs. severe was significant.  
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Table 5.3 AUC of ROC for potential predictors 
 POF P value Major infection P value Mortality P value 
Clinical scores within 24 h of admission       
   SIRS 0.68 (0.55-0.81) 0.01 0.67 (0.48-0.87) 0.096 0.72 (0.53-0.91) 0.037 
   BISAP 0.81 (0.71-0.91) < 0.001 0.83 (0.72-0.94) 0.002 0.90 (0.80-0.99) < 0.001 
   APACHE II 0.74 (0.62-0.87) < 0.001 0.87 (0.75-1) < 0.001 0.86 (0.70-1) 0.001 
   SOFA 0.79 (0.68-0.90) < 0.001 0.82 (0.64-0.99) 0.001 0.83 (0.66-0.99) 0.001 
Biomarkers within 24 h of admission       
   WBC (×109/l) 0.62 (0.49-0.74) 0.066 0.67 (0.47-0.86) 0.087 0.67 (0.46-0.87) 0.085 
   Haematocrit (%) 0.58 (0.43-0.73) 0.253 0.60 (0.35-0.86) 0.316 0.52 (0.3-0.74) 0.848 
   Urea (mmol/l) 0.75 (0.63-0.86) < 0.001 0.86 (0.74-0.97) < 0.001 0.83 (0.69-0.98) 0.001 
   Creatinine (μmol/l) 0.74 (0.62-0.86) < 0.001 0.83 (0.71-0.96) 0.001 0.91 (0.81-1) < 0.001 
   IL-6 (pg/ml) 0.67 (0.49-0.74) 0.018 0.73 (0.57-0.87) 0.031 0.73 (0.54-0.91) 0.045 
   IL-8 (pg/ml) 0.76 (0.64-0.89) 0.001 0.80 (0.67-0.94) 0.005 0.89 (0.78-0.99) 0.001 
   Circulating histones (μg/ml) 0.92 (0.85-0.99) < 0.001 0.78 (0.62-0.94) 0.005 0.96 (0.92-1) < 0.001 
Biomarkers at 48 h admission       
   Urea (mmol/l) 0.82 (0.71-0.94) < 0.001 0.92 (0.86-0.97) < 0.001 0.97 (0.95-0.99) < 0.001 
   Creatinine (μmol/l) 0.61 (0.44-0.78) 0.129 0.62 (0.36-0.88) 0.253 0.86 (0.65-1) 0.002 
   CRP (mg/l) 0.89 (0.84-0.94) < 0.001 0.83 (0.75-0.92) 0.001 0.86 (0.79-0.93) 0.003 
POF, persistent organ failure; SIRS, Systemic Inflammatory Response Syndrome; BISAP, Bedside Index for Severity in Acute Pancreatitis; 
APACHE II, Acute physiology and Chronic Health Examination II; SOFA, Sequential Organ Failure Assessment; WBC, white blood cell; CRP, 
C-reactive protein; IL, interleukin.  
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Table 5.4 Comparison of predictive values of the most effective predictors 
 Cut-off values Sensitivity Specificity PPV NPV PLR NLR 
POF        
    BISAP (within 24 h) ≥ 2 68.4 82.8 26.5 96.7 4.0 0.38 
    Circulating histones (within 24 h) ≥ 5.4 μg/ml 82.6 94.4 61.3 98.1 14.7 0.18 
    Urea (at 48 h) ≥ 8 mmol/l 60.9 94.7 56.0 95.6 11.5 0.41 
    CRP (at 48 h) ≥ 250 mg/l 80.0 80.5 29.1 97.6 4.1 0.25 
Major infections          
    BISAP (within 24 h) ≥ 2 75.0 80.5 12.2 98.9 3.8 0.31 
    Circulating histones (within 24 h)  ≥ 5.4 μg/ml 44.4 88.1 12.9 97.6 3.7 0.63 
    Urea (at 48 h) ≥ 8 mmol/l 66.7 91.4 24.0 98.5 7.8 0.37 
    CRP (at 48 h) ≥ 250 mg/l 77.8 77.7 13 98.8 3.5 0.29 
Mortality            
    BISAP (within 24 h) ≥ 2 87.5 80.9 14.3 99.4 4.6 0.15 
    Circulating histones (within 24 h) ≥ 5.4 μg/ml 88.9 89.9 25.8 99.5 8.8 0.12 
    Urea (at 48 h) ≥ 8 mmol/l 100 93.2 37.5 100 14.8 0.00 
    CRP (at 48 h) ≥ 250 mg/l 100 77.1 10.9 100 4.4 0.00 
PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio; NLR, negative likelihood ratio; POF, persistent 
organ failure; BISAP, Bedside Index for Severity in Acute Pancreatitis; CRP, C-reactive protein.  
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Figure 5.2 Comparison of ROC curves in predicting POF. ROC analysis comparing circulating histone levels within 24  h with either (A) CRP 
within 24 h and at 48 h or (B) urea within 24 h and at 48 h, in predicting for POF in acute pancreatitis patients (n = 236). Dash line represents ROC 
reference line. 
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Figure 5.3 Comparison of ROC curves in predicting infection. ROC analysis predicting infection in acute pancreatitis patients (n = 236), 
comparing circulating histones within 24 h of admission are to (A) CRP within 24 h and at 48 h after admission, (B) urea within 24 h and at 48 h 
after admission and (C) white blood cell (WBC) counts, neutrophil/lymphocyte ratio, IL-6 and IL-8 within 24 h of admission. Dash line represents 
ROC reference line. 
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Figure 5.4 Comparison of ROC curves in predicting mortality. ROC analysis comparing circulating histone levels within 24 h with either 
(A) CRP within 24 h and at 48 h or (B) urea within 24 h and at 48 h, in predicting for mortality in acute pancreatitis patients (n = 236). Dash line 
represents ROC reference line.
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Figure 5.5 Correlation between histone levels and percentage of leucocyte 
viability on within 24 h of admission. Circulating histone levels (µg/ml) were 
correlated with percentage of leucocyte viability in acute pancreatitis patients (n = 62) 
within 24 h of admission.
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5.4 Discussion 
In this study, we demonstrate for the first time that levels of circulating histones are a 
robust index of disease severity and capable of predicting POF and mortality, better 
than indices currently used in the clinical setting within 24 hours of admission. 
Moreover, we provide supporting evidence that BISAP within 24 hours as well as urea 
and CRP at 48 hours have good predictive values for POF, major infection and 
mortality, encouraging their routine clinical use before new markers are developed. 
The consecutive nature of patient recruitment and short time from onset of pain to 
sampling, stringently applied, adds strength to these conclusions.  
 
BISAP, which contains blood urea nitrogen (BUN), Glasgow Coma Score, SIRS, age 
and presence of pleural effusions, is a recently developed and validated clinical score 
primarily for the prediction of mortality in acute pancreatitis.294, 295, 327 Our study has 
shown that BISAP predicted POF and morality reasonably well, inferior only to 
circulating histones within 24 hours of admission, justifying its clinical use. However, 
it is a composite of five elements, two of which are scoring systems themselves. 
Furthermore, the need for an upright X-ray examination may hamper its timely 
application. On the other hand, we did not observe robust predictive values for SIRS, 
APACHE II and truncated SOFA, consistent with current literature.295 As clinical 
scoring systems generally suffer from their cumbersome nature and are not 
intrinsically superior to routine biomarkers, clinicians still prefer simple laboratory 
assays based on novel biomarkers.  
 
BUN is a key component of BISAP and has been validated for predicting mortality.328  
A recent study shows that a rise in BUN within 24 hours of admission is strongly 
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associated with higher rates of POF and pancreatic necrosis.312 Findings from our 
study corroborate those from previous studies and show that urea at 48 hours (≥ 8 
mmol/l) had similar predictive values to circulating histones within 24 hours (≥ 5.4 
μg/ml); both were very effective for mortality prediction. Urea at 48 hours identified 
all fatal clinical outcomes with high specificity (93.2%) in our cohort, highlighting its 
importance for mortality prediction. However, urea was inferior to circulating histones 
in predicting POF, but better for major infection.  
 
CRP is one of the most widely accepted and used measure in predicting acute 
pancreatitis severity, but was evaluated primarily based on the 1992 Atlanta 
Classification.314, 317 In this study, CRP at 48 hours (≥ 250 mg/l) had relatively strong 
predictive values for POF (AUC: 0.89; 95%CI: 0.84-0.94), major infection (AUC: 
0.83; 95%CI: 0.75-0.92) and mortality (AUC: 0.86; 95%CI: 0.79-0.93). Circulating 
histones had better predictive values in terms of POF and mortality compared to CRP, 
but was less effective in the prediction of major infection. CRP only became useful 48 
hours after admission and circulating histones outperformed CRP for early prediction. 
However, CRP values also reflect disease progression, successful intervention and 
improvement, something as yet untested for circulating histones and so the continued 
use of CRP should still be strongly recommended. Mechanistically, CRP has recently 
been shown to rise later than circulating histones in a trauma-induced lung injury and 
serves as a detoxifying molecule to block the histone binding to cellular membranes.265  
As the emerging role of DAMPs continues to unravel in experimental and human acute 
pancreatitis, the relationship of CRP to circulating histones, HMGB1, DNA and other 
DAMPs warrants further investigation.   
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The value of hematocrit in predicting severity of acute panceatitis has been 
controversial. We could not confirm predictive values reported by a recent large cohort 
multicenter study.312 This discrepancy may be because previous studies looking at 
hematocrit, urea and BISAP were not as stringent in limiting time from the onset of 
pain to hospital admission, thus limiting their findings. Our study strictly applied pre-
defined inclusion and exclusion criteria and assessed patients early following disease 
onset, making our findings more reliable. We were unable to observe statistically 
significant predictive values for neutrophil/lymphocyte ratio or white blood cell count 
within 24 hours of admission. Other clinical biomarkers such as albumin, total protein, 
hemoglobin, bicarbonate, prothrombin time, adjusted calcium and magnesium had 
little predictive value for POF and mortality in out cohort (data not shown). IL-6 and 
IL-8 had low to moderate predictive value. These findings collectively support the 
utility of circulating histones in the early prediction of acute pancreatitis severity. 
 
The most studied DAMP in the acute pancreatitis setting is HMGB1. Based on 
previous reports 329, 330 significant release of HMGB1 also occurs beyond 24 hours in 
experimental acute pancreatitis thus implying it may not be useful in the early 
prediction of POF. In contrast, we have previously demonstrated that levels of 
circulating histones rise within 2 hours in experimental acute pancreatitis325 and early 
in human acute pancreatitis as demonstrated here. We observed strong correlation 
between peak histone levels and pancreatic necrosis in animal acute pancreatitis 
models, 325 however histone levels within 24 hours of admission in this study did not 
correlate with MCTSI or predict pancreatic necrosis. This discrepancy may be due to 
the time point of blood collection, or indeed represents a fundamental difference in 
disease progression, as pancreatic necrosis occurs several days later in humans than in 
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animal models. Therefore, pancreatic acinar cells are likely to contribute very little to 
levels of circulating histones in early stage disease. Instead, immune cells such as 
neutrophils may contribute to the majority of histones detectable in blood released as 
they may be released during NETosis,125 as well as primary and secondary necrosis. 
Our observation that histone levels were strongly associated with the proportion of 
dead/dying peripheral leukocytes supports this argument. Therefore, histone levels 
may indeed reflect the intensity of systemic inflammation and auto-amplification of 
inflammation, thus determining disease severity.  
 
In conclusion, circulating histones predicting major clinical outcomes, particularly 
POF within 48 hours of disease onset, and are more effective than any available 
clinical marker. Measuring circulating histones is of great clinical importance and 
holds immediate translational potential. As such measuring circulating histones may 
be candidates for integration into current scoring systems to enhance the early, 
accurate and robust stratification of severe acute pancreatitis and to ensure timely, 
appropriate care of high-risk patients. 
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Chapter 6 – Elevated circulating histones are associated with multiple organ 
dysfunction syndrome in patients with acute pancreatitis 
 
 
6.1 Introduction  
 
 
Acute pancreatitis is one of the most common digestive diseases that require emergency 
admission301, 331. The incidence of acute pancreatitis has escalated from 5 to 30 per 10 
million people over the last 50 years in the United Kingdom332. Approximately 15-20% 
of acute pancreatitis patients experience a complicated clinical course with 
manifestations of organ failure, local complications and major infections304, 333. These 
local and systemic determinants formed the basis of the Revised Atlanta Classification 
(RAC)300 which stratifies acute pancreatitis severity into mild, moderate and severe. The 
“severe” category, defined as presence of persistent organ failure (POF), especially 
multiple organ dysfunction syndrome (MODS)286, 305, 306, 334, 335, has been well 
established to be the most critical contributor to mortality, but the underling mechanisms 
remain to be elucidated.  
 
Studies that have attempted to link pancreatic necrosis to MODS are not conclusive yet. 
How a single organ lesion triggers the systemic inflammatory response syndrome 
(SIRS) and the subsequent MODS remains elusive. However, it is generally recognised 
that immunological factors336 play important roles. Inflammatory cytokine storm is 
believed to be the fundamental factor in the pathogenesis of SIRS and MODS in acute 
pancreatitis337. This process is characterised by an initial sterile inflammation that results 
from injured pancreatic acinar cells, the primary victims of acute pancreatitis338, 339. 
Necrotic or apoptotic acinar cells release their intracellular pro-inflammatory contents, 
such as histones, high-mobility group box protein 1 (HMGB1), DNA, mitochondrial 
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components, adenosine triphosphate and heat shock protein 70 into the extracellular 
space to trigger cytokine release and enhance inflammation274. These cellular 
breakdown products are collectively called damage–associated molecular pattern 
molecules (DAMPs)274. The role of DAMPs has been increasingly identified in critical 
illness and some of them (e.g. HMGB1 and cell-free DNA) have been shown to correlate 
positively with disease severity in both experimental models and patients with acute 
pancreatitis274.   
 
Intra-nuclear histones are the most abundant nuclear proteins that play essential roles in 
DNA packaging and gene regulation. However, released histones following extensive 
cell or organ damage, such as in severe trauma271, liver injury322 and severe sepsis213, 320, 
are toxic to various mammalian cells causing injury to MODS including the heart, lungs, 
kidneys and liver213, 271, 275, 276, 320, 322, 340, 341. Recent reports showed that in the lungs, 
neutrophils extracellular traps (NETs) could release histones locally and damage 
epithelial cells340, 342. Cellular toxicity results from direct membrane binding and 
resultant calcium influx271, 343. In addition, circulating histones are directly pro-
inflammatory by stimulating leucocytes to secrete cytokines that include tumour 
necrosis factor-alpha (TNF-α), interleukin (IL)-1, IL-6 and IL-8322. This process 
involves Toll-like receptor (TLR)-2, TLR-4 and TLR-9. The involvement of TLR-4 and 
IL-6 in the pathogenesis of acute pancreatitis has been extensively described344, 345. 
Recently, histones were reported to activate NLRP3 inflammasomes278, 279, 342 to 
enhance the release of IL-1beta (IL-1β) and IL-18, which are also reported to play roles 
in ACUTE PANCREATITIS346. Histones are also pro-thrombotic through endothelial 
damage, von Willebrand factor-mediated leucocyte recruitment, platelet activation and 
the protein C anticoagulant pathway322, 347, 348 and may enhance MODS by impairing 
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microcirculation. We have reported that extracellular histones can directly trigger 
neutrophils to release myeloperoxidase and form NETs271, the later further releases 
histones. Therefore, a vicious cycle may exist to further damage microcirculation and 
enhance organ injury340.   
 
In chapter 4 we showed that circulating histones are significantly elevated in mouse 
models of necrotising acute pancreatitis and associated with pathological scores of 
pancreatic necrosis and distal organ injury349. In chapter 5, we further demonstrated that 
on admission elevated circulating histones (≥ 5.4 µg/ml) are accurate predictors for POF 
and morality in patients with human acute pancreatitis.   
 
In this chapter, we examined (1) whether circulating histone levels are correlated with 
clinical severity scores, proinflammatory cytokines and individual organ injury markers; 
(2) whether circulating histones are associated with organ failure status; (3) which factor 
(e.g. POF, pancreatic necrosis, and infection) is principally associated elevated 
circulating histones.    
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6.2 Patients and Methods 
6.2.1 Study population and ethics 
Consecutive patients primarily admitted to Royal Liverpool University Hospital 
(RLUH) between 2010 and 2015 were included. A first episode of acute pancreatitis, 
established by clinical symptoms, laboratory tests and/or imaging as defined by 2012 
RAC admitted within 72 h of symptom onset300.  Exclusion criteria were: (1) age < 18 
or > 85 years; (2) trauma, pancreatic neoplasm, pregnancy and chronic pancreatitis as 
aetiologies; (3) advanced pulmonary, cardiac, renal or malignant diseases. Referral 
patients with POF admitted to Intensive Care Unit (ICU) fulfilling the above criteria 
were also included.  
 
For primary admitted patients, peripheral blood samples were obtained within 24 h of 
admission. For referral patients, blood samples were taken at RLUH ICU admission and 
daily for up to a week. Blood samples were also collected from heathy volunteers. Serum 
and plasma were isolated and stored at -80°C in the National Institute for Health 
Research (NIHR) Liverpool Biomedical Research Unit Control and Acute Pancreatitis 
Biobanks, according to protocols approved by local research ethics committees (REC 
references: UoL000933, 11/WNo01/1, 13/NW/0089 and 10/H1308/31). The collection, 
process and storage of samples stringently followed standard operating procedures 
(SOPs) according to Good Clinical Laboratory Practice (GCLP) standards. 
 
6.2.2 Clinical data collection  
Extensive clinical data were prospectively recorded and maintained in an e-database. 
SIRS, Acute Physiology and Chronic Health Evaluation II (APACHE II) and SOFA 
scores (at least one of the respiratory, cardiovascular or renal systems302) were calculated 
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within 24 h of admission for primarily admitted patients or daily for referral patients, 
respectively, according to published definitions295.  
 
POF was defined as at least one organ having a SOFA score of ≥ 2 for ≥ 48 h. Local 
complications (pancreatic necrosis; acute peripancreatic fluid collection, APFC; vein 
thrombosis) were defined as per RAC300 according to enhanced computerised 
tomography (CECT). Pancreatic necrosis was quantified using the modified CT severity 
index294. Infection was defined as positive culture from body fluid, blood and tissue. 
Major infection was defined as presence of infected pancreatic necrosis and/or sepsis. 
To study the association of these variables with circulating histones, local complications 
and infected pancreatic necrosis were calculated by 7 days before or after sampling, 
while transient organ failure, POF and other infections were calculated by 3 days before 
or after sampling. 
 
6.2.3 Blood sample analysis  
Circulating histone levels were determined by Western blotting as described 
previously265, 271, 320, 325, 350, 351. Cytokines/chemokines, including IL-1β, IL-6, IL-8 and 
monocyte chemoattractant protein (MCP)-1 were measured using commercial ELISA 
kits (R&D, Abingdon, UK). Arterial blood gases, serum cardiac troponin T, urea, 
creatinine, bilirubin, alanine aminotransferase and albumin were reported by the 
Department of Clinical Biochemistry of the RLUH.  
 
6.2.4 Statistical analysis  
Continuous variables and categorical data were described as median with interquartile 
range (IQR) and number and percentage, respectively. Mann-Whitney U test and 
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Kruskal-Wallis H test were used to determine statistical differences between two groups 
and three or more groups, respectively. Spearman rank correlations were used to analyse 
the associations between two continuous variables. Univariate analysis was performed 
for the association of each variable with circulating histones by bivariate logistic 
regression. Multivariate analysis was further performed included variables with P < 0.1 
from univariate analysis. These variables were age (≤ 60 or > 60 years), aetiologies 
(biliary, alcohol and other aetiologies), Charlson score (< 2 or ≥ 2), transient organ 
failure (presence or absence), POF (presence or absence), pancreatic necrosis (absence, 
< 30%, 30-50%, ≥ 50%) and major infection (presence or absence). Circulating histones 
were transformed to dichotomous variables according to cut-off values of 5.4 μg/ml 
(Chapter 5) and 20 μg/ml271.   
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6.3 Results  
6.3.1 Patient characteristics and clinical outcomes 
A total of 260 consecutive primarily admitted patients and 52 referral patients were 
included. The patient characteristics and clinical outcomes are shown in Table 6.1. There 
were 235 primarily admitted patients did not develop POF during hospital stay (176 
mild and 59 moderate; Non-POF); 25 developed POF either within 24 h of admission 
or later (POF < 24 h). All referral patients had POF prior to transfer and the POF 
persisted at least > 48 h after RLUH ICU admission (POF > 48 h).  
 
For primary patients, the median age was 55 years with 124 (47.7%) males. A hundred 
thirty-three (51.2%) patients were biliary aetiology, followed by 53 (20.4%) alcohol and 
others. The median Charlson score was 0. There were 21 (8%) patients needed intensive 
care, 32 (12.3%) developed APFC and 37 (14.2%) had pancreatic necrosis. Ten (3.8%) 
patients underwent pancreatic drainage and/or necrosectomy, 14 (5.4%) manifested 
major infection and 9 (3.5%) patients died, all of them were from the severe group. The 
median length of hospital stay was 7 days. The median age in the referrals was 61 years 
with 28 (53.8%) patients were males. Biliary was also the leading cause with 22 (42.3%) 
patients, followed by 13 (25%) alcoholics and other aetiologies. The median 
comorbidity score was also 0. Patients were referred at a median of 7.5 days (4-12.8) 
after primary hospital admission and all patients needed intensive care when transferred. 
Six (11.5%) patients were detected APFC and 44 (84.6%) had pancreatic necrosis. 
Twenty-three (44.2%) patients received surgical intervention, 45 (86.5%) patients 
developed major infection and 11 (21.2%) died. The median hospital stay was more than 
10 weeks.   
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Table 6.1 Patient characteristics and clinical outcomes  
Demographics Primary 
n = 260 
Referral 
n = 52 
Age, years, median (IQR) 55 (42-69) 61 (43-73) 
Gender, males, n (%) 124 (47.7) 28 (53.8) 
Aetiology, n (%)    
    Biliary 133 (51.2) 22 (42.3) 
    Alcohol 53 (20.4) 13 (25.0) 
    ERCP 11 (4.2) 1 (1.9) 
    Drug-induced 5 (1.9) 0 (0) 
    Others 58 (22.3) 16 (30.8) 
Comorbidity: Charlson score, median (IQR) 0 (0-0) 0 (0-0) 
Days to referral, median (IQR) NA 7.5 (4-12.8) 
RAC severity category, n (%)   
    Mild  176 (67.7) 0 (0) 
    Moderate 59 (22.7) 0 (0) 
    Severe 25 (9.6) 52 (100) 
Need for HDU/ICU, n (%)  21 (8.0) 52 (100) 
Peripancreatic fluid collection, n (%) 32 (12.3) 6 (11.5) 
Pancreatic necrosis, n (%) 37 (14.2) 44 (84.6) 
Pancreatic necrosectomy and/or drainage, n (%) 10 (3.8) 23 (44.2) 
Infected pancreatic necrosis and/or sepsis, n (%) 14 (5.4) 45 (86.5) 
Mortality, n (%) 9 (3.5) 11 (21.2) 
Days of hospitalisation, median (IQR) 7 (4-14) 74 (46-128) 
IQR, interquartile range; ERCP, endoscopic retrograde cholangiopancreatography; 
NA, not available; RAC, Revised Atlanta Classification; HDU, high dependence unit; 
ICU, intensive care unit. 
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6.3.2 Circulating histones are significantly correlated with clinical severity scores, 
proinflammatory cytokines and individual organ injury markers 
We first analysed the correlation of circulating histones with clinical severity scores, 
proinflammatory cytokines and individual organ failure markers. Results of Spearman 
correlation analysis are shown in Table 6.2. It appeared that circulating histones had 
strong correlation with serum IL-8 levels (rs = 0.566), followed by SIRS, APACHE II, 
SOFA, IL-1β and IL-6 (rs = 0.321-0.425). Circulating histones also signifcnatly 
correlated with respiratory (PaO2/FiO2, rs = -0.373), cardiac (cardiac troponin T, rs = 
0.321) and renal (urea, rs = 0.22) injury paramers. However, circulating histones were 
not signifcnatly correlated with creatine, bilirubin, alanine aminotransferase (all P > 
0.05). 
 
6.3.3 Circulating histones are highly associated with organ failure status  
As circulating histones were significantly correlated with clinical severity scores, 
proinflammatory cytokines and individual organ failure markers (assessed at the same 
time when blood was drawn for histone measurement), we postulated that circulating 
histones were associated with organ failure status. The circulating histone levels 
according to different groups are shown in Figure 6.1. There were no significant 
differences in circulating histone levels among healthy volunteers (median 0.81 µg/ml 
[IQR: 0.38-1.6]), mild (1.1 µg/ml [0.5-2.1]) and moderate (1.4 µg/ml [0.5-2.8]) patients 
(all P > 0.05). However, the circulating histones were dramatically elevated in the 
primary severe group (22.9 µg/ml [5.9-40]) when compared to these three groups (all P 
< 0.01). Furthermore, the peak circulating histone levels of the referrals (34.1 µg/ml 
[21.5-80.6]) were even higher than that of the primary severe patients (P < 0.05; Figure 
6.1A).  
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Table 6.2 The correlation of circulating histones to various parameters  
Variables rs P value 
Clinical severity scores   
    SIRS 0.349 < 0.001 
    APACHE II 0.425 < 0.001 
    SOFA  0.397 < 0.001 
Proinflammatory cytokines   
    IL-β (pg/ml) 0.376 < 0.001 
    IL-6 (pg/ml) 0.367 < 0.001 
    IL-8 (pg/ml) 0.566 < 0.001 
    MCP-1 (pg/ml) 0.014 0.285 
Individual organ injury markers   
   PaO2/FiO2 (mmHg) -0.373 < 0.001 
   Cardiac troponin T (ng/ml) 0.321 < 0.001 
   Urea (mmol/l) 0.22 < 0.001 
   Creatinine (µmol/l) 0.083 0.113 
   Bilirubin (µmol/l)* -0.094 0.161 
   Alanine aminotransferase (U/l)* -0.008 0.053 
   Platelets (×109/l)  0.04 0.094 
SIRS, Systemic Inflammatory Response Syndrome; APACHE II, Acute physiology 
and Chronic Health Examination II; SOFA, Sequential Organ Failure Assessment; IL, 
interleukin; MCP-1, monocyte chemoattractant protein; PaO2/FiO2, partial pressure 
arterial oxygen and fraction of inspired oxygen. 
*Biliary aetiology excluded.  
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We therefore analysed data according to Non-POF (primary mild and moderate), POF 
< 24 h (primary severe) and POF > 48 h (referrals and severe) categories. The correlation 
of circulating histones and parameters significantly associated with histones to organ 
failure status are shown in Table 6.3. All the parameters were significantly different 
among the three groups in SIRS, APACHE II, SOFA, PaO2/FiO2 and circulating 
histones. There were significant differences for either two groups for all the other 
parameters assessed. Spearman correlation analyses revealed that the circulating histone 
levels were most highly associated organ failure status (rs = 0.693), closely followed by 
SOFA (rs = 0.658), IL-8 (rs = 0.625), APACHE II (rs = 0.619) and PaO2/FiO2 (rs = -
0.565). While other parameters (SIRS, IL-1β, IL-6, cardiac troponin T and urea) still 
had significant correlation with organ failure status but the rs values were less than 0.5. 
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Figure 6.1 Circutlating histones are aossicated with organ failure status. The blood 
sampling time was within 24 h of admission for primary patients or at RLUH ICU 
admission and daily for up to a week for referrals. Comparison of circulating histone 
levels among heathy volunteers (n = 48), primary disease categories (RAC: mild = 176; 
moderate = 59; severe = 25) and referrals (n = 52). *P < 0.05 vs. healthy volunteers; †P 
< 0.05 vs. mild or moderate primary patients; ‡P < 0.05 vs. primary severe patients.  
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Table 6.3 The correlation of circulating histones and other parameters with organ failure status  
Parameters Group 1 (Non-POF) 
n = 235 
Group 2 (POF < 24 h) 
n = 25 
Group 3 (POF > 48 h) 
n = 52 
P value* rs|| 
Clinical scores      
    SIRS 1 (0-2) 2 (1-12) 2 (2-3) < 0.001† 0.475 
    APACHE II 5 (3-8) 9 (6-12) 16 (12-19) < 0.001† 0.619 
    SOFA  1 (0-1) 2 (1-4) 7 (3-9) < 0.001† 0.658 
Inflammatory parameters      
    Circulating histones (µg/ml) 1.2 (0.5-2.3) 22.9 (5.9-39.6) 34.1 (21.5-80.6) < 0.001† 0.693 
    IL-1β (pg/ml) 0.6 (0-2.6) 2.3 (0-5.7) 2.8 (1.5-4.8) < 0.001‡ 0.369 
    IL-6 (pg/ml) 24.8 (7.6-62.2) 60.5 (19.7-154.8) 122.5 (30.8-230.8) < 0.001§ 0.408 
    IL-8 (pg/ml) 11.7 (1.2-25.6) 47.6 (18.4-173.3) 71.1 (41.8-131.5) < 0.001§ 0.625 
Individual organ injury markers      
   PaO2/FiO2 (mmHg) 368 (321-414) 295 (176-358.9) 190.5 (161.6-224.1) < 0.001† -0.565 
   Cardiac troponin T (ng/ml) 5 (3-11) 17.5 (6.8-35.5) 15.7 (4.7-40) 0.001§ 0.397 
   Urea (mmol/l) 4.9 (3.7-6.2) 6.9 (4.8-8.9) 7 (4.1-12.1) 0.003§ 0.272 
POF, persistent organ failure; SIRS, Systemic Inflammatory Response Syndrome; APACHE II, Acute physiology and Chronic Health Examination 
II; SOFA, Sequential Organ Failure Assessment; IL, interleukin. PaO2/FiO2, partial pressure arterial oxygen and fraction of inspired oxygen.                             
*P value indicates comparison among three groups. †Any two groups’ comparison was significant. ‡Group 1 vs. Group 2 was significant. §Group 
1 vs. Group 2 or 3 was significant. ||All P < 0.001 in Spearman correlation analyses.  
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6.3.4 Univariate and multivariate logistic regression analysis 
Results of the univariate analysis are shown in Table 6.4. In the univariate analysis, we 
found that POF, pancreatic necrosis and major infection were significantly associated 
with elevated circulating histones (≥ 5.4 μg/ml). Whereas age, gender, aetiology, 
comorbidity, transient organ failure and other local complications were not significantly 
correlated to elevated circulating histones.  
 
Results of the multivariate analysis are shown in Table 6.5. Fitting the positive 
parameters (at a cut-off of P < 0.1) from univariate analysis into multivariate logistic 
regression model, we found that only POF had significant association with elevated 
circulating histones for all primary patients (OR = 57.1, 95% CI: 14.2 to 229.8, P < 
0.001). Pancreatic necrosis (regardless of necrotic size) and major injection, however, 
were not found to be statically significant (all P > 0.05). When primary and referral 
patients were combined together, both POF (OR = 121.5, 95%CI: 29.1 to 506.9, P < 
0.001) and major infection (OR = 4.6, 95%CI: 1.1 to 19.8, P = 0.041), but not pancreatic 
necrosis, were significantly associated with elevated circulating histones. When the 
circulating histone cut-off value was ≥ 20 μg/ml, a known concentration for direct 
cytotoxicity271, POF was even stronger associated with elevated circulating histones in 
primary patients (OR = 98.1, 95% CI: 14.4 to 669.0, P < 0.001). Similar findings were 
obtained when primary and referral patients were merged (OR = 177.2, 95%CI: 33.4 to 
941.2, P < 0.001). However, major infection was not further shown to be significantly 
correlated to the increase of circulating histones in either primary patients or the 
combined primary and referral patients (both P < 0.05). These findings strongly suggest 
that POF was the dominating factor that associated with raised circulating histones.  
137 
 
Table 6.4 Univariate logistic regression of risk factors for elevated circulating histones 
 Primary  Primary and referral  
Variables (at histones cut-off ≥ 5.4 µg/ml) OR (95% CI) P value OR (95% CI) P value 
Age, years 1.06 (0.52-2.17) 0.866 1.32 (0.80-2.20) 0.267 
Gender, males 0.90 (0.44-1.82) 0.765 0.90 (0.55-1.49) 0.686 
Aetiology     
    Biliary 0.73 (0.36-1.49) 0.387 0.70 (0.42-1.16) 0.163 
    Alcohol 0.75 (0.30-1.92) 0.552 1.10 (0.60-2.02) 0.751 
    Others* 1.74 (0.84-3.62) 0.139 1.01 (0.58-1.77) 0.974 
Comorbidity: Charlson score 1.31 (0.59-2.89) 0.511 1.13 (0.63-2.03) 0.676 
Organ failure     
    Transient organ failure 0.70 (0.23-2.10) 0.523 0.51 (0.22-1.20) 0.122 
    Persistent organ failure 73.67 (19.81-273.92) < 0.001 137.10 (52.31-359.33) < 0.001 
Pancreatic necrosis     
    No necrosis† 2.11 (0.83-5.35) 0.116 1.60 (0.77-3.33) 0.207 
    Necrosis < 30% 2.10 (0.72-6.13) 0.176 2.60 (1.21-5.60) 0.014 
    Necrosis 30-50% 4.54 (1.22-16.98) 0.024 7.89 (2.95-21.12) < 0.001 
    Necrosis > 50% 6.53 (0.89-47.91) 0.065 17.47 (6.40-47.69) < 0.001 
Major infection 11.00 (2.93-41.24) < 0.001 31.08 (11.60-83.31) < 0.001 
OR, odds ratio; CI, confidence interval. 
*Include endoscopic retrograde cholangiopancreatography, drug-induced, idiopathic and unknown aetiologies.  
†May include local complications such as acute peripancreatic fluid collection and/or vein thromboses. 
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Table 6.5 Multivariate logistic regression of independent predictors for elevated circulating histones 
 Primary  Primary and referral  
Variables (at histones cut-off ≥ 5.4 µg/ml) OR (95% CI) P value OR (95% CI) P value 
    Persistent organ failure 57.2 (14.2-229.8) < 0.001 121.5 (29.1-506.9) < 0.001 
    Necrosis < 30% NA NA 0.9 (0.2-4.6) 0.923 
    Necrosis 30-50% 1.2 (0.1-10.8) 0.853 1.5 (0.2-11.0) 0.713 
    Necrosis > 50% 1.7 (0.1-40.0) 0.731 0.4 (0.1-2.6) 0.332 
    Major infection 4.3 (0.7-28.4) 0.126 4.6 (1.1-19.8) 0.041 
Variables (at histones cut-off ≥ 20 µg/ml)     
    Persistent organ failure 98.1 (14.4-669.0) < 0.001 177.2 (33.4-941.2 < 0.001 
    Major infection 4.1 (1.2-11.5) 0.092 4.4 (1.4-14.0) 0.14 
OR, odds ratio; CI, confidence interval; NA, not applicable. 
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6.4 Discussion 
This study supports our previous observations in acute pancreatitis mouse models349 (Chapter 4) 
and patients (Chapter 5) that circulating histones were elevated in severe disease. The present 
work found that circulating histones were significantly correlated with clinical severity scores, 
proinflammatory cytokines and individual organ injury markers. Circulating histones not only 
significantly elevated early in patients with severe acute pancreatitis but also even more so during 
disease progressing. We also demonstrate significant associations of distant organ injury and 
severity of the diseases with the levels of circulating histones. Moreover, multivariate logistic 
regression analysis reveals that POF, but not pancreatic necrosis or other factors, was most 
closely associated with elevated circulating histones. These data strongly suggest that histone 
toxicity may play an important role in the development of distant organ injury and even MODS 
in acute pancreatitis as reported in other diseases213, 271, 277, 322.  
 
The role of extracellular histones to be important proinflammatory mediators in sterile 
inflammation has been increasing recognised199. Recently, we325 and others125 have shown that 
circulating histones and NETs (major constitutes are histones) were elevated in experimental and 
human acute pancreatitis respectively. Furthermore, anti-histone antibody rescued mice from 
death in experimental acute pancreatitis222 and neutralising reagents polysialic acid prevented 
trypsin and signalling activation in isolated pancreatic acinar cells125. To elaborate these findings, 
we have demonstrated most of the primary severe patients had circulating histone levels ≥ 5.4 
μg/ml, a concentration that accurately predicted POF and mortality in the Chapter 5. There were 
56% (14/25) primary severe and 78.8% (41/52) referral patients had circulating histone levels ≥ 
20 μg/ml, a known direct cytotoxicity level in in vitro studies271. However, the circulating histone 
levels in mild and moderate patients remained low and were similar to healthy volunteers. In the 
correlation analysis, we found that circulating histones were strongly correlated to acute 
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pancreatitis disease severity and stage where patients with fully established POF had highest 
circulating histone levels. These data demonstrate that elevated circulating histones may be 
important proinflammatory mediators that contributed to POF in acute pancreatitis. 
 
The toxicity of histones to different organs, such as the lung, heart, kidney and the liver has been 
demonstrated in different animal models213, 271, 275, 276, 320, 322, 340, 341, 343, 352. In our previous study, 
we found that in mouse acute pancreatitis models, the organ injury markers are associated with 
histone levels. In this study, we also demonstrate that the biochemical markers of most affected 
organs in acute pancreatitis, the lung, cardiovascular and renal systems, were significantly 
correlated to the levels of circulating histones. The PaO2/FiO2 ratio is an indicator reflecting 
whether the patient has hypoxemia or not when the blood is sampled. In the very early stage of 
acute pancreatitis, hypoxemia is not only affected by respiratory function per se but also by other 
factors such as abdominal pain and fluid therapy. The hypoxemia will be corrected in most of the 
patients once the pain is controlled and they respond to fluid therapy. This is the case for moderate 
patients in our study as there were about 1/3 of them had PaO2/FiO2 < 300 mmHg, a cut-off value 
for acute respiratory distress syndrome (ARDS) as per Berlin Definition27, but most of them 
recovered very soon without any need for intensive care. Circulating histones elevated 
simultaneously or preceded to ARDS in primary severe acute pancreatitis and much higher levels 
were observed in the referrals, all of whom had ARDS with 55.5% (29/52) suffered from 
moderate/severe ARDS. Therefore, elevated circulating histones within 24 h of primary hospital 
admission may be a better indicator than PaO2/FiO2 < 300 mmHg for long lasting hypoxemia 
and impaired respiratory function. Interestingly, in patients with serum cardiac troponin T levels 
tested, there were 16.8% (20/119), 60% (12/20), 42.3% (22/52) had cardiac troponin T ≥ 14 
ng/ml for patients with non-POF, POF < 1 d and POF > 3 d, respectively. These findings are 
indicative that the cardiac injury may be a common phenomenon in acute pancreatitis. In support 
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of our data, a recently study6 has shown that brain natriuretic peptide353 and cardiac troponin I354 
levels (both are indicators for cardiomyopathy) were significantly elevated in severe acute 
pancreatitis at the first day of admission and positively correlated with SOFA score, serum 
procalcitonin and C-reactive protein levels. Similar to sepsis320, 351, 355, these novel findings 
highlight that in severe acute pancreatitis there was also substantial cell death in myocardium 
(e.g. caused by histones). Therefore, the previous overlooked cardiac troponin T levels may 
deserve to be routinely monitored in severe acute pancreatitis. Urea, but not creatinine, also 
significantly associated with circulating histones, albeit the correlation factor was weaker than 
those obtained for PaO2/FiO2 ratios and cardiac troponin T levels. These observations are 
suggestive that urea outperformed creatinine to reflect renal function, consistent with previously 
findings that blood urea nitrogen is a relative good early predictor for severe acute pancreatitis295 
and mortality328, 356. 
 
Circulating histones have been shown to directly induce liver injury352 and hepatic failure is an 
independent predictor for morality of acute pancreatitis335. However, the levels of bilirubin or 
alanine aminotransferase, markers of liver injury, showed no correlation to circulating histones, 
which was different from the observation in acute pancreatitis animal models349. This 
inconsistence may due to different aetiologies as alcoholics were associated more severe liver 
injury335. This may also due to the overall low incidence of liver injury in our cohorts. Circulating 
histones have been shown to induce coagulation in diseases such as sepsis357 and coagulation 
abnormalities have been linked to severity of acute panreatitis65. However, we did not find a 
significant correlation between platelet counts and circulating histones. In fact, there were only 
9 patients distributed in different severity groups with platelets < 100 × 103/mm3. In another 
study, coagulation failure has not been demonstrated to be an independent predictor for hospital 
mortality of acute pancreatitis patients335. It is worth noting that all the samples were collected 
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either within 24 h of primary hospital admission or less than 3 weeks of admission, representing 
a relative acute stage of this disease. Further time-course studies are needed to investigate 
whether there are correlations of circulating histones to liver injury and coagulation in acute 
pancreatitis, especially in the disease late stage.  
 
The source of circulating histones is not fully clear. The strong correlations to pancreatic necrosis 
scores in both animal models349 and patients indicate that the death of acinar cells could be a 
major contributor. However, in many patients, the extents of pancreatic necrosis were not closely 
associated with circulating histone levels, indicating that other sources co-exist.  Previous studies 
suggest that immune cells, such as during NETosis, may release substantial amounts of 
histones340, which may occur before acinar cell death and trigger local and systemic 
inflammation278, 279, 358 as indicated by the significant increase in proinflammatory 
cytokines/chemokines, such as IL-1β, IL-6, IL-8 and MCP-1359. However, a direct evidence of 
immune cells contributing to the elevation of circulating histone is still lacking. In our study, 
multivariate analysis revealed that POF, but not pancreatic necrosis, was significantly and 
dominantly associated with elevated circulating histones using their relevant cut-offs. These 
findings suggest that MODS may be companied with large number of cell death which in turn 
contributes to histone elevation. In addition, histone-enhanced NETs formation271 may also 
release histones. Recently, extracellular histones have been shown to induce lymphocyte 
apoptosis in an experimental sepsis model360. As lymphocyte apoptosis has also been associated 
with severe acute pancreatitis in both animals and patients, it may well be that the circulating 
histones could be responsible for these results and in turn apoptotic lymphocytes further release 
more circulating histones. Therefore the actual scenario is complicated and could be a vicious 
cycle that drives certain acute pancreatitis into a severe form although the pancreatic injury could 
be severe at the onset. The associations established from this clinical study was in favour of POF-
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induced cell death was the major source of circulating histones. However, there is a limitation 
that the causal-effect relationship between pancreatic necrosis and POF and the real source of 
circulating histones due to POF cannot be clarified without further investigation.   
 
Circulating histones significantly elevate in patients with severe acute pancreatitis and strongly 
correlate to disease severity and stage, clinical severity scores, proinflammatory 
cytokines/chemokines and parameters of MODS. Cell death resulted from POF may be the major 
sources of circulating histones, which have great potential to serve as prognostic markers and 
therapeutic targets for the management of severe acute pancreatitis in near future.  
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Chapter 7 – Overview 
 
In the Chapter 2, we first and systemically tested the cytotoxicity of full length and truncated 
histone subclasses. In order to synthesise truncated histones (N-terminal or C-terminal), we first 
generated anti-histone single chain variable fragment (ahscFv) and control IgG chain variable 
fragment (cscFv). The expression of ahscFv and cscFv was confirmed by Coomassie Brilliant 
Blue. The binding capacity of ahscFv and cscFv against histone H3 was test by Western blot, 
shown ahscFv (but not cscFv) bound to the histone. The binding capacity of ahscFv to histone 
subclasses was further confirmed by gel overlay and biosensor analyses. Therefore, the ahscFv 
was used in the subsequent studies.  
 
We found that all the fluorescein isothiocyanate-full length and 3 truncated histones (H1.1 C, 
H2A N, H3.1 N) bound to the cell membrane and induced calcium influx in an endothelial cell 
line. Other truncated histones did not bind to cell membrane, nor induced calcium influx. These 
data imply that a portion of histone subclasses still have cytotoxicity effects even when histones 
are degraded (truncated), highlighting the necessity of measuring all forms of circulating histones 
(histone-DNA complexes, free or truncated histone subclasses).  Having this idea in mind, we 
endeavoured to develop an assay to measure all forms of circulating histones using xMAP 
technology in Chapter 3. We successfully generated the stand curves in buffer system, but the 
recovery ratio in spiked plasma was low and failed to detect the histones in patient plasma which 
were detectable by Western blot. Our work adds a layer of evidence for the difficulties of 
developing a rapid, reliable assay to quantify all forms of circulating histones as currently only 
histone-DNA complexes can be commercially measured by enzyme-linked immunosorbent 
assay. 
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In Chapter 4, we tested circulating histones in three experimental acute pancreatitis models in 
mice with graded severity. Four intraperitoneal injections of caerulein induced only oedematous 
acute pancreatitis with little systemic inflammation and minimum rise of circulating histones at 
all time points tested. Early and significant elevation of circulating histones was observed in both 
12 caerulein injection model and sodium taurocholate (NaTC) intraductal infusion model. Both 
of these models developed marked pancreatic necrosis and distant organ injury with the overall 
severity greater induced by NaTC. The circulating histone levels were significantly associated 
with pancreatic necrosis and multiple organ injury parameters. We thus postulated that the 
sources of circulating histones may from both injured pancreas and distant organ injury products.  
 
In Chapter 5 and Chapter 6, we went to testify our hypotheses in human acute pancreatitis 
admitted to Royal Liverpool University Hospital (RLUH). In Chapter 5, we included a 
consecutive cohort contained patients admitted within 48 h of disease onset to hospital admission 
to see whether circulating histones would have a predictive value for major complications of 
acute pancreatitis. Interestingly, circulating histone levels did not differ from heathy volunteers 
(n = 47), mild (n = 156) and moderate (n = 57) acute pancreatitis patients (classified by Revised 
Atlanta Classification300, RAC). Circulating histones only marked elevated in severe acute 
pancreatitis (n = 23), a group of patients who had developed persistent organ failure (POF) during 
the clinical course. At a cut-off value of 5.4 µg/ml, circulating histones accurately predicted POF 
with sensitivity and specificity of 82.6% and 94.4%, respectively, higher than all clinical scores 
and biochemical markers tested simultaneously. Circulating histones also had good predictive 
value for mortality as mortality only occurred in patients with POF which circulating histones 
can accurately predict. However, circulating histones did not predict or correlate with pancreatic 
necrosis or any local pancreatic complications, highlighting other sources may exist. In line with 
this thought, we have observed that circulating histones were strongly associate with leucocyte 
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viability. This observation opens up the possibility that apoptotic neutrophils or neutrophil 
extracellular traps (NETs) could be a significant source for circulating histones.      
 
In Chapter 6, we analysed circulating histones and clinical data obtained from two separate 
cohorts of patients. The first cohort included 260 consecutive patients (mild = 176; moderate = 
59; severe = 25) admitted within 72 h of symptom onset and sampled within 24 h of admission. 
The second cohort included 52 constitutive patients who were referred to the Intensive Care Unit 
(ICU) of RLUH. All these patients were referral for potential management of local complication 
and had ongoing POF prior to transfer. Blood samples were obtained when they arrived RLUH 
ICU and daily for up to 7 days. The peak histone levels from referral patients were used through 
the study. It was found that circulating histones were significantly associated with clinical 
severity scores, proinflammatory cytokines and individual organ injury parameters. As 
circulating histones accurately predicted POF and were associated with disease severity 
parameters, we reasoned that circulating histones could reflect organ failure status. In another 
word, circulating histone levels would rise when disease severity has progressed. In agreement 
with these thoughts, when compared with the primary severe patients sampled on admission, 
referral patients had much higher elevated circulating histones. As circulating histones did not 
significant elevate in primary mild and severe patients, we merged these two groups into Group 
1 (no POF). Primary severe patients would have POF < 24 h when sampled regardless when the 
POF occurred, we therefore allocated these patients as Group 2 (POF < 24 h). Referral patients 
consistently at least had POF > 48 h prior to sampling, these were designated into Group 3 (POF 
> 48 h). Values of all clinical parameters, proinflammatory cytokines and organ injury parameters 
tested as well as circulating histones were significantly different among groups. The circulating 
histones had an even higher correlation than that of Sequential Organ Failure Assessment 
(SOFA) score to organ failure status, highlighting the close link between circulating histones and 
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organ failure. To further address the association between circulating histones and organ failure, 
we carried out univariable and multivariable analyses. The analyses revealed that POF had 
predominant association with circulating histones. The experimental and human studies in acute 
pancreatitis suggest: 
 
Elevated circulating histones occur in POF < 24 h and rise to even higher levels during the 
progression of POF in acute pancreatitis;  
 
POF but not pancreatic necrosis most significantly correlated with elevated histones in acute 
pancreatitis;  
 
The sources of circulating histones in severe acute pancreatitis warrant more studies; 
 
Histones may have a pathogenic role and might be targeted to treat POF in acute pancreatitis. 
The proposed role of circulating histones in acute pancreatitis is shown in Figure 7.1. 
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Figure 7.1 Circutlating histones in acute pancreatitis. Pancreatic toxins cause intial injury to 
the pancreas. Extracellular histones and other inflammatory mediators are relased to stimulate 
resident immune cells and circulating neutrophils. Apoptotic, necrotic neutrophils and neutrophil 
extracellular traps (NETs) release more histones and inflammatory mediators to further stimulate 
more neutrophil infilation and NETs formation. Stimulated neutrophils NETs, histones and other 
inflammatory cytokines cause multiple organ dysfunction syndrome (MODS) which in turn 
induce more release of circulating histones, triggering a vicous cycle: uncontroled MODS, 
coagulation and death.  
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Supplementary Table 1 Histone precipitated human plasma proteins* 
Gene name Protein 
Lipoprotein associated  
APOA1 Apolipoprotein A-I 
APOA4 Apolipoprotein A-IV 
APOB Apolipoprotein B-100 
APOC3 Apolipoprotein C-III 
APOE Apolipoprotein E 
CLU Clusterin (apolipoprotein J) 
GPLD1 Phosphatidylinositol-glycan-specific-
phospholipase D 
PON1 Serum paraoxonase/arylesterase 1 
Proteinase inhibitors  
SERPINA1 α-1-Antitrypsin 
A2M α-2-Macroglobulin 
ITIH1 Inter α-trypsin inhibitor heavy chain H1 
ITIH2 Inter α-trypsin inhibitor heavy chain H2 
ITIH3 Inter α-trypsin inhibitor heavy chain H3 
AMBP Protein AMBP (contains α-1-macroglobulin; 
bikunin) 
Complement associated   
C4BPA C4b-binding protein α chain 
C1R Complement C1r subcomponent 
C1S Complement C1s subcomponent 
C3 Complement C3 
C4A Complement C4-A 
Blood coagulation   
FGA Fibrinogen α-chain 
FGB Fibrinogen β-chain 
FGG Fibrinogen γ-chain 
F2 Prothrombin 
KNG1 Kininogen-1 
Immunoglobulins  
IGHA1 Ig α-1 chain C region       
IGHA2 Ig γ-2 chain C region 
IGKC Ig κ-chain C region 
IGLC1 Ig λ-chain C region 
IGHM Ig µ-chain C region 
Cell adhesion  
FN1 Fibronectin-1 
THBS1 Thrombospondin-1 
VTN Vitronectin 
Transport   
ALB Serum albumin 
CP Ceruloplasmin 
TF Serotransferrin 
TTR Transthyretin 
*Adapted from Pemberton et al. 2010214
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Supplementary Table 2 Novel identified histone binding molecules 
Studies Histone types* Binding assay used Molecules 
Friggeri et al. 2012361 H3 ELISA  Mer receptor, αvβ5 integrin 
Allam et al. 2012277 H4  Microscale thermophoresis TLR2, TLR4/MD2 
Lam et al. 2013362 H4 ELISA 
Microtiter plates 
Human serum albumin, neutralised serum 
albumin 
Abrams et al. 2013265 Histones ELISA 
Gel overlay 
C-reactive protein 
Nakahara et al. 2013323 Histones Quartz crystal microbalance twin sensor Recombinant thrombomodulin 
Wildhagen et al. 
2014363 
H3 Western blot and precipitation 
Surface plasmon resonance 
Antithrombin activity depleted heparin 
Zhang et al. 2014364 H4 ELISA N-acetyl-heparin 
Westman et al. 2014365 H1, H2A, H2B, H3.1, H4 ELISA  
Surface plasmon resonance  
MBP-p33 
Daigo et al. 2014366 Histones, recombinant 
histones, histone peptides 
ELISA 
Surface plasmon resonance 
UV-visible spectrum  
Pentraxin 3 
Chaaban et al. 2015367 Histones or recombinant 
histones 
ELISA  
Surface plasmon resonance  
High-molecular-weight hyaluronan, inter-α 
inhibitor protein, heparin 
Westman et al. 2015368 H4 Surface plasmon resonance TLR4/MD2 on THP-1 cells 
Wygrecka et al. 2016369 H1, H2A, H2B, H3.1, 
H4, citrullinated histones 
ELISA  
Filter binding assay  
Microscale thermophoresis  
C1 esterase inhibitor, recombinant C1 
esterase inhibitor, reactive centre-cleaved C1 
esterase inhibitor 
ELISA, enzyme-linked immunosorbent assay; TLR, Toll-like receptor.                                                                                                                
*All histone subclasses were recombinant.  
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Supplementary Table 3 Effects of extracellular histones on different cell types  
Cell types General in vitro and ex vivo findings  Anti-histone strategies  Relevant receptors 
Epithelial cells     
A549 cells341, 369, BEAS-2B cells364, LA-4 
cells340, MLE-12 cells340, mouse alveolar type 
II cells369 
CTHs or H4 induced calcium influx, cytokine (IL-1β, IL-6, IL-10, TNF-α) production and cell 
death (PI or LDH) in multiple cell types; H1 and H4, but not H3, caused significant cell death 
(LDH) in MLE-12 cells. 
Anti-H4, α-histones, APC, 
heparin, polysialic acid, C1INH 
NA 
Hepatocyte cell line L02370 CTHs dose-dependently induced cell death (Cell Counting Kit-8 and LDH). Heparin, α-histones NA 
Pancreatic acinar cells125, 222 H3 did not cause significant secretion of HMGB1; H2A, H2B, H3 and H4 caused significant 
increase of trypsin, chymotrypsin activities and cell death (trypan blue); H3 and H4 significantly 
increased p-STAT3/t-STAT3; CTHs dose-dependently induced cell death (PI). 
Polysialic acid NA 
HEK293 cells322,371, parietal epithelial 
cells372, podocytes372 
CTHs dose-dependently induced TLR2 and TLR4 gene expression in transfected cells, 
respectively; CTHs induced APC generation in thrombin/TM complex expressing cells. 
NA TLR2, TLR4, TLR2/4 
CHO-K1 and CHO-A745 cells367 CTHs induced cell death (PI). NA NA 
Endothelial cells     
HPMECs271, 369, MLVECs373 CTHs induced cell death (PI or LDH). ahscFv, α-histones, APC, heparin, 
C1INH,  
NA 
HCAECs374 CTHs or subclasses (H1, H2A, H2B, H3, H4) dose- and time-dependently induced tissue factor 
mRNA and protein expression, activation of NF-κB and AP-1. 
NA TLR2, TLR4, TLR2/4 
EA.hy926 cells213, 265, 271, 365, 366, 375 and 
HUVECs178, 213, 265, 271, 366, 374, 376 
CTHs or subclasses (H1, H2A, H2B, H3.1, H4) induced calcium influx, depletion of IκB and 
activation of p38-MAPK, NF-κB and AP-1, elevation of tissue factor and sTM, release of large 
vWF elevation and cell death (PI, FITC-anti-annexin V and/or PI, or LDH); CTHs or H3.3 and 
H4 (but not H1, H2A, H2B) induced up-regulating of tissue factor and down-regulation of TM375. 
Anti-H4, APC, heparin, polysialic 
acid, CRP, MBP-p33, PTX3 
TLR2, TLR4 
Glomerular endothelial cells372  CTHs dose-dependently induced TNF-α mRNA expression and cell death (MTT). α-histones TLR2/4 
Cardiomyocytes    
Murine cardiomyocytes355, mouse HL-1 
cardiomyocytes351 
CTHs caused cytosolic ROS production, calcium elevation, impaired mitochondria; CTHs dose-
dependently caused reduction of contractility and induced calcium influx and cell death (PI); 
CTHs disturbed both functional and electrical responses of heart. 
NA NA 
Immune cells    
Peripheral neutrophils109, 271, HL-60367 CTHs induced IL-6 production and NETs formation; CTHs induced cell death (PI) was acerbated 
by a hyaluronan inhibitor 4-methylumbelliferone.  
ahscFv, IAIP, HMW-HA TLR2, TLR4, TLR9 
Peripheral monocytes368, 377, MM6378, 
U937370, THP-1377 
CTHs dose-dependently induced cytokine production (IL-1β, IL-6, IL-8, IL-10, TNF-α) and cell 
death (PI and LDH); CTHs or H3 and H4 (but not H1, H2A, H2B) dose-dependently increased 
FXa and tissue factor generation as well as PS expression; H4 induced CXCL10 production in 
CD14++CD16+ monocytes.     
Anti-H3, anti-H4, UFH, CRP TLR4/MD2 
Mouse peritoneal macrophages361, 
RAW264.7 cells222, 374, Kupffer cells322, 358, 
J774 macrophages372  
H3 or H4 significantly inhibited phagocytosis of apoptotic neutrophils or thymocytes by 
macrophages. 
H3 dose-dependently caused significant secretion of HMGB1; CTHs significant induced 
elevation of activated caspase-1 expression and TNF-α production; CTHs or subtypes (H1, H2A, 
H2B, H3, H4) dose- and time-dependently induced tissue factor mRNA and protein expression; 
lysine-rich CTHs dose-dependent release of vWF antigen, angiopoietin-2 and P-selection; 
arginine-rich CTHs induced vWF-platelet string formation. 
APC TLR2, TLR4, TLR2/4, TLR9, 
NLRP3 
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Human peripheral DCs279, Human monocyte-
derived DCs379, murine BMDCs372, 380 
CTHs induce TNF-α production; H2A (10 µg/ml) induced significant loss of ΔψM but not cell 
death (7-AAD); H4 stimulated significant expression of NLRP3 proteins. 
Anti-H1, anti-H4, α-histones, 
APC, heparin 
TLR2, TLR4/MD2, TLR2/4, 
NLRP3 
Human peripheral lymphocytes360 CTHs dose- and time-dependently induced early apoptosis that was associated with p38-MAPK 
phosphorylation, ΔψM decreasing, Bcl2 reduction caspase-3 activation. 
NA NA 
Peripheral platelets265, 275, 276, 323, 362, 365, 367 CTHs dose-dependently induced calcium influx, platelet aggregation, thrombin generation, PS 
exposure with elevated expression of P-selection and FV/Va; H3 and H4 significantly induced 
platelet aggregation. 
APC, heparin, CRP, HSA, IAIP, 
HWM-HA  
TLR2, TLR4 
Human erythrocytes365, 381, 382 Biotin conjugated core histones (each 0.4 µM) bound to but did not penetrate human erythrocytes 
or erythrocyte ghosts. 
CTHs and subclasses (H1, H2A, H2B, H3.1, H4) caused significant haemolysis; CTHs dose-
dependently induced PS exposure and increased procoagulant parameters on human erythrocytes. 
APC, UFH, MBP-p33 NA 
CTHs, calf thymus histones; IL, interleukin; TNF-α, tumour necrosis factor-alpha; PI, propidium iodide; LDH, lactate dehydrogenase; APC, activated 
protein C; C1INH, C1 esterase inhibitor; NA, not available; HMGB1, high-mobility group box 1; p-STAT3, phosphorylated signal transducer and 
activator of transcription 3; t-STAT3, total STAT3; TLR, Toll-like receptor; TM, thrombomodulin; HPMECs, human pulmonary microvascular 
endothelial cells; MLVECs, mouse lung vascular endothelial cells; ahscFv, anti-histone single chain variable fragment; HCAECs, human coronary 
artery endothelial cells; NF-κB, nuclear factor-kappaB; AP-1, activated protein 1; HUVECs, human umbilical vein endothelial cells; MAPK, mitogen-
activated protein kinase; sTM, soluble thrombomodulin; vWF, von Willebrand factor; FITC, fluorescein isothiocyanate; CRP, C-reactive protein; 
PTX, pentraxin 3; MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium; ROS, reactive oxygen species; NETs, 
neutrophil extracellular traps; IAIP, inter-α inhibitor protein; HMW-HA, high-molecular weight hyaluronan; FXa, Factor Xa; PS, phosphatidylserine; 
CXCL, C-X-C motif chemokine; UFH, unfractionated heparin; NLRP3, NLR Family Pyrin Domain Containing 3; DCs, dendritic cells; BMDCs, 
bone marrow derived DCs; ΔψM, mitochondrial membrane potential; 7-AAD, 7-aminoactinomycin D; Bcl-2, B-cell lymphoma 2; HSA, human 
serum albumin. 
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Supplementary Table 4 Release of extracellular histones in murine sepsis models  
Studies  Murine 
experimental 
models* 
Histone-based 
treatment 
Potential histone 
interacting 
receptors or 
binding molecules 
In vivo findings  Treatment effects  
Xu et al. 2009213 LPS (1 or 10 
mg/kg, i.v.), CLP, 
TNF (0.75 mg/kg, 
i.v.), CTHs (50 or 
75 mg/kg, i.v.)  
Anti-H4 or anti-H2B 
(20 mg/kg, i.v.), 
APC (5 mg/kg, i.v.), 
PC (2.5 mg/kg, i.v.)  
NA Significant elevation of circulating histones was observed in 
LPS challenged mice (or baboons); at 50 mg/kg CTHs 
caused lung neutrophil margination, endothelium 
vacuolisation, intra-alveolar haemorrhage and thrombosis in 
mice; at 75 mg/kg CTHs induced rapid death within 1 h.  
CTH-induced death was completely prevented by co-
administration of APC; anti-H4 partially protected death 
induced by LPS, CLP and TNF; anti-PC converted a non-
lethal dose LPS to cause death, an effect partially prevented 
by anti-H4, but not anti-H2B. 
Li et al. 2011383 LPS (10, 20 or 35 
mg/kg, i.p.)  
NA  NA LPS dose-dependently induced significant death of mice 
associated with dramatic elevated circulating histones and 
Cit-H3; serum Cit-H3 levels were most associated with 
severity of LPS-induced sepsis. 
SAHA pre-treatment reduced LPS-induced (20 mg/kg) 
elevation of circulating histones and Cit-H3 and increased 
acetylated H3. 
Allam et al. 2012277 LPS (10 mg/kg, 
i.p.), LPS (1 
mg/kg, i.p.) plus 
CTHs (10 mg/kg, 
left renal i.a.) 12 h 
after LPS, renal 
I/R 
Anti-H4 (20 mg/kg, 
i.p.), CTHs digested 
by APC (500 nM) 
TLR2 or TLR4 
KO 
CTHs significantly induced renal injury associated with 
increased mRNA levels of renal cytokines (IL-6, TNF-α, 
iNOS), TLR2 and TLR4 of mice primed by LPS (1 mg/kg); 
LPS (10 mg/kg) induced significant tubular cell apoptosis; 
I/R induced elevation of renal mRNAs of Kim-1, cytokines 
(IL-6, IL-12, TNF-α), chemokines (CXCL2, CXCL10, 
CCL5), ICAM and neutrophil infiltration. 
APC digested CTHs, anti-H4, or TLR2 or TLR4 KO 
significantly reduced CHT-induced renal injury in LPS 
primed mice; anti-H4 significantly reduced renal injury 
induced by LPS or renal I/R. 
Liu et al. 2013360 CLP, CTHs (60 
mg/kg, i.p.) 
NA NA CLP induced peripheral lymphocyte apoptosis and 
elevation of circulating histones at 6 h of disease induction; 
CTHs induced significant lymphocyte apoptosis at 6 h of 
histone injection. 
NA  
Wildhagen et al. 
2014363 
LPS (20 mg/kg, 
i.p.), CLP, ConA 
(30 mg/kg, i.v.) 
AADH (570 
µg/mouse, i.p.), UFH 
(114 µg/mouse, i.p.) 
NA All models induced systemic injury and were associated 
with significant death of mice within 80 h. 
AADH, but not UFH, significantly reduced the tail bleeding 
time; AADH reduced ConA-induced elevation of circulating 
histones and death; AADH also significantly reduced LPS-
induced increase of TNF, lung injury and death; both AADH 
prophylaxis and treatment significantly decreased CLP-
induced death. 
Iba et al. 2014384 LPS (8 mg/kg, i.v.) 
in rats 
NA AT (125 IU/kg, 
i.v.), rTM (0.25 
mg/kg, i.v.), or 
AT/rTM 
LPS induced significant depletion of WBCs and platelets, 
reduction of plasma fibrinogen and elevation of circulating 
histones. 
The treatments significantly restored WBCs, platelets and 
plasma fibrinogen levels, and decreased circulating histones.   
Daigo et al. 2014366 LPS (16 mg/kg, 
i.p.), CLP, CTHs 
(50 or 60 mg/kg, 
i.v.) 
PTX3 (N-terminal 
wild type; 5 or 12 
mg/kg, i.p.) 
NA LPS induced dramatic increase of circulating histones with 
time; LPS, CLP or CTHs (60 mg/kg) induced significant 
lung injury and death in mice 
PTX3 significantly reduced lung injury and death induced by 
toxins. 
Kusano et al. 2015385 LPS (40 mg/kg, 
i.p.) 
Anti-H1 (4 mg/kg × 
2, i.p.) 
NA LPS induced acute lung injury (with histone release) and 
death with significant elevation of plasma cytokines (IL-1β, 
IL-6, IL-10, TNF-α) and histones. 
Anti-H1 significantly reduced LPS-induced lung injury, 
systemic inflammation and death. 
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Kolaczkowska et al. 
2015386 
MRSA (1-2 × 107 
or 5-10 × 107, 200 
µl, i.v.) 
UFH (400 U/kg × 2, 
s.c.), PAD4 KO 
Anti-vWF (50 
µg/mouse, i.v.) or 
ADAMTS13 (3 
µg/mouse, i.v.) 
MASA induced accumulation of bacteria in the blood and 
tested organs (liver, spleen, kidney, lung) with marked liver 
necrosis, NETs formation (γ-H2AX and NE colocalisation) 
and increased serum ALT. 
Neutrophil depletion (anti-Gr-1 or CD44 KO) abolished liver 
necrosis and plasma ALT increase; UFH, DNase I, vWF 
inhibition, PAD4 KO, NE KO or NE inhibitor (sivelestat) 
significantly reduced γ-H2AX area, liver necrosis and serum 
ALT. 
Kalbitz et al. 2015355 
 
CLP α-histone (65 µg per 
mouse, i.v.) 
NLRP3 or caspase, 
C5aR1 or C5aR2 
KO 
CLP-induced significant elevation of circulating histones 
that were associated with abnormalities in systolic and 
diastolic parameters, reduced left ventricular stroke volume 
and cardiac output. 
Neutrophil depletion, KO of C5aR1, C5aR2, NLRP3, or 
caspase significantly reduced CLP-induced elevation of 
circulating histones; anti-histone treatment revered the 
deranged cardiac dysfunction. 
Wang et al. 2015178 LPS (Salmonella 
typhimurium; 50 
mg/kg, i.v.), CLP, 
CTHs (50 or 75 
mg/kg, i.v.)  
Heparin (3 or 10 
mg/kg, i.v.) 
NA LPS and CLP induced significant lung injury, elevation of 
plasma histone-DNA complexes and death; CTHs also 
induced lung injury and at a higher dose caused death 
within 1 d. 
Heparin significantly alleviated lung injury and death 
induced by LPS, CLP and CTHs. Heparin also reduced LPS- 
and CLP-induced increase of plasma histone-DNA 
complexes. 
Lee et al. 2015387 CLP, LPS (S. 
aureus; 2 × 108 
cells/mouse, i.p.) 
NA PLD2 KO or 
inhibitor (4 mg/kg, 
s.c.) 
Both CLP and LPS induced significant multiple organ 
injury and death; CLP induced lung NETs formation (Cit-
H3 and PAD activity). 
PLD2 inhibition significantly reduced, while CXCR2 
antagonism (SB225002) acerbated multiple organ injury and 
death; PLD2 inhibition significantly increased lung NETs 
formation.  
Alhamdi et al. 
2015320 
LPS (E coli K-12, 
108 colony-
forming 
unit/mouse, i.p.) 
ahscFv (10 mg/kg, 
i.v.)  
NA LPS dramatically increased circulating histones and plasma 
cardiac troponin levels associated with impaired left 
ventricular function. 
ahscFv significantly reduced cardiac troponin I levels  and 
improved left ventricular function.  
Kawai et al. 2016352 LPS (10 mg/kg, 
i.p.), I/R model†, 
CTHs (25-50, 75 
or 100 mg/kg, i.v.) 
Heparin (10 mg/kg, 
i.v.), albumin (1 
g/kg, i.v.) 
NA Both I/R and LPS significantly increased serum histone-
DNA complexes; CTHs dose-dependently increased serum 
cytokines (IL-1β, IL-6, TNF-α, IL-10), sTM and tissue 
injury (lung, liver, kidney); CTHs at 75 mg/kg caused 
significant death within 60 h and at 100 mg/kg caused very 
rapid death within 2 h.  
Heparin, but not albumin, significantly reduced CTH-
induced tissue injury and death; boiled CTHs caused 
significant less death than the natural CTHs.  
Biron et al. 2016388 CLP Cl-Amidine (50 
mg/kg, s.c.) 
NA CLP induced release of circulating histones, NETs 
formation (Cit-H3) in peritoneal cells, peritoneal fluid and 
plasma; CLP induced multiple organ injury (elevation of 
IL-6 in lung, liver, kidney and spleen) and significant death. 
Pretreatment of Cl-Amidine reduced NETs formation, 
systemic injury and death. 
LPS, lipopolysaccharides; i.v., intravenous; CLP, cecal ligation puncture; TNF, tumour necrosis factor; CTHs, calf thymus histones; NA, not 
available; APC, activated protein C; PC, protein C; i.p., intraperitoneal; Cit-H3, citrullinated H3; SAHA, suberoylanilide hydroxamic acid; i.a., intra-
artery; I/R, ischaemia-reperfusion; KO, knock out; TLR, Toll-like receptor; IL, interleukin; iNOS, inducible nitric oxide synthase; CXCL, chemokine 
(C-X-C motif) ligand; CCL, CC chemokine ligands; ICAM, intercellular adhesion molecule; ConA, Concanavalin A; AADH, antithrombin activity 
depleted heparin; UFH, unfractionated heparin; rTM, recombinant thrombomodulin; AT, antithrombin; WBC, white blood cells; PTX3, pentraxin 3; 
MRSA, methicillin-resistant Staphylococcus aureus; s.c., subcutaneous; PAD4, protein arginine deiminase 4; vWF, von Willebrand factor; NETs, 
neutrophil extracellular traps; γ-H2AX, phosphorylated H2AX; NE, neutrophil elastase; ALT, alanine aminotransferase; NLRP3, NLR Family Pyrin 
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Domain Containing 3; PLD, phospholipase d; CXCR, C-X-C chemokine receptor; ahscFv, anti-histone single chain variable fragment; sTM, soluble 
thrombomodulin;  
*Mice were used if not otherwise stated; †About 30% of blood volume was moved via cardiac puncture, and blood (heparinised) was reperfused into 
the vein after 1 h of ischaemia. 
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Supplementary Table 5 Release of extracellular histones in murine acute lung injury models  
Studies  Murine 
experimental 
models* 
Histone-based 
treatment 
Potential histone 
interacting 
receptors or 
binding molecules 
In vivo findings  Treatment effects  
Saffarzadeh et al. 
2012341 
LPS (10 
µg/mouse, i.t.) 
NA NA LPS induced NETs formation in the lung tissue (Cit-H3 and 
MPO colocalisation) and BALF with increased neutrophil 
infiltration and elastase activity in BALF. 
NA 
Caudrillier et al. 
2012389 
LPS priming (0.1 
mg/kg, i.p.) plus 
anti-MHC-I (H2Kd 
; IgG2a, κ; 0.5-4.5 
mg/kg, i.v.) 
Anti-H4 (10 mg/kg, 
i.v.) 
NA LPS plus anti-MHC-I induced acute lung injury was 
associated with lung NETs formation and increased platelet 
infiltration, elevated plasma histone-DNA complexes and 
significant mortality. 
Anti-H4, aspirin, tirofiban (an anti-platelet drug), or DNase I 
significantly reduced lung injury and NETs formation; anti-
H4, tirofiban or DNase I completely blocked LPS/anti-
MHC-1-induced death. 
Abrams et al. 2013271 Trauma induced 
by a heavy object 
falling on each 4 
limbs; CTHs (50, 
60 or 75 mg/kg, 
i.v.) 
ahscFv (10 mg/kg, 
i.v.) 
NA Trauma caused multiple organ injury with significant 
increase of plasma sTM levels and circulating histones; 
CTHs induced lung NETs formation (Cit-H3), multiple 
organ failure and elevation of sTM; CTHs at 75 mg/kg 
caused rapid death. 
ahscFv significantly reduced trauma- and CTH-induced lung 
injury and increase of sTM; ahscFv dose-dependently 
prevented CTH-induced death.    
Bosmann et al. 
2013340 
LPS (E coli 
O111:B4; 40 µl, 
i.t.), IgGIC†, 
CTHs (50 mg/kg, 
i.t. or 100 
µg/mouse, i.t.) 
Anti-H4 (250 
µg/mouse, i.v. + 50 
µg/mouse, i.t.) 
C5a or C5L2 KO LPS, IgGIC and C5a induced acute lung injury were 
associated with significant elevation of circulating histones 
and histone-DNA complexes in BALF; CTHs caused 
significant lung injury associated with severe disturbances 
in alveolar-capillary gas exchange, release of alveolar 
albumin, inflammatory cells, LDH, cytokines (IL-1β, IL-6, 
IL-9, IL-12, TNF-α, GCSF) and chemokines (eotaxin, 
CCL2, CCL3, CCL4, CCL5) in BALF. 
Anti-H4 significantly reduced severity of C5a-induced lung 
injury, evidenced by reduction of alveolar albumin and 
multiple cytokines and chemokines; C5a KO, C5L2 KO, or 
neutrophil depletion (anti-Ly6G) greatly reduced C5a-
induced elevation of circulating histones in BALF. 
Zhang et al. 2014364 HCl (0.01, 0.1, 0.3, 
0.5 M, 2 µl/g, i.t.) 
Anti-H4 (20 mg/kg, 
i.v.), heparin or NAH 
(2.5, 5, 10, 20 mg/kg, 
i.p.) 
NA HCl dose-dependently increased circulating histones and 
histone-DNA complexes; HCl at 0.1 M induced significant 
lung injury evidenced by reduced PaO2 and increased lung 
MPO activity, lung wet/dry ratio and lung histopathology 
score and plasma APTT levels; HCl at 0.3 M caused 
significant morality within 24 h of administration.  
Both heparin and NAH improved lung injury and 
coagulation parameters with NAH had better effects; both 
heparin and NAH dose-dependently reduced HCl-induced 
death with best effect achieved by highest dose of NAH (20 
mg/kg); anti-H4 significantly reduced HCl-induced death;   
Zhang et al. 2015390 HCl (0.1 M, 2 
µl/g, i.t.) with or 
without CTHs (20 
mg/kg, i.t.) or H4 
(5 mg/kg, i.t.) 
Anti-H4 (20 mg/kg, 
i.v.), heparin (250 
IU/kg, s.c.) 
NA HCl induced lung injury associated with elevation of BALF 
and plasma histones, LDH and MPO activity; 
administration of CTHs or H4 alone resulted in mild lung 
injury but significantly acerbated HCl-induced lung injury 
and mortality. 
Anti-H4 and heparin significantly improved HCl-induced 
lung histopathological score associated with reduction in 
BALF cytokines (IL-1β, IL-6, , IL-10, TNF-α). 
Wygrecka et al. 
2016369 
Bleomycin (2.5 
U/kg, i.t.), 
influenza A virus 
(102 PFU, 50µl, 
inhaled), S. 
C1 esterase inhibitor 
(C1INH, or iC1INH; 
600 IU/kg, i.v.), α-
histone (10 mg/kg, 
i.p.) 
NA Significant evaluation of circulating histones were observed 
in all acute lung injury models; bleomycin or CTHs induced 
typical acute lung injury histopathological changes that 
were associated with increased lung neutrophil infiltration, 
wet/dry weight ratio and mRNAs expression of 
C1INH significantly reduced bleomycin-induced lung injury 
and cytokine levels in the BALF; iC1INH significantly 
reduced CTH-induced lung injury and cytokine levels in the 
BALF and rescued mice from death. 
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penumoniae (5 × 
106, CFU, 
transnasally), 
ventilator, CTHs 
(50 mg/kg, i.v.) 
cytokines/chemokines in the lungs and proteins levels of 
cytokines/chemokines (IL-1β, TNF-α, CXCL1, CXCL2) in 
BALF. 
LPS, lipopolysaccharides; i.t., intratracheal; NA, not available; NETs, neutrophil extracellular traps; Cit-H3, citrullinated H3; MPO, myeloperoxidase; 
BALF, bronchoalveolar lavage fluid; i.p., intraperitoneal; MHC-I, major histocompatibility complex-I; i.v., intravenous; DNase I, deoxyribonuclease 
I; CTHs, calf thymus histones; ahscFv, anti-histone single chain variable fragment; sTM, soluble thrombomodulin; IgGIC, IgG immune complex; 
KO, knock out; LDH, lactate dehydrogenase; IL, interleukin; TNF-α, tumour necrosis factor-alpha; GCSF, granulocyte-colony stimulating factor; 
CCL, CC chemokine ligands; HCl, hydrochloric acid; NAH, N-acetyl-heparin; PaO2, partial pressure arterial oxygen; APTT, activated partial 
thromboplastin time; s.c., subcutaneous; C1INH, C1 esterase inhibitor; iC1INH, reactive centre cleaved- C1INH; CXCL, chemokine (C-X-C motif) 
ligand. 
*Mice were used if not otherwise stated; †IgGIC protocol: anti-BSA IgG (125 µg/mouse, i.t.) followed by BSA (1 mg, i.v.), rmC5a (endotoxin level 
< 1.0 EU/µg protein, i.t.). 
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Supplementary Table 6 Release of extracellular histones in murine acute liver and ischaemia-reperfusion injury models  
Studies  Murine 
experimental 
models* 
Histone-based 
treatment 
Potential histone 
interacting 
receptors or 
binding molecules 
In vivo findings  Treatment effects  
Huang et al. 2011358 Liver I/R, liver I/R 
plus CTHs (25 
mg/kg, i.p.) 
Anti-H3 or anti-H4 
(20 mg/kg, i.v.) 
TLR9 KO or 
inhibitor 
(ODN2088; 100 
µg/mouse, i.p.) or 
MyD88 KO 
Liver I/R induced significant increase of liver H3 and H4 
and circulating histone-DNA complexes over 6 h. 
Anti-H3 or anti-H4 significantly alleviated liver necrosis, 
MAPK proteins, IL-6 and TNF-α as well as serum ALT; 
receptors inhibition prevented liver necrosis and elevation of 
serum ALT induced by liver I/R or liver I/R plus CTHs. 
Xu et al. 2011322 ConA (30 mg/kg, 
i.v.), APAP (500 
mg/kg, i.p.) 
Anti-H3 or anti-H4 
(10 mg/kg, i.v.)  
TLR2 or TLR4 
KO 
ConA and APAP both induced significantly elevation of 
circulating histones, cytokines (IL-6, TNF-α) and mortality 
after 2 or 6 h of disease induction.  
Anti-H3, TLR2 or TLR4 KO greatly reduced mortality and 
associated cytokine elevation; anti-H4 also significantly 
reduced APAP-induced mortality. 
Wen et al. 2013391 GalN (700 mg/kg, 
i.p.) plus LPS (40 
µg/kg, i.p.), GalN 
(300 mg/kg, i.p.) 
plus LPS (15 
µg/kg, i.p.) 
Anti-H4 (20 mg/kg, 
i.v.) 
NA GalN/LPS induced liver apoptosis and necrosis, increased 
MPO activity, plasma ALT and TNF-α in circulating 
histones and histone-DNA complexes; higher doses of 
GalN/LPS induced significant death within 12 h. 
Anti-H4 significantly reduced liver injury, systemic 
inflammation and death induced by GalN/LPS.  
Huang et al. 2014392 Liver I/R NA TLR9 inhibitor 
(ODN2088; 100 
µg/mouse, i.p.), 
hepatocyte 
HMGB1 KO 
Liver I/R induced significant increase of hepatocellular 
acetylated histones and γ-H2AX and increased serum 
histone-DNA complexes. 
KO of hepatocyte HMGB1increased nuclear instability led 
to increased release of histones, liver injury and systemic 
inflammation induced by liver I/R; TLR9 or PARP-1 (DNA 
activated receptor) antagonism prevented these effects.  
Huang et al. 2015109 Liver I/R, liver I/R 
plus CTHs (25 
mg/kg, i.p.) 
PAD4 inhibitor 
(YW3-56 or YW4-
03; 10 mg/kg, i.p.) 
TLR4, TLR9 or 
MyD88 KO 
Liver I/R induced significant increase of mRNA of liver 
inflammatory cytokines (IL-1β, IL-6, TNF-α, CCL2), liver 
NETs formation (Cit-H3 and γH2AX) and necrosis, and 
elevation of serum Cit-H3 and ALT; Liver I/R-induced 
circulating NETs formation was acerbated by CTHs. 
PAD4 inhibitors, DNase I, KO of TLR4, TLR9 or MyD88, 
or adoptive transfer of TLR4 KO or TLR9 KO neutrophils to 
neutrophil depleted wild type mice significantly reduced 
liver injury and systemic inflammation associated with 
reduced liver and circulation NETs formation. 
Wen et al. 2016370 GalN (500 mg/kg, 
i.p.) plus LPS (10 
µg/kg, i.p.), ConA 
(20 mg/kg, i.v.), 
APAP (500 mg/kg, 
i.p.)  
AADH (300 U/kg, 
s.c.)  
NA GalN/LPS, ConA and APAP induced marked liver necrosis 
and mortality over 24 h; the liver injury was associated with 
elevated plasma cytokines (IL-1β, IL-6, IL-8, IL-10, IL-18, 
TNF-α), ALT and circulating histone-DNA complexes.   
AADH significantly prevented liver necrosis, systemic 
inflammation and mortality induced by liver toxins.   
De Meyer et al. 
2012393 
 
Hypoxia, tMCAO 
and reperfusion† 
with or without 
CTHs (10 mg/kg, 
retro-orbital i.v.) 
Anti-H4 (10 mg/kg, 
i.v.) 
NA Hypoxia induced significant increase of plasma histone-
DNA complexes; cerebral I/R caused dramatic increase of 
plasma cell-free DNA and histone-DNA complexes; 
addition of CTHs significantly increased I/R-induced infarct 
volume and worsened neurological function. 
Anti-H4 or DNase I significantly reduced I/R-induced 
infarction volume and alleviated neurology functional scores. 
Savchenko et al. 
2014347 
 
Myocardial I/R PAD4 KO vWF inhibitor 
(ADAMTS13; 
I/R induced myocardial NETs formation (Cit-H3) and left 
ventricular infarct that were associated with reduced 
PAD KO, DNase I, ADAMTS13, or DNase I plus 
ADAMTS13 significantly reduced myocardial NETs 
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3460 U/kg, retro-
orbital i.v.) 
ejection fraction and elevated plasma histone-DNA 
complexes. 
formation, left ventricular infarct, circulating histone-DNA 
complexes thus improved cardiac contractile function. 
I/R, ischaemia-reperfusion; CTHs, calf thymus histones; i.p., intraperitoneal; i.v., intravenous; TLR, Toll-like receptor; KO, knock out; MyD88, 
myeloid differentiation primary response gene 88; MAPK, mitogen-activated protein kinases; IL, interleukin; TNF-α, tumour necrosis factor-alpha; 
ALT, alanine aminotransferase; ConA, Concanavalin A; APAP, acetaminophen; GalN, D-galactosamine; LPS, lipopolysaccharides; NA, not 
available; MPO, myeloperoxidase; HMGB1, high motility group box 1; γ-H2AX, phosphorylated H2AX; PARP-1, poly(ADP-ribose) polymerase-
1; PAD4, protein arginine deiminase 4; CCL, CC chemokine ligands; Cit-H3, citrullinated H3; NETs, neutrophil extracellular traps; DNase I, 
deoxyribonuclease I; s.c., subcutaneous; AADH, antithrombin activity depleted heparin; tMCAO, transient middle cerebral artery occlusion; vWF, 
von Willebrand factor.  
*Mice were used if not otherwise stated; †An ischaemia stroke model.  
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Supplementary Table 7 Release of extracellular histones in murine acute pancreatitis, peritonitis and glomerulonephritis models  
Studies  Murine 
experimental 
models* 
Histone-based 
treatment 
Potential histone 
interacting 
receptors or 
binding molecules 
In vivo findings  Treatment effects  
Kang et al. 2014222 L-arginine (4 g/kg 
× 2, i.p.) 
Anti-H3 (20 mg/kg, 
i.p.)  
Anti-HMGB1 (20 
mg/kg, i.p.), 
pancreatic 
HMGB1 KO 
L-arginine induced elevation of pancreatic γ-H2AX, H3, H4 
and cleaved caspase-3 and was associated with significant 
death. 
Anti-H3 or anti-HMGB1 significantly reduced, but 
pancreatic HMGB1 KO acerbated severity of acute 
pancreatitis and mortality. 
Merza et al. 2014221 Taurocholate (5%, 
i.d.), L-arginine (4 
g/kg, i.p.) 
Thrombin-derived 
host defense peptides 
(GKY20 or GKY25; 
0.5 mg/mouse, i.p.) 
NA Taurocholate induced necrotising pancreatitis associated 
with dramatic release of pancreatic histones, MPO and 
elevation of serum amylase, IL-6, CXCL2 and lung MPO; 
L-arginine induced marked pancreatic oedema, neutrophil 
infiltration and necrosis with increased serum amylase and 
lung MPO. 
Both peptides significantly reduced release of histones, 
pancreatic injury and systemic injury in both models. 
Merza et al. 2015125 Taurocholate (5%, 
i.d.), L-arginine (4 
g/kg, i.p.) 
NA NA Taurocholate induced pancreatic NETs formation (EM), 
release of H3 and H4 and cell-free DNA with elevated 
plasma DNA and HMGB1, all associated with pancreatic 
and systemic injury markers assessed at 24 h; L-arginine 
also induced pancreatic NETs formation and elevation of 
plasma DNA. 
DNase I or anti-Ly6G significantly reduced pancreatic 
injury, pancreatic NETs formation and histone release; 
DNase I also reduced systemic injury evidenced by reduction 
of plasma HMGB1, IL-6, CXCL2, MMP-9 and lung injury. 
Ou et al. 2015325 Caerulein (50 
µg/kg/h × 4 or 12, 
i.p.), taurocholate 
(3.5%, i.d.) 
NA NA Taurocholate or 12 injections of caerulein induced 
necrotising pancreatitis, multiple organ injury and elevation 
of circulating histones when compared with 4 injections of 
caerulein or saline controls; circulating histones were 
significantly associated with pancreatic necrosis score and 
organ injury parameters.    
NA  
Allam et al. 2013279 
 
Acute peritonitis: 
Necrotic EL4 cells 
(30 million, 150 
µl/mouse, i.p.), H4 
(250 µg/mouse, 
i.p.) 
APC (5 mg/kg, i.p.), 
anti-H4 (20 mg/kg, 
i.p.) 
NLRP3 KO Necrotic EL4 cells or H4 induced significant neutrophil 
recruitment into peritoneal cavity. 
Necrotic cell-induced peritoneal neutrophil recruitment was 
nearly abolished by APC, anti-H4, or NLRP3 KO. 
Kumar et al. 2015372 
 
 
Glomerular 
necrosis: Anti-
GBM serum (100 
µl/mouse, i.v.) 
Heparin (50 
IU/mouse, i.p.), APC 
(5 mg/kg, i.p.), anti-
H4 (20 mg/kg, i.p.), 
PAD4 inhibitor (Cl-
amide; 10 mg/kg, 
i.p.) 
NA Anti-GBM serum induced severe glomerular necrosis, loss 
of podocytes and inflammatory cell infiltration, associated 
with increased urine albumin/creatinine ratio. 
Heparin, APC, anti-H4 or PAD4 inhibition had similar 
effects of reducing anti-GBM-induced glomerular necrosis; 
delayed histone blockage also significantly improved 
glomerular necrosis; the combination of anti-histone 
modalities did not enhance therapeutic effects. 
i.p., intraperitoneal; HMGB1, high motility group box 1; KO, knock out; γ-H2AX, phosphorylated H2AX; i.d., intraductal; NA, not available; MPO, 
myeloperoxidase; IL, interleukin; CXCL, chemokine (C-X-C motif) ligand; NETs, neutrophil extracellular traps; EM, electron microscopy; DNase 
161 
 
I, deoxyribonuclease I; MMP-9, matrix metallopeptidase 9; APC, activated protein C; NLRP3, NLR Family Pyrin Domain Containing 3; GBM, 
glomerular basement membrane; i.v., intravenous; PAD4, protein arginine deiminase 4. 
*Mice were used if not otherwise stated.  
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Supplementary Table 8 Murine histone-induced coagulopathy models 
Studies  Murine 
experimental 
models* 
Histone-based 
treatment 
Potential histone 
interacting 
receptors or 
binding molecules 
In vivo findings  Treatment effects  
Fuchs et al. 2011275 CTHs (10-50, 60 
or 75 mg/kg, i.v.) 
 
 
UFH (50 mg/kg, i.v.) β3-integrin KO CTHs dose-dependently (10-50 mg/kg) depleted platelets 
from circulation and prolonged tail bleeding time; CTHs at 
higher doses (60 or 75 mg/kg) caused death within 15 mins 
of infusion.  
UFH and platelet depletion (anti-GP1b) completely or β3-
integrin KO partially protected histone-induced death.  
Abrams et al. 2013265 CTHs (75 mg/kg, 
i.v.) 
CRP (1.6, 2.5, or 10 
mg/kg, i.v.) 
NA CTHs caused lung oedema, haemorrhage and thrombosis 
with rapid death in mice. 
CRP significantly reduced lung injury and dose-dependently 
protected mice from CTH-induced death. 
Nakahara et al. 
2013323 
CTHs (20-95 
mg/kg, i.v.) 
Recombinant human 
sTM (40, 80, or 110 
mg/kg, i.v. or 110 
mg/kg × 2, i.v.) 
NA CTHs dose-dependently induced death of mice, deletion of 
platelets and white blood cells, deposition of platelets and 
fibrin(ogen) in the lung, acute right-sided heart failure and 
ventricular arrest, reduction of plasma fibrinogen and 
increase of APTT and PPT. 
sTM pre-treatment significantly prevented CTH-induced 
platelets depletion, reduced organ dysfunction (lung and 
heart) and rescued mice from death. 
Kowalska et al. 
2014371 
CTHs (20, 50, or 
75 mg/kg, i.v.), II 
a (8 U/kg, i.v.) 
plus CTHs (0-20 
mg/kg, i.v.) 
UFH, ODSH (0.5, 5 
or 50 mg/kg, i.v.) 
NA CTHs dose-dependently induced plasma APC elevation, the 
levels of which were significantly higher with low dose II a 
infusion or in platelet factor KO mice; sublethal, but not 
low or lethal, dose CTHs caused significant elevation of 
plasma APC.  
Both UFH and oxygen-desulfated UFH abolished sublethal 
CTH-induced APC rise; only ODSH increased APC 
generation upon lethal CTH challenge; ODSH, but not UFH, 
at low to moderate doses did not significantly induce 
prolonged APTT. 
Westman et al. 
2014365 
CTHs (0.75 or 1.5 
mg/mouse, i.v.) 
MBP-p33 (1.5 
mg/mouse, i.v.) 
NA CTHs (0.75 mg) infusion caused significant haemolysis and 
platelets depletion at higher dose (1.5 mg) caused rapid 
death in mice. 
MBP-p33 (an endothelial surface protein) significantly 
reduced CTH-induced haemolysis, platelets depletion and 
death. 
Chaaban et al. 
2015367 
CTHs (50 mg/kg, 
i.v.) 
IAIP (50 mg/kg, 
retro-orbital i.v.), 
HMW-HA (90 
mg/kg, retro-orbital 
i.v.) 
NA CTH-induced thrombocytopenia associated with prolonged 
bleeding time, elevation of cytokines (IL-1β, IL-6, IL-10, 
TNF-α,), chemokines (CXCL1, CCL2) and lung injury.  
CTH-induced thrombocytopenia and tissue toxicity was 
significantly prevented by pre-treatment of IAIP or HMW-
HA. 
Iba et al. 2015394 H3 (25, 50 or 100 
mg/kg, i.v.) in rats 
UFH (350 or 700 
U/kg, i.v.) or LMWH 
(2 or 4 mg/kg, i.v.) 
NA H3 at all doses cause significant death; H3 also significantly 
reduced WBCs and platelets as well as increased plasma 
fibrin/fibrinogen degradation products, ALT and BUN 
levels. 
 
Both UHF and LMWH significantly reduced rats from 
histone-induced death, and improved coagulation parameters 
and systemic injury inflammation parameters. 
Alhamdi et al. 
2016351 
CTHs (20-75 
mg/kg, i.v.) 
ahscFv (10 mg/kg, 
i.v.) 
NA CTHs induced cardiomyopathy and pulmonary 
microvascular obstruction; CTHs dose-dependently induced 
NETs formation (Cit-H3) and fibrin deposition in the lung 
tissue. 
Anti-histone pretreatment significantly restored cardiac 
function. 
Lam et al. 2016376 CTHs (75 mg/kg, 
i.v.) 
NA NA CTHs induced significant elevation of plasma vWF and 
thrombin-anti-thrombin levels as well as decrease of 
platelets. 
NA 
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Michels et al. 
2016395 
CTHs (10-40 
mg/kg, retro-
orbital i.v.) 
NA NA All CTHs increased vWF and angiopoietin-2 expression 
and depleted platelets. 
NA 
CTHs, calf thymus histones; i.v., intravenous; KO, knock out; UFH, unfractionated heparin; CRP, C-reactive protein; NA, not available; sTM, soluble 
thrombomodulin; APTT, activated partial thromboplastin time; PPT, partial thromboplastin time; ODSH, partially desulfated 2-O, 3-O desulfated 
heparin; APC, activated protein C; IAIP, inter-α inhibitor protein; HMW-HA, high-molecular weight hyaluronan; IL, interleukin; TNF-α, tumour 
necrosis factor-alpha; CXCL, C-X-C motif chemokine; CCL, CC chemokine ligands; LMWH, low-molecular weight heparin; WBCs, white blood 
cells; ALT, alanine aminotransferase; BUN, blood urea nitrogen; ahscFv, anti-histone single chain variable fragment; NETs, neutrophil extracellular 
traps; Cit-H3, citrullinated H3; vWF, von Willebrand factor. 
*Mice were used if not otherwise state
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The work presented in the thesis was conducted when I was a PhD candidate studying 
in the Institute of Infection and Global Health at the University of Liverpool between 
May 2011 and April 2015. I have done all the work and written up the thesis, except for 
the specific contributions listed as follows: 
 
In Chapter 2, Dr Simon T. Abrams performed experiments on FITC-histone membrane 
binding and histone-induced calcium influx and cell death in endothelial cells. In 
Chapter 3, Dr Dunhao Su assisted me for the generation of anti-histone single chain 
variable fragment. In Chapter 4, all the samples from in vivo experiments were provided 
by Mr Zhengxing Cheng from Southeast University of China. In Chapters 5 and 6, Dr 
Wei Huang and Mr Peter Szatmary assisted me with data collection and analyses.  
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